var title_f33_42_34464="Prenatal ultrasound unilateral kidney adrenal";
var content_f33_42_34464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound longitudinal view, normal kidney with adrenal gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longitudinal view of a normal kidney and adrenal gland in the third trimester.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tulin Ozcan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34464=[""].join("\n");
var outline_f33_42_34464=null;
var title_f33_42_34465="Cutting zipper mechanism";
var content_f33_42_34465=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutting the zipper mechanism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The zipper mechanism consists of two faceplates connected with a median bar. The technique most often recommended for release of entrapment within the zipper mechanism involves cutting the median bar, which allows the zipper to fall apart, releasing the entrapped skin. The median bar may be cut with wire cutters, bone cutters, or a mini hacksaw.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34465=[""].join("\n");
var outline_f33_42_34465=null;
var title_f33_42_34466="Seborrheic dermatitis diaper area";
var content_f33_42_34466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile seborrheic dermatitis involving the diaper area",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34466=[""].join("\n");
var outline_f33_42_34466=null;
var title_f33_42_34467="Megalocornea";
var content_f33_42_34467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Megalocornea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Notice the corneal clarity as revealed by the red reflex. The ruler on the forehead allows the corneal diameter to be measured without an examination under anesthesia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34467=[""].join("\n");
var outline_f33_42_34467=null;
var title_f33_42_34468="Tinea pedis onychomycosis";
var content_f33_42_34468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea pedis and onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAUEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3JZVmmKHeqAAkL0zVggCA7HIcnAzztxTbTMcBdVHykg5PTFN053uS8jdyRn0rreh80izPG3l4D7cfxDjP4V8z/GG1msPiXftMSftSQ3SkcDBUKf1U19NTbwqKhHXknpXgv7Rlo48TaJdh93n2bQY6YMbk/j9/9K5cZH902etkk+XFJdzk9Qnm/sz7OZMbX3gA8c4/mBVPQr5tO16O5G4xyKJMZ6c1a1GAxWllKsiuZMAqAeMdOvtVK7jW1khnEbGFSCMjqO4r5xto++dnGzPpnwveC50gFDkEblOMfrVPWIHLqACuCGJHt1H41k/DzUllsYwFZQihQCMY9P6V0mpwmRWcnEqHcBjsQMn8xXbUSqUkzw6S9nVaMLQLw299LA/IUkjLfhxXVyNsJVvkLKMqTnPGf51x1wgttT8zaF3dCF7/AF7ZrphdR3VrGsYBlwqntk57mqw8248r6BXivaKS6iZ/0ZZ87ipChD1A+lLp8sjSBDyhU7wOMH1HpUVw7MdrADOCvXH4mnKDDKNgwdoY4OQfaq57aIrRxJlCrKqyM7NsAyFyQfftUk6I8YULnAOVJwQaXzANu8qSegGc96jWVXGwErjgK3HP1qGzJt6MjwRCQfnTbzznn09aisoZLfdI20kklcE4X296mCtK2FYsp4B757f4VCsjKHDklB1ABGR7UQffY1i200X3u22LtY46FT1B+vaq04LheY2C8bhwW9z60C4KbWDDZgnaP4s1XJVztC7Czc8ZHqcelUpN6NiUOxnaq0kkR8ldpHX1qrBdFVi87KPzuXOcZ6VoX7NFktGNzIBkrgH6e9YMySL5MiHcSMDPOevSspO713OqEbxOv004DbXySQNp6CrupRExgqNpz344rF0ueQOUEeWZ9qqTxmty8LSR5YbVQnAz1I9D6VvBe7Y42nGorHPpEkUzMR8hPB/M/wCFNiYxOxaMYZiPx65pk81xFdvEqK0IDZy3J9gMdKaJxM0eFyVkIOO2OAKiLbep01IN6sq6pYvAZJbV3LMwLEdM9P5VctdQiaD94VVlXoB8wPQ/yNaflq8TRZLKV2gNjHavNfEzy6RfSyySkwtyTu6/X25P41vUtG00eby8/wC7E8T3bXl4ILfcycbyRjr2/Gr2gWwiiKIpWQY43chh9fp+lU9Kj+1WC3QKswO59wJyD3z60G+lguCMEMTz228+tYRk7qUjonT93kj0OkjuM3TQnI2DO7t9avQzKVeIDLA8EnoMcmsbS2EzEbgAw2sxUkYzz/StO4ZraGZyAHB56/dq41E9yYU18Jm6jp5V2eFnyTnOeM/Sq8RZ5kRGkGCc5JyxrdtmS7hQRk7AvPHNVobVjLJsVjgnnoRmsaiT1OqE3Tdn0I7eSaJFcKzKo+YZ6+3NOt0kkneR5DGGbcqA5x7++Kt28TbHDglcbgxIIPsfpVK5iaIq6oPm4+Xv6EHtisHFLVHTCfM3YwfEySvCWuH2IUIXC/ex0+nrXkfjQyASE7lyD93pxXqmqzGeR4nyY8DO852+4HrXmPi6NSrqo3Ebtpz+taUtJnRVT9k0+x5Xp8rbcM7YDOAAferolkPBkbAXHWs22zHNcxtgMJMgntV3qsh27myOnAGa+lpP3UfGVlaTLyyy7yFYjgMRu9utSxzyIwKMMhiMY45//XVJSNzMwUbAo2ipCzbdnU53fX/OTXQmccka20/89G/M0U/y1/5+B+Roq7EH2v5Uh8qJNwXHz56n3q9AggRU29ugFfM3i7496nO19aaBZ21rAWeKG6di8hXOA4HQE9e9eeW/xL8XW+kyafHr995TkEu0m6QfRz8wB9jXGZRw1R6o+2ZEjEe+dljQ9dzBQK8A+NHibRfEmvaPaaNeC8m07zhO0efLBYpgA9z8p6V4VqXiPV9UiWLUtVvrqNTkCWdnCnHuam8K3SpqkYcBlPbrXNi1ejKx6OXYd08RGbZ7B4rjhk8N2XlKfOLK+QNuPTPH1qjqlrFLpwO/cFGcf3SeQKhv70XsZjiYYXAAwT8qnj6dSas2c5uLV0cgyxRbFIH3sdz+FfNXbPu6cPdTOs+EOs5V4mVvNUr1Jwfz6V69NDGVMqs54ywbspAHA+tfPvg24ew1dPnVIy4I3N94nPH59K+gbJw1vGG4JXbkdD659K7MLLmg4nkY+HsqqkupgapatcweSZAHYnDAdPek0YyW8ZhlDEr0bP6j0rVmtkWXco47kjjOe1Z15bvbuj2u5VHJ57Z9Km0oSuNtTjymgCpRQJDnj73fNNRggLIQpHfHWq8bB0jBk5+9tAyT9M/Wre5EKqvAPGCOK3ad+Y51LlXKyJFZkLyDLD5t46D3p0MhuLUhpDtGSccnI64/CoZzIZXjgXAYbjzkcd6lhiKbiylQMOeMg+pqEtdTVrS43eRhASseNpLHOKVVcSE5DnJUN0IPr9KfcQoIATg7iSeeKlaEkqznCHgupyDmjdbFJq2hWDl+Y3IjHBBHK+4/GpJisbKFVs+/GPWkmJi2jIKDhQvIIPb61ELiIo5c7tpAHbB75/CpTtLcqzeqI72Npoi0qbhjg+n09frXOXMq2kkccuVZmGMHkHH/ANauj1CVgGHl+XEcH0OT0/Cuea2J1ASFkCINvJ4Htn61lVai13Oij8OpsxEzGMQknnJwBg/X8q1t4vEVUP3TkL3/AArndMhMl0WJbOBGdr8gHnPvW/bSRW3krMQCCd2Bgjvya6YVG0ctWPK9DP1iDy4TJuTfj7o6tk9MDvVe0RFjUAL5uc5z39qt6xdoNzBN5JyqgdT6+1YE1/5EjecRGrnIUDA4HQD6/wBayk/e0KdR8lmWdV1KayjYoTgnIA5zx0A9axG2ahEJJh5rnn514HoD/jXOarqp1DURYo3CEZZui4J44roiuyxiD7lMmAiD+MEY5/ACiMubUzlTtbTVl2x06G208W5dTI53EqeOv8uOtZ2paTM25xuDHGSeA5yc9e1dTHDIgXcAdowRnkdOv5GrM1oJ7dlmDMeSBn+ZFXUk2rFU4qOvcw9DidQpcYOOmc9D0+lat026GbeoC7TuTPHTrWZHH9jlfcoOHG18Zbvxx2q0N3lhsbo92dp7Hv8Ah7VNOTSsYzp2ndk2nxpbWUYTcTgbCCefrmlimLOwZdvBy4PGBVgsqQuQcbR9wgZz+Fc473stw5XMUCgdFzvPvn096c7JnRRSqN3NmOZPMRFXCF8jaeTzjkf1q7dFY4nkXPB+6RkFunPtzWWsCS+SkbutwME49QPX09qtJ5KWzW0TlGBzhuxPelzL4WdDgtGjiNdeH7TIfNHnKMybF2jHTpXl/iPY0v7pAECjAHY969I8RWyWUspyXdyCT1I9fx715xqiLHNniWMdW7ms4tRdj01TvDQ8su0WPWLpCcbwCPzqxljk4PLbSc/kaPEUZh1SKXAyzFf8KjbJYow5J6j0FfQ4aV4Hw+Lhy1GTKx2yrj7w6t/SpQwYK4woZdvPYiq0bBmB64BA9KlBXbGN3QHd7V1xfc4ZLU0dp/vN+f8A9eio9w/vPRS90NTFlYGVsep6UzeSSAxPFNfAlbDZJJJApGLDqCAB0rnOuxJvwP8Aa7Vf0aQpfxsCCcisz5VA43betXNL3fbosdeSayrawaNKWk0en6Lc+VemOb5OdygEY/vY5+ldz4fs45ILnKssbMF3sw+Vs5yM988elcFqACWml6ijYkcGOVcde4b+Y/A12fg+7Mwid3/cxO0iRldxZj1569hXzrjrqfVKbcbos6hpU9nGtzxvaQhdhxtXrz2ycdfavV/CeoMNNhmYmX91uYMvLHHb3rAsdMSW2nLb2hByAWBB4+8B+JFXfD+3R7n7L5UiMoJBzlWHqD+VPD3pz12Zji3GtC27R1BuY2tF83f02DA5Xn0+pFZ7sYsRvIHl3EL23D+nParFyCjF4SyyYAxjhgfp70z7OI8yOylGcbZUz9NpH5HNdVZNt36HJS5eX1KCSiaPdCyeZnbmM525POfyq3CCrbiTIwIwT0PrUc1v9mu5AoQsxBJ4BJHqe9W7dS9kAVAPY8cUrq1jOUlF+Q6JzvVGGcghSpzkelI8fmEjhgpyG5556Gn2+JCoBOVYjp96ntESWEcgJV8N260RTkuYnmsyJVMhViWbOFC+h9PY1MzxuXE4VVA2nJwfpj64oNspkddx8xSAcHjkfzquAVeZJAZEbo5z8nufoaErmsbSIrmSJAYwyN688j/CqcVorXgn2sJGwHJJ/QVII4YiWPzTscMxPUdBVy3jCx5kCtLt+bt+NRq1qbuXIvdF1S2MFsQGG7Axlccd+a45rkSxMsh2Sbsf7uc84rsdXyYECszwk9MY4xyOua4i6uIluVCPn5gpABxt5xzWOKSvdaG+Di5QOo8OxsgSRwRHvyuzkkAY5qTU7xJb54ol3FPmJAyDn196i8OTD7BIqfMgDA9fWmxOUuHZU2gHsO3+cVopLkik9zkqL35N7otXkA06zDy87lBUBuVyM5NeQ+MdcdlFrEivKc4KHPHbHoetdZ48125kkgg2sgYBWyOD2/CuatdFYrLJNtMvIZSMYHYfma0xFVfBDYWDwzf7yqN8NaPPG8cxQPK6hpHK5OTn9OK7N7Lyp4bkZ2xMA3PykDge3Wq2mILaBYZjhlPLH+Lr+nJroJJx5aRKpYZ+6Rwcjr9Mgmopq/SxpXnLm0Ft5TIQV+Yu20A9j6n9K37aNXiVH+ZTyST36cfrXJRwPZOwdWIB3K5ONx7/AJY/Wums2aHZ5vz9hkcAelaJte60RNXimmY2uWAVyYxlnXb05/wxUGnITuy+4gbfm5BIHNdVexRy24kcEu3c/wAhXOC3ZZZAFGMD5QOuf8KzkuSRCftI2YySc+U6srPJ90Ad+/6VSvtSt7C3Z71lTcpX5v4vw9atkBJzFI5LbcAgdBjtXEeOzJcIII1D7DnPQ9KTk3G9jqwdKNSoovY27zW7QWjOZC2PusrdAetUj4iS7tt9i8ZlQggSKRk+tcBPNIbJC2IXBAzu5NWdH1BrU/NBwflV1G18/wAvTrWCk29T6KOAhGF92XNSvJ7q1lW6jYuclmPH4g+vauRvs+Xtx8gyx4weP616BOUksmceUyuTkHAKjPOB0J4rgtWjaOT5izBs/e4PXp+VaLQl6xaSseeeLI9yI6csv7zis+OUMC6YUEZz2A9K6HW490o4GGUrx0+lcrGpgkeBs4XLL7ivbwc7Kx8NmFP94y0mdvAzxgk8VKpBYkg44wv4VFGCX+bnjNPiJKqVGR1Jr0YnlNGlvX0P5mipPJ/2aKdmRoc1KQZJPlw24nkUmSwUZO33P8qH3F2wOA3f6mkZQwXB+YE7vb2FYHYOB4JwSBzWhoyb7zPOEUtWeBzlhhTitvw5GG889ioGWrnxD5abZth1eokeozWiXXhW3MZUq0fXByGz6/gePes7wtctbu0UjuhjPBHXJ9B+ArfhC2ejwxSIQwjCsuOM/wB7Hr0/OsbTIlmvHO5FBJ5xjJPOPavnpyex9TRTtqey+FNXDWkaFGLs205HGSM4/L8q6DX4pQEurWIu0BVyAOWXv+Qryfwtqsuny+VdyyGAEFcnhgOw+temWWtCVFSTLRE4LEYK98H6CqpTUlaRhWpyhPmijVMy39tA8RkWRQGeMcHIIPJ9+alt/OmtdiMS28xgnOcZ4yPp39qq2kTG/Zi4ijk4y6g4wR6evFPliazlkeSXER53DufUfpXXJNxvfc44ySfIvkTXhK26uwQgDnnp2Az3ORU1o22Jn3tsBGRjAPqartuOxQuVmKqSDkDPRj+NOikWOeWNmZQF5z90+hoWxnVjdadC8i+YzExgjhwQcE9ccVLFb+YryJ80nDBQeCc9KEkBijkYlCBhSO2e/wBMj86hu73yAyygBiMNg49+nrVctnYwu5L3TSV1TEg5ycMjjJXj1rOlzGpbe5ZiflHPy+lMkmkdTMrAqwB3dT7ZqDUJLi0QNtbJGTjpj2oqJrUKUrMieHzSANnyfd77h1qWJXeRztYOenqcVkG/USLvTDE4BHYHpn1q+JZX2v5xUhlIGc4HtWHPGV7ndK5NdkeV8wD5UsWHXPoK4a+KC6ZUiIIwQw/n+HNdrNcxkGByysR94cE8+tcZrRWO6SUSMql9pAA49vrWVd7WOrCStdM6Hw8IobVsbhvYEZbJJIqyrhUlaZWOMhSMdM1zPha9tY7ttjzlQcEseOnP15ro9TnRbWUIu1mQhSp2k89qqmlJKXY5cSmp8vcpHTINTtxKwXernaB9OnuKxdcaRUnyFXy14HQsNvPP5flWz4d3i3gA3gbyAztz9QKl8TWUTJMAXMrfe9FB4wP61ryxlF30ZVLmhNK+hyMV+JggYAeUu1MjPTkjHr15roPDcpklfdJ5iRjdk+/p9cYriVf7PrjmRF8gkFRg8Ajg+4PTFdbo7SxWieeeVIIC845Py/TPP41jGVmrHRVhodTcxLcWSsx+cMGCkcewqXT5xKPNlyAuTtJ5AHrVeDDxFRNvjbJ3EYJA9/xNVL2GSCeFUZwm/cyDAGMfdJ/WuxNyal2OGMEny33OojmW4QlVZiy53NxtHpj1qleR7JPNUKFzxipbGV8KGGHIBYdvapJDGIQJB15UDuKVZc5KXK7I5nW28mNbkLtCkk8cjA5zXm+oeIInvJILiPKHlZlGHTnqK9E12Brm2f5mUsep5H5fgK8q8TaVLFJvUnIG7OMcdsDrXJV5kz2cqjSm3GW5UvLdXbzY382JQfmHbFJDK9peSMTGYwoG3dx7H/8AVVjSmt5wbRiYs4BYcc/T61Z1HQ5UVY9u6N24fsV9cdqyjG7PeU0vcmU9Qfy3zGfvKCE5xjjoa5m+u5Jd78NuyQPTntXUatJDBH5LWmQoCsTzk/X6Vzssce1nVflGBjGO386vd2MZ/DexymqoHZiuNqjOT29j+dc1rUIikgmxjbgP9DXT3m4CcMBhht5HvWbqlsstlj72Rz6ivQoT5bHyWPo80mzFjYbcbRuboDUoOSSBkn8OlVLKQk5kPzICrZ68VZX/AFcQ5JPIH+Ne1B3Vz5yas7Gn5sn99qKixJ/kUU+YnlMaTliAMAMep75pG4KsCBxwcZpZjh3ztGDj3pijJGAenpWR0IegG4nnPet7wv8ANPIBzl1698Vz4HQ8En0rovCQK3DupGSSOa5cY7UmdmBhz14pHp80yrHGVHzEbefw/wAKraWjQXO5k3lWBY46YPoe+TRpLFoGWZgeGwDgleOoqezWR3uWBKtkEE9QP88V8431PsvZctkdFq9pCHEgjEagE7Qchuev15PFXLTUZ49kMCsdo3EDrg9x61blsv8ARLK7bY25dm1TkGtKKxHlkQqHwOC4+5jJGO/GfyPtS1UrJGclHl1L1lqP2mzRY22yY+VWJPA/piukJXUdMaNZFJTDZXOQAv8An865CzXylAt2RJAgQOOVkIOeD9OP/wBVReHr+4s9SuftEixo4PD8cgfl/wDXrsw2J5XaXU8uvhm/fhpY6jT7swTv5ssmJMLJnsecfqKsz3kU24D70DkyHPDDqPp1rGE3+kq6yBYZBnG8fNz14/StRLVJDI8IBjeLr6n6UObs4oznCL1ZNa3pEChmKp0HzDHPoao3NzMSdx8xYhgg8ll7c+tQKUilEZDlZeQccK/UjNWGtnJjaVCGYAjAyD6gn1xTcpTje+xlCCi7Mx18USwCSKYEsB8uR972/A4Fa0fjNZraKK9wHIyQMHnHXj6VDLppjeScOrMwwoIGB9PyrKn0Iyn7VHG5lUYABAK8cE/Ws4zqx2e5r9XoVOljZi1K2u3RGHlvn5Tgcf8A68Vsrb28iorOI2HygY6cdfWuJhtLi2eJIN0zsSN+eIyOeMetWJJNSjmE00rJubBQDIA7HPp0qliXd88bmdTCtP3JWOy/sHcplSV3RscschePzrz/AMT6VdxOQJ12ZYsNxII9MY/zitJPEE9s/k/vGXH7wRjP1FZWteI4uFwwJXIPXIz/ADpyqUZx00sTRp4qnO+9zDt5X02eNWY5T75x8zJwQfSuhl1Nb52gdZGYgHzJF2lQSCR9PpXIw+dqmookbfIWILseMYIwP510stqI9klkf364Lbs4z2A9R7+lYpae5sejKLTXtNztbPzTBavsHmEEkoOi49fpirOsQyLbiWPBA4yRuCnt/Pp7UaUwTT4I/MDkrudh09wPbJ6066u5Vt5UwrTgfIM8Nz6V1KHPGz6nHd306HlviI7tUCpt2qyhWOMehOe3Tiui067AtovMkA2nDHruyMjp0HP6Vyl/Af7XLMHCSOZCd3CjPQflW3pIiZXjjkBYsCflycjI/Sua6T1PSnBcquddpG6aBm8liyDAwcA5PUewArbtrPzIDJtC7eSR1x6e9Zek3UbRxIxwVHln5uvp/Kt/zsnYj5x1Oew7H1rsoSSVjycQ5XskNscxqXcfKegB5NOviJLfzSFC4ztAPAHGf61Xm2lDIJEIyQCO57ircwDwfdUoemTkVty82lzlUmpJs56+1C2FmjMSocMckYBx/Wuela1mDO6BP4lLDgjsf/rV12p2NtemIBVeNFPygdPYe3eql3okMtujMCARk47D+7j8evvWNSLlomenh50oax0bPKNR0s2d4HhhXJclJAwwSOwpZLvzzM14zGXbuz90f59+9ani1mi1SJfKeIowUH0OOT/KsW8wHeR5ml3DZkDIJx0IPSuVq0tOh9NG9SEXLexmzGG7mjTeSu44bJUfXms2+jeNRtlMqZyGHGD2q9cpgrLbPvmIIMe3HT2rOnjlNwhZcP2GMZo1T1FUi2jm76FgxD5ZzzwM1VeAMgViM44P+Nb15Ac7ZBtG7ggVnXYAbbxweOcZrWMrJHkVqPM2cDqEZg1JhjIkGfxH/wBapVck5PQj5eateJoijpKONrcn2PBqhE3y8c/Ln6cV7mGnzRPj8XT5ZtGp83+c0UbV/vfrRW5zGPL/AK58Dg5HH86Ttgsc4H406VcTOACOTjPc0jAcD0HzGoNQ2jHAOO9dH4cDLEkhHykkZxXPNyny9Bj/APVXcaRaiLTrNXB+ZlPsc1wY+XLC3c9PKY3rqXY7LRLZJIpZ8fvFUKuTzk8VLYS+RFdeaQBjuMsQfT6c1DKRbyyRRqijaCoAyMEdqxvNle4jRz93Cg+tfPtXPs6a9rLyPcdNSOTQLJLZzKvysAp/MEdqs3H2WKe2wfKnVcNGRwwHBH8jXH+BbidxbwNIwRXLDIztGMV3CiRLllEfnLEM5bGec4I9ehGfpWsdXzHJWp+yla4yGMuVUJGCnzFV4yDyB+nasbWmbyjMUJSSUAqyg5A6f149q6q2ik8x2wS24MwI4I9jTr6wS5spIpoEeKVcbdxXPfr2571o4cy5jz51YxdmUNOm0+7to/JEAlQcCMDIOOw65q/ZXKi8aEoV8obmLdXB9PSucghbSb1NsKAMfvAZx7GuqV1YBlGCwz09+KuDU9drbnDUlyu26ZJeWiyGSUR5fIKkHrxwMUlkxIXCMwTcSGH3fX/GtDcXiWRgobG046gE/wCPNVZwYroOPlUsQy4zkfSt1ZSuupk3zImkt1BAEbleDgdPrUMsKRQ7YyTIPQ9R3yakgmkexj2DBCgAP1K1A96isLeQGM7SI8nk46/zrTkXUdJyY1YUkugNhGQArDkdMdKZc2JbONp24Xk8Ed/rimxTpPcywBimcZPTPuKsmRnZd6bS4wvvt7n0zXO4JuzWpvLmvoYsukw3DssMRUOu3cvykk/4Vi6/4VhW2SSZSY0BwSPmwM9ffiu0RkIX5SGVgSN2Ov8AOq/if5rASeYEjXlsrnIAPBx165odJcl7bGlCtOM1E800TTz9s8wHCpuGD2Axnj8q6+OziuJ0UAuzHL7xycE/KPTGc/zrB0KZ2vJJ8HyiGiyy5IGFOfbsa63TlkRd5+abc4HoAD/Pis6Xc7MS3Ftlu5jit7aFs4V1AY59PU0ul2KzGVIuATuX5s/hTnjN15m4rwcAr/Djpj39qr2z3VrOwB/dKD9a6YySlqjzGpONovU5LxVpU8F7OWQuvBLKOBz3PpXGxXJsJNgYhTlc56c5Ne1X0kV1EY5k2Ow29ccetcBr2hoWuI7bLJsaQYGTuHYZ6k+tZ1qEbuUWb4XEzb5KiH+HJ2mX7YHbzSoO4DAGP55rZ8ReJF07TRLBh5pOPLwc+5FcFo322KyVRbsTIC8fXkA449On6Vna/e37SWs8uP3RwAP4WHqPU4zXKpNJqJ61LCKrUTnsdNp/i26sYfNnQTIz8gscqGPUe1d1oXiG21RWSF2BT5WRjyG9PT8R2rzSxjW8QPE2JHY/u84GSueO/P5VraFot1Z3cN8ZRuRvm8tiAGGRub2PGa1pTlHYWKw9CpfpI9Sl27UaNSjbvnz0qw10k8I3SFZEG1lHcD0qmtz58DEDDZAbjoarxzB5GikkVUVsBjwfr9a7bpr3TwacNbPoZuuafZy3wuGYk4JQscAkf5FcTdW+bh3gfMoO7OBggcdSPWus1CNJr1bKS7Z3PzIYvvqp6jFcT4gX7PJNFbII1JKtvUgjHAwMcCuWaaXM+59NglKyje+hRvpE+0RDcJfMB3YxuUkfrXNalcLDMFXjk4yO9WryOWIeaSfMA555OO+ayb6LzCZNxbJzyeffFZSd9D0pUla7Ykr/AGiVMIwAz0PeszVLb5z5fA6jNakMahd+Omec81DexrGCegPHH86al1POqJPQ4PxKpawcjkAZrEtmJyTnGMce9dJr67rS4QjoCBj6Vy9t/qcn+6MV7WDl7p8ZmULVGjoOP7x/IUVBti/55vRXdc8uyMubIlOSW+Y7QabkgjJBYHoe9OkG2Q4IXJJppIzjJ5Oc45qDUcuWZRx9/wDrXorEOlkowMsMj0HrXn9kglureNRyTuY13C5aSA5xj/GvLzF6pHt5PHWUjpr9Csscjbm+UAfMSOaoR2kkrLLEpHO0N2Ht+tbD2x+wJIrqDIFLjuDnp7Vf8O2Yn3wMMbXzgnAOD0rxZaPQ+soS5VzG/wDDoyf24qTRkylSgJGRjB/+tXoVgVnmeBTsuo+dxGPlz3/L9a5vTLKODUIJbcqk5UlQ3yoTnt68119wjRXDyXixl0O0lByvf69a6sPqvmefjKinO67FiCSVT5UygoU4YHjg4P4UpcOsXGVHAw3UeuKt2LReUdjKyEfKCMnPcClmgUr5TxlWzgEckflXXyWV7ni1Zrms0ZeoRQGLGcFjjJ557GsrSpJPNuYrh9ssR24bjnrx7Hnmt1okDlEyzK2QzckGsTxXARJFqEJKTIAshPIK/wCP8s1zShyv2hEZJ+4dNZybGMcrJGrDCt2J6VBcR5VGySNvPGehwM/z/GqpuDcLbyEKQgxlOc47n9au3CnyiiMFEgLI5BODXS7ImC+8ZZXUDRiO3/fTHKMoHDDqD+FRXVukxyQH53GHH3T+PSs/RrmSyH2W/XcUdgWReGzyDn8f0q9eXGyVTJG+GAIcdOOn+TWkpqcFZlRTpVHEqzJH9oEsZUq5O3jGADyv51asXhuV2SyEBclOvY8Z9azykf23zUwct87KcbRjnP4+laFl9mltXu4JBLFJ/qmUbVZeRgGsotanVVsl5jnhjeUfL8y4BJGDj/DpU+sxRtpjAhVyCOm7I9arum6JUWXEhACnuP8A61W5lDWPlOGyo5OcA8frWUtbmN7Si7nARLDHfSbfLMsgVhjgE9Pyxmuw0wbrZXDoWA+VlP3jz1/SuOvoZI9UUsyqiP8ALjjg9cV1/h/yxEkpOYm+bdgcjB4/lXPhXeVmd+LV4Jo0bWASPiQqVRicAdM8/nSm33yFTGVXJCHOQxrGXW4W1O4gtwssiDOGIXYffPUY9KksvEkf2cs/mGaM/vSU2ng9h3H616C5XE4vqte97GL4v1drfEUUDv8AMw+U4yQByD3PXisfTrm4uopxcw7GeRT55b7uOq4+hH4Z71vOlpcwyCaIKNx2SiTpzz9Mk1m/2b5F5M8hcqNvlocBXbgHj9f6Vy1HNant0/ZKn7Nxs0bmlWNtLbxsCjP5Tgq2DhmzuPsOetYP/COW2oXdyHDeZJGG2xt8jNgce3f/AAp+iT22l3syvMFRmaMI4JK5xwx/LGeK6Cd1aO0wjROjL9w8HjGTTUo2Se5xVOehN8rephHwXaWU0c0CNHJEMMvog/hz3Pv7mpFf+zrlYJ4hJGTszvO/pyM9Nv8AKtu4uGlSKJ1eOOThvlJwe3P15FQyRq2n+YUha4K8F14Zs/p3yKupGNvdOenVnJ3q6k1ndXCQE28DwBVCiNuQx+vTFRNqPlbn2GUFQ0i91+uD/wDWqjJBdrHbG6mf5GCFYWwee+08Af8A66zLzT5EMl5asyycbd55P07f0NSpTTsjT2cObVk+qqNQFvcWpXzWk3YVucEHg9+3WsS/UtL50aNKiR+WUBBKA9VcZ9D1P1rO1fV8XkeyFoNQU4Min5XbpwOxqOe6uHkxKPs7smFcD5g2flHHY46c0c97pnuYdOMUZN3I83EIVgpJHbI6Hj8O1ZbRoIoQMAFjlj9fT6VcuLmXa0kmBKvzAKuAMnkYrPljlMcMn3csR07Z64rnO92aFu40iuJNgGzeTt6euOfpWde46csMYBPbNdJGICiTBlYlQTvXgnuPwrI1nbHIVQr0BPIJx68cVVu55k9GcL4gX/R5MY6HpXJWf+qAX72M59OK6vxKStrNnHQ8+tcrbR5RR1IXBAPevZwS90+PzR/vWbvmS/8APUflRUe5fUflRXocz7nkW8jKlAE8gC9/WmgAqxYnAHGRT5AVfpkFic0xWOOSBjt61maGnoEe/UWfaBtUmuvgRneKM46jJNc34Ti3yyHGeQCa69SovBk8ZxivDxsr1D6nKadqN+529haC70+OJEywTzC27AwPr3P+FPtJGheFlbPzNnI+6cVDo9+r6dPZumJHICuQPlA5zz6n+VP04gXEas7CMbioIx1NebOOt0e3h9b3O0VhdabA0qZeJRyuR7n8816BZGKVIblVb5l+dW5zgcfyrhvDAkNnIrYe3LFjhuQAK6fQ7vzAYY2YTxBhyueo9a68G/e9TzsbFvRdDbREMilF8ogc7egPXNMkPlq3nHcME8fyqXT5XuFxPEI/kwOdpJHc0+eAZCIS3X5c9OOMV6UvhujxajtKzKccAuMmNyrglWB6GqWr2LXNlNa7iokQ/N3Ueo9T7VsBs8Iu4qoyemf8+tNnjMEbOrqxJB4GSKwlBON2ZKo1M5rwxb+XbLBEzEJ/ePU45OT/AJzW/dthLRCw8psgvyegrH0wxxag6S5jX5nX5sg9Tj61fv8AE0SQxsqHb5gCnJVsdP50UI3p3NFd1tdipqLfvXSAq4YhSQRx16VUu5Be6e8YMhniUAhuj4B4/Hj6Vxuh2F+fFCCS1vkTIZvMzhQD3Pcenaux1AzQX0ZSPCjIZgOMf0Nc9CfMnzK3Q78Vh1DlUXd7mX4cv5Wuvs1yqJHKeARxnPT/AD2rrdOhS3t1jgUKkQKIijKgdMGvPtZ3W99C4w6btx2AkqMDn/61d9pEyXcabFKhkBUlcAHHH4Zq1FJ8iJr2cVNdSncSxx7SrkuhLJGFPTp1+uKuxSl9OkkcrjHOD0I54qCexdoy0sjEhQGJGf8A9VU7BWV7iLzDJEw3EEH8gKT0laZLipK8XsczrMjfa/MISXA3Ko6gjnP0/wAK6HSpn/siUpt3Kfkxj0Ax6Z56etcf4l0+a11lEtWkO5gyKBnC4wB/Ouj0K7kstGH2kAyHdISgAwoyTx3wfzrnhG02j0KutONjntMtb4+J5ZoAA2XLxTHG7A4z3HOeR/SupuNJuLuP/R448OQzIrfKmeoOeefXrSaPcTXF9vuPLSYnhew3D1PODjP41tnzbe0Z4WZwmdqsQAR/tE9cdK7KcI+zsnowxOLn7RWST0ONsrOe3uUjERZ5P9Y7AnYQMKeevY8elbMHD7ZNtxMw3DzGwN2cNgdiCM/ialtpHurtLhpf3SSeWA69SMY47ck8Grl5EqS+dKoeeNsAgfcVuR9e9ZRgoqyHVrOTtLcxbeITW915iqm1icA/dyf8SetallEu54m3bX6KRjaMdj3qnJ5pv/Lhwi5Dls5VuR1H5/jWhbI6blfaGHzKuMKV9qcaab5jkxM3bcj8kySlppCVUheWI/T16ce1OmMm5huDBXBJC4P1Pp064qpcyooleOQm3bhsrkgg8j357VoWkjPbIwG5kYKS2FO3/a7+lVf+Yxgmldme6o08kq5iZjtYOeM9flPp9KovJPbO5cmZztGSDgL6j/PatLUn5ULKVCxsxyARkHsD2qtpd7bvHGzTMpUbVZv7x6getS3Hm31NbNLmscP4muLFr+IqJSTkMxTGSenHdelc7qU6x3W7zpBIDkKp+XIOcj0rpPGUFvcwmQK0koIGEONjdzj8P1rhPMkR/LcApnO0cFT6+1YTZ7eEXNBPsaOpXS3TvJBGnYMVAXD45/DrWexmaJGxuxleuOc5z79f0pIblBcsgAMMg25XjkdPxzVpIlwmXAyNo3KeuR3o66dTf2vLox6tm0kDblMQJ5Ax+IrIvJQUdmAbJ9ua0iztKy7lATIIbv8A49Kyrtl2MgHy9RxyTj9K0jFto5K9RWZxHiuXNrITgnp9K5+BSRkY4XHp+Na3iiTO2HqS2CB7cms23B4G3c5XJz617OEjaNj4vHTvNs0to9KKseQv/PytFdnIefzsw5vvSZILbiQTRk8gEs3ZqVwfMkyOh2j0oIIZV3YB4rJuyuapX0Ov8F25WNnOAeo9jW1JGWuI2BxuOetUvCgAwu4op6kDpWnfL5k+VVgo9PSvm8RNubZ9rgIclJLyNIytA6yIAdyYyOdpPr+VdNozRs9rDJE28sVLkY696x9IaOazcOhZgD83QZ7ZrR06O4tlWRzMrqd44OG57f0rKKtudibtoepaZp8ctuZbViQiFTuY4DZ/+t2rZ0JI1eQTRDc4I3hu/fp68VznhLxFE2y3upFSRflG/g4B6139qscgMiFGhwAGVc/kf613YeCdpQZ4uLrTheFRD4ELRjBRwgx8/JJH/wBaopApfMZbI4BPOP607YCrsMgIcNz2z1/WpnZIYH3LnYcgg5yvuOtdjjFrU81u7uhkUGEZ9+V6hQPWqNy8rHBG1sgdPwFXpEKxIyjeBwQT05qtINxJAChj6ZbNYzbcdDNXvdnLysk2sBZw2xdyjnqe5P0PGK6O2bNtGw+UFtqhBkqOnJ9+a52/t2/tJLoqmwn5jy3X29MgV0UNyJLJVXAUsQyg4I9KmjpFxZrXlZx5SX5ITkxA87SF7Ke+f6VQuSk7SiMZG0rGc5z6fjgmrMfmqkMsUi5Gc4OODUcN1E7PHt8uVnyuSDjA4HFauV4pNWNIPS61MDU9PhSKBmiGyFtoVehz61o2ZKspiG2RTtYAZPbj/Cnzjzkn8yNiPM+ZCehHGeO1GnSAYVkCuOST3HQHFRyWei0JcmrxZpysojLxnPmZAGM8n19TWdavJDeuhjAYep4Ax/U1oMvmQbXLKVORxjknP0rn9V1JNPkiLFt5baCMnjuSKyra2bN8NFzvBK5zfjm4exvJLo4RnQBX3c59R2A9eKwDrF/qWmR+UuIvL++vPBbA/qPxFWfGbya8YXQZRQGwOMHGCPbv+FUNHuorCW2ghU53FX56cj5T/j7CuSfuzbWx9ThqMY0FdXkjvbSMPdWn2JWihgjbfEWywfGWVj+oq+TPcyzxoirLbOJPnJIKHqDzznnr6+1ZulSLa273Mrq4XLHaMGUD19D0B7/nVpdWht4pgX86WOMyExAlZYz0XPdl6V202t7njVoScrxV7F21eI3WyII8cwGXI79R17dqr647vZyw48tiMI7YYEg5Ax36VVsoXlU3RncrNDmIsBhTjBGO3JzWTc6jdXWpJEU3AkOp4zwAOR29awrT6IIU7z5k9je0mzSCMO7t5pALZHJOBkflWP4jnnttQtPL/eWYG/5EDFcHnPGRkd66RL0iwEMkbJMh3EpHgKRzwTxtrkr11vybmFTA8nyxyA4ETZw2fUHPQ9a3vGEeVEYWMqlRzmaULylIrjzCdw3s7RgjHo/YHnr7VNDdGNwt64eDA2SRkgr2xzy3P9KrW7+RaGNoxFZhl+fPDv0zjqR/PtUWqOLOSK4a3ME8jGOHkEuD1baenbg4rPXc3jBN2sVP7WVrqSUM80EBCyZXhQRwwB/LHqaXHmLm0dvMYtIzD7rk46KP88Vys7yXF/OJTttxiVgWxyepPc+uP8a2tMvzMCsNxsjbjy9nII6EAfzrmVSzOqpQ5Umht1bRxlluj80i5EjMcbQvHyjnr1rlPEummC4Z4XSKTOChH3x1yPb612c9g26Y72H8KuwBUkfeAHXuDzk9a52/la5uBuQxiMAHZznkj5fWrdm3YdGTvdGFHppa182NdqgqSemASR+PSmTCLyiI2IYDdgnGR6/WtydpNslvAYxC8ZfB/gIwWI/I1zsciR3TBjiQdNwzxk5H5Zo8iknK8ihLIyP8rk7QCpHesS9um80gdjwB0+la+or5csqx4KBvlweox1/GuY1OQKznIAye1a0U2zjxtRQg2cnqsvm6iwblU4OPeiEEMAGOAP8AIqvbg3EzOefMYnbVuFTu2kquDzk/pXu0Y2R8ZWldtmlth9KKMR/7P5UVtqc5kS/62QEdG+UDvzSQ4e5i6cNihgzXBIAABOM/561Lpp33WeoAP51zVXaDOuirySO48P7iihDg5/ya21VZi4bh84AH8z/nvWZoyeVbBgwB24yeoNaOlOuZd2AoUkdCc185Ud5an3dOKVNFzSLryHkQNgMChPbB68d69E0O0trzaJZWESAJGrEHrknI/E1wOn28b3ZVVUZHXsPbH1ro9BujpmqM0reZGAAoKnHI5xnuKy5tddi6lN8r5NGdzJoCi3LW4DHcCr9x9K6LRLy809YobiFmhJxwd2fRj+lR+HNTs9QhVIGjLA42471umFUZdwGQMtvTgV6OHp2SnBng4iu5fu6qHy3EZCuhTYV2vuH6/wAxT9PfzkWRm/d7SWLdcfT2qMQsgiZ1Rlbk5/u07O6SRQq7CfzHr+ldvM+p5rkkuUs3A4ZQD5RIfaeB2GaqX4f7u75skA5H+TU7uWgRnYPtTt1xnofeqVz5tzcp5Lny1Ids8knoM1Ek9bChv6EV1alo3BjAI9OO9QWwCRtEV3MG4LHpWm8yt8hwcg55x/nkVj+asd0TJk9BwM5+hrlslO76mi5pR1Ivtklr5m1Rx820HnI7Umv27T2Edxp25ZseYWPJA6//AFqdrOnm4sz9lZVlZWBZhkH0OfxrP0G8uoLgQXpwqqVPHBxj8qtSUL05rQ6be6qtPp0NTQZx/ZsaOEDOMOH65J5HrUl9YyyXSSxdIQQVGec+nHQdaiuIdkTXduMJ5oHTHGev5VpWd00xCW8xDhDvQ9CAfX1rSF/hZyzqXbqR3Io5BMqW53FgNyHPQehPrXnGpy3MniGeBpGl8skMm/YWwOx9O/PWu72xlm+ZlmBLjB7Dp/hVLUdPEupR3MCJ5zRkZYZyR3/LNZVYWasepluIjTk7rdficxJFZTOZC6ht5+ULt+XjJAHf0FZt3penxRW/2aPEb5GWByzZ6ZNbviHSmuIs20ZUquTzyznrk+3+FQpBcpZTRscsyiJZGG5o2wcYHPXjn8axlT1dz2YVVypqXyNi3guJ7ERSyKJZVY545ByMezAZyaZb20lkLCZ2zJHbGCZm+VcjGCR3PvxmqyXLqIoblmE6TLs2kZcHG7noOck57VqatJ5bwMg80qFBRB8pR8Zbn06g1pBe7eJ583OMuXoy/ZRGC3TdAI8sQGc5DrkgEj0xWZbR239oQpLHvfBIbGDgHr/9arl9uthAoV5Sg2s0YCgt7j1z1Peuc0O9jvdVmTcoe3wASeX3HkD6GorXU0jCnBzhKRs+LLtUghntnaWSIhfK2lgy9yfauW0WZ9RvZkUlFuCrzAvlVCcZ4+76Y9K0vGdzLc3sNrE5heKQK7iPEcYfqAfXANM0SSBp1j08uIYgYSYhnzs9cY555Yn0GO1VUvKep3YamqeG21ZD5smo6yIGBtbeH54mKkBgMgMT6Dsfeo/EAM9huncxxs4MjyMG3EHggkcdc49PWt7TLOTUJLu5gixYEiGGFyVE6qOTx90Z6DvivJ/Herebrk1qhkjtwQrITkhgME57/Wsa6cE79Tow8VVnyrTlRfmdb/UJXWQSRI4zkEgleBg1uaWYkvNkQaK4DYG4cj1/CsfSo3gsggUJgFSWGd4HU898EGtiG3jMqLdkwk4PytyDjoffn6VyQbNKsk9OhsxfZpJJIfMKzKzOpA+Vu44PeuQ1CSH7TJcwofKZv3iqMFeMhvxPp2rehv0jiJkg2yo65C9Q3UH3z3rm9Zuljt2ESRqGXaABy3zdT7/XpzXQ2pGFPSTKBnYQxQ3ILuSArKeobI/rWHeCVSEzlkb5uP51cuLtZrVhGoWRCEGPQjt9DVJ2d5Cq7CducnuCM96qKZqpJMh1mR3xJjnYucDuOOtcFrs5S3mzgHbXd3bCWy24JZPlPAH0FeceJH33YhBzufv6Dmu3DxvI8XNpcsLGdBGqIN3VenvVtccAAgFeTjOagVjy2OWXGOuBUo4jBYAscdDXtx00Pk5u5p7ov74/Kil2/wDTP+dFVZ9vwMzEm5eTnhW6ipbM7bvvgjvUU4CySHHOefrmn23/AB8KZMAt69cVy1VeDOyk7STO9syfs2egxzW74bhW9uHiZ0hTqZpAdoHYcZ5J4xWLpIhls1DPg45NdB4YLSO8DIrIvzkKnIx0Yn2ya+albm1PvKd3Tuiy9hNYXnlXHyTbFlG1gQQeQR+FdTCuImTY0gbaQyjJXco/Pr+lROhuNKtEvIkuFjkcQ3SH5iM58st3GORnpk1taaksNuPscDqEn8xF80bskAYJ79M+341Cgm99DfnvFNmJp2py6Pfw3GHeEjDfUHFev6Vqtnq2nxSW8kZZVGc/ePPp2rgdV0g3GnpIIlhmEhDh3Cg5Genfmtfw1ZR2ZEwhljcDa2cKGHHIrrw0p0Zd0edmFOnWiqi0kjtx5bsQTuB6+uf/ANdTNKTFgIVGNvpznis6C4jWMeWCqch2GMcjrUqyebErJIpYddp6EV3qVtj5ypBskusFXUDcX549ckH/AD71NaSosLHdtcgBhjHIODx+VUftJeVVcoPLwxA6nPX+VW2jCs8x+UHIYZ6Zqr30M7dJBIcW5xtJ7Hrn61jXaAvvfdgYxjg9OB/OrxnKO8bNuyQAcc02Yq8bxuQeB+H+e1ccrW0OuC5dGWbVN8MM42gFWAx7noap32mbnZ4eBIgOPXHSmwMyRMm7JAwpA71bjvPPiaGIEsBtz1KGtpqMkkyIKUW+UwbW9SJkgkP7vI+Vsg+vU1t2+EuWktiAJM4Oc4HTA/WoLiyjLIZAWcLtbjvSofJdASNi5yemMilTly+7LRE1kr3j8yedlWRH2gpt+Y9dvHI/Got0fk5wwliIPTNRJIXBK7DCMhsfeAxwRViGFXhCysqnGMt16U563SHC0bNgYRdCUxnK/wB4E8Gsm9n8iN/MVxtX5eBy2e1a6IsKtErY2HIz3FZOvQNNbFog+4A4K9TWFSeh6OHs58r2MVkj1SKVYHEExb/XbScOPbvU2gQPHHNDNIZo7iUM3zcRsMDGT0B9OgzVXTbWW0tpEbzIWVQD7sCeQfXFWEEkupJcWaMsRjV9rgfMccg4PAI5+tY05PSfU9OotHCL0N0TvLZvvjXzB8pJOOMZ5/xrivDUUcviJ2VRG0jAwlecHaWbaMcjg1sz6x9qlMSbY1ZzFIenU/JnuB1FYxuXGqo9jMQ1mpWRFON+7KgD6ZP4VUppzT6Ixo0pQjKO1zU1KT+0LpVkEkEJDQzuFPIIySP+An34JxWDZ3F5bXFrdWNqWjhQ2zPHgBkC7mz74J5/nXbavdpPp+2O2w+0DONwXjB59jgfjXFWVwto0tupnaF9g5B2jBO8kdQe4Iz9K1rOKlub4SblTacfkdlrXiGbT/DEd1DbHIjUxgLlSD05U8dutfNuoag+oa488+N7S44HA5Jr2jxHq8SaEsMReRZol8zj5WIHTHY5AIP1rwuwjb7Qs0o4+0EHsOtY4iXtJa9EXQiqMdrNs9R02J9RUCJWOF3Ow4PXv/LitVIxFELiQNvRDtLD7/pj+VLoCCPTRGHJUKXJZeS2Rn+Y/WpLy8tfIXbF5kycjdwqnGRx3HtXLCOzLk3KVktDPvrt5pZpkjSDKlWAJ+Zc8+vQ8CsLUJy9qtyi7sLllfrkYBB+mfxyK17m+821Vo5E8vj5VQJ168e1crqP2iG4dWO0A7SCcjPbit2raovk+RQMqAbxkBsqy4wRn19s02EgMuc7hHt7kZPQ/TtVW6RuSSMk45PrUnmI0aNtwGG0kZ6+n0NaRZzvqLcSL5E21dqH5h65HWvMtUkNxq8rLg7MKBn8a7DVrv7MZVJwCu4Y7eorh4GJzJ825yW49zxXo4SGt2fOZrWu+VFhGwxLYH8P4VIhID4CjOBuI6CmqVUhSoBHzMB1NSqGKgHADHgY6816sT5+TNPan/Pc0Unzf3h+dFO67E2MGRv3snQZOfoacP8Almc5Vep6UhUGWQBRweB6nvUkXkra3DS+YJQo8oKAVyTzu9OPSudq6sdN7M7Lw9IXhZACxUYIzg4ra0+R7e6ZtzxHJ5HHFcz4anCTQsG27lwTXeyRgmGXKksec8ZHHGK+ZxEbTaPusBVvSVzZ0XxE8ekS2E8cbw+YHViB8pIwxyO545PpijTNTlW7XYyNluwOM9PwqAaeqsVihMTvk7SQVx1zTtLU2csZu0ZYmcHenVOea5rNNXPTh7OzaW56fo1vLqCG4uId7P8ANs3dOmT9K2IYFQhTCSu4EZPTA/lWLok7wyg2hadMfPghsAcZ579P1zXRNfRknerFGHGxMbvp+FenRcZRueFiXO9raA4UsU6gcsR6UiqI5MqDtXAwp6r6n86gnmkVW8pFJHI5wRx3H5VNbxZhKSExtIMsB3PHStW20eda25P5A85nC8kbVOM4H071ZjkUGUJjzBgYBJ7c/wCNU72B/IJWR1KEFHU5yAfSm2MhgLRFhuZSUU88lcE//XrRSWqkc9SF1zImvoztKRKCRyTzn17VnxTZlEjKWTAHPPpzW5E7PFl2AmCgso65BxnNZN6oeUgMI1ZcAYwA3ODxWFSDvrsbUanNGzGxybboLIAImYggN3HNXokWzlYbAsSjcNo6g8Dp3rlpYLl74iCTKGM9/ut7VvafcCSAGRH8wfLlxwfWrou8bPdEVY8ktOpqs0jwkuBvBK57ZFR3ZXYhTG5TyP8AD1qC3me7jeNwCwkLdcjp/OprV8MAw3DHJIyMVTu527mVSDi7kQOzJG0huV9SfrRZuW2KwQn88D3/ADpt2qorKgaPI4B5z/8AX9qQBVKuo4A6g7RjFLrqwatG5anVDEWjGWVuWbjNV5R86qMMSuRngGmzpIgWRWZxuxhiOeOM1CTLuRwAZQDsUnHbpmlKNtzro35U7nM69cMk0Vq6gRls9+fU8d6thZvJZpEHmKu1SesjAcHjsR29KqzNLNev9tSGKSOTdGAfmxmm65DPNeQyN5fl4BAHXIPDL9M1jyvVnspp8sNjntcBs5ZpnaWMsEd0HBY5xnPtiqNhdyG7W63hXkXCknocgg49flFaWu2NzPZ2X2iRzJCWDrnJUZyM+vY/jVCxtpBMypGoTlQ0nAHcH3964qicZpI7oyi6eu56JBturWKe03GMEM4LDpjjp36VzWqzeRAyrsV0G9HPG4DCsM9/X866vw1dwJpixxsiqDuyoByfU461zfiW7eWZpreH5bKUmeMrlmiYEPx0+6Tz+NehWSlBSPJoX9q4taI5PxBc2WoaRNKjFJVBUMp5YZyrH1PUGvKdNmH237O7D5bjOSegI7V6HrWmwW13cxxSmSNG+UH+JWGQw+vXFeZx4i8UR4UFGb8OO9cqveSfY9GsklDl7o9asriO3YsXny8aoEVfvNx1z0wAa0rWBt/mSW67gPnJOcA8c/nnisTTUVGV2ysY+b5m3Y4613nhcW19dzQhRKSP4IychiOS1Rh4c0rdSq0/Zx5jB1jTjp8EssSbg5wxTOFJHTB9a4G+nMoHmABlADep716r41hktIgJS0gdCrqRj5geCOx44rzLUbVBAGXL7ievb3+vbmumpT5XZE0pc8OZmBdysu3AG1jyAev1qG1mBDoTgHkc8bhSX4KEkMWIbBz14qvgtvdM4HPWnFanLO6uznPGExKIhOGdsHjnB71jrlQi5A2g/KK0PFTrJcwEAhTIPrVAL97OQuMr3OBXsYRWifI46fNUbLEe4OqgBWORxzgf5NKoZjtVskjGcZpgyiqzKctx15xT152phhtHJ7kV2o8xmhhvX+VFNzH/AHD+dFPQNTIfiZ2GcAkE9KUAbdpOOR1pHwxfK45NCNk7uRg96wNzV0WXDIM9Gr0CItJYExOpaNwWB6nOfX6V5rpf/HyikYDdK9K0lvItDuHJxyORivBx8LTPrsmrXpWN2y1OS7j8l1QMMHIGcgDocVeKJcTwQNuEzEjcQRlecce2K5yKeUAGBgB1JGcnn1q+mo+a37xVMmD8zHofSvObXU+ihC9uU9D8LW6FUSZ2j2/KCDtzweh/mDXW3cptk2pK06xchdoXqP4TgD865Dw5aTtZRSebIitgkbgQzYOSM/Su3FrN5eZZVZcbSMA4/Hua78L8DujysZZT1ZHFOzITcMm7+6pBJye56GpIGCFiolMSnIAHIPoKjjtWhCKzYLEqCRnHofaliZGcm4BSRTtBHyhsdCPWqt5nl1Ip6xNR9jIpYHDjBIziqbCONxIzDYeDng59aoa/dy2Gn+bG/oVwADn096868QeKL66tj5LrGSd2Y854649DjHHtROaje5WEy+ddXi9D1Wa/gDqglEUhxnPIODjj3qW6Ecybo2+bG1S2Rt718/2/iC7YqssxeIZJPucZGT06A/nXV6F4hvYtqQzSTIWVnR33FeT0J/LHtSWIUlY9KWSOnG8Zao74hUMe5SCo2sSw6Z6k+mau27bZ5oWTkkEY/hPoP05qhJfW9/p4lUkocclemMev1ohuH+1ojq4YDpnkjvzRGfK9NTxa9N633Rrq0cUiy/KBN94Zz82ev9KUHE5i3NsHIO3jnt71XuZbfzIoDKGjk5VsfxA1PKCwEiN0IUknO0H/AOvXW3rYwu5JNkk0AcA43MFJCg+vaqsXzW8aOGRw20cZwQf8Kux4eOIE7iARyMfWqSwvbTSKfmSPEqsfTkEVnJ8ruFrxt1RbmViYlZSoDA/dwCPrTLnLrI4AVypIU+noafJI8kSnYDDuxnt68Vi3urxpNEIiJHc4C5+YnoPl/Kib5G9dGb4aMqiVuhiwxW93HcTOjeereYX53L1AGe3QfhUei3Muoyi3eLfLb4kRyevYj8qti8guJTHMoWVm5GR6f5NXpYIbe4MsML8R5Zl5JA5/E1zN6aM9V1LXTWr28in4kP2SyllD7W2p16MO3Hr/AIVxStJvVVcsm75Vbj+X5V1GvXkk0U1u6lVj5+YcsDgge+MkVy2mshVcIMjO1lGdvUHI+nc1yVWpTsdmDi1Td9zrPC0zBnSBDJnJeAgAkDg7D6+1VtQumt4WuG2vC6l4nVSxdD8p3A8qVB5HqK1tE0+GfyHJEBYAK6N8wfqGx654rN1eJLDxJMLqBLa4lcb0XIQ8ECUf3o2z8w6qfXGa7oqSpJnPGUXWaOO1eASaLC+FjurVzbyAH5mTAMbH3AJH4V5aqhPEIA+Yhjj34r1fUdiu8kczfZ3RonHXy5F/hP8AeAOcH0Iryu4Ty/FW0425Nc7Wr9DvatZ+Z6ZokkZT98ZNpXjAzzxgZ9K6nw9qEtlfOkciYxjyQDlgewx3H9a4rSJPNUJk4CjnHH412XhqdLa+gb7PJKowjGFyGbuM4p4aPvIMRC0HdXLvjIWctshjjOCobzHRuDjnrya8yv2kDBTuYhd2B34/lXpPiyJnlWaZ7lI3wBGuCioR2xx1wOa4C7EWZFQsqYJAA5BHT8P8a7cRvcyw8f3Zxd2jNwCAW/Kq8uYlYDJBUjBH3ePWr+oK/m5O0Drw3b+lZl6zkMerfz96xhqcuJ9xM5TWX8zVLdEIxuLZboKhXKgtyM55x6elR3hM2qkryAvP51MeGcbiGB2+uB3r3MNG0D4jEyvIeI3ZkVGBLgE46DHNSu0shUnI3KFBHcDjP61E2FQooIIzlvUelSjhSAWUKNufWunQ42aHlRep/KimeWv+3+RopX8g1MVuJHw5zu6DvzSEZV9v3enP9KWb70m4ncW4OOaQEb1LAisjpuW7Bgl9FgYIcDNeiQTCWIhVYEZxjoDXnVl82oRZP3m4wK9C0hRH80w5xwp4zXjZnbmPocl6luzgkIcEncp4I6VdEQ2lQV2rlsHqeeRW1b2L/JPEgUFSxGM/nUF5ZIJxJhtoyApwCT/hXkKN0fVUat3Y2tHcJFbI8s0MaIULJKQBn27Z/wAa7rS7uaW68hLqeRAPljnALE9cnA4HNeZ20V1gAMsm/s3BAArrtEn1GxufNa3EYXaSUYMcYx+tdVDVWSFiqfNC/U7Wa6VmePdl8cBxgd8n+VQLJFdwZCMWGWB9wPU9BmqN1cHUbZJEyj/Mu4nB5O38/wDCoLO5RbmSJ1WMq22MbuGGOS2f0rSpJ7M8Hkun3J9elLaXJbTyRqWHEmcq+OcHivMNRtpbWxmEkqBnO5Ah3IxB4OexP/1q9XvJbWRJInk3gAfcPI9AFPauR8RaXaNKxtJCJHQBo3XaD6Zx6Y61jVV3dHbgMQqfuNbnnEqIvH3IpfvHGT07Vr2jGK33S4jjRSp55U44xj14qpe2y/Z4wuZJCS2M9D9elWLcK6lC+6UgIQO4IyP61hHdnuRqc2p6b4eeN7GCCWIB5SWxu6AgEnPvWxe2UbRRKwlyGIDqNzEdTn2rl/B8chn3Txs0UWNgOdvp+td3O23+EHapATdjdz0ruoLmWuzPl8d7ld2MLTbeZHjW7VZBwFYLgjPQ4roIAER0UqAeoHOAR1qOyt1azjxncnocHPoacU2k/NkY/wC+TW1O0Dz6r5paDooy6q6sjN/fVcZYe1JLBO80onbzFPIGehqC2dUDxqcANyM96txsSiFT8x/lTm+ZWFKbi7IikV2UIGYDIb/Oa47xeJnuoDCsalvuF+GauviJuJcDay9/Q+1R6hZRXTRebGjKhLZxnBxwf1pun7SNjbDVvYTuzynS9SddbjF0reah2qMcnI5zn39elekT3iRoz2o8yZVDPbhuV9h+Fee6tp8Wna/IQcEoeQfu5U85/Wte2uZrnS5JCGWS3DSSOnBcBFbJ9Qen4ivPSlBNHr1oxq8tSJiazdrI0Jjcxqx2hf8AZBOM+nXpTEle1Mc7kHJ7Nznvn14rn1vHnvI3uFOG6K/VeT/+uut0t2N3CsxiMTjapyAFJziuZb6nppezgaumS3SvNc2rB02iR7ZuXA6de3XP4UeL9Vh8Q6ftdHhuLDDBtmGQngg85Uf1p0bwjUluRI67x5Mnl4R85GCM8EZ65qXxLZW1yjXVpJ/xMol2HA2pdR5G6OVexHqOMV6NK6p6M47x9pGTWvTy9Tg3vPPtpLZ3VXiJfeoxu4AJx6nArhtfSGLV4JIWyhBUH0rsdZhieBbqzUrGHO0NztwfuH8+vcVzXiWM3WnpNGoDW/zH1PPI+vNc7vzWZ6k4p07xRqaPeENHnOWPb0r0jw1fxWo3hhv4wMdcdM+/vXjWnXYAjY9+hrqtKmuZgr2sxecchFYBwB7dCPWnQqOnLQiuoTjds9F17Uku4ZMMEUhVVeScdz7dv1rz7V5WhuZjGo6FNindg5HFT3mpzwwKJYcSZA5bjn/9Vc/dXzyuXk8tc88DHP0rsnU9ojGioxVovQz5Fxuxu56g8flWNqCjy2GeOcE9a1Wk3Alxnjj29qw9akEdsxJwB60qMdTzszklBs5Fdr3NzIxJw20CrJDBmGQF/uioLQssTDA3yNvPoO9WIyB+8ODyRg9ya9+lG0Uj4OrK8mPzHv2oWbB+/jrxSqmY+FJJIGD/ADpMlF2ZGWAY+1PbggBiCPvZ9fpWpzs1sD+9D+dFQeSn9/8A8doo/rcVjFlP75+ehOfrnikIxubO7HftUknzSlfuqzcsR2zzUbEbWAYFQ3ykjkisdjpJI3KTRynIwwGR0Neh6Xc+YkZbL7evPOfUe9ec9FbcDnPb/PtXX6JM0luvzcHk5PSvJzOHuqR9BkcvfcGew6H5a2QEikKzbFHQn3P5Y6d637zTYZbHNwg2hMsy4PHbrz14/CvOtN1aQ2RhkJkVV+XB55//AFVft9SmDtsafylyJAOS3oD7c8140ZW0Pp1hpN8yZ0NhpsEd3GWaSNiw3g5xjHHArqAi/wBlYiutgQExqowT7H1HrXK3erahPcQpHb7GLKSY8ZY4yMeuOMZ6V2umyzyaeFkhUMw2FiwJU/QetdNGTinZmeK54xUpGHd3US2CkljMhIfBwGyOufUHpWVqd5FbxlLxnjnfksWOCVXI/X8OK6O5s1aFVll+VjgqFAGCf6kYrkddt4TDIZvObZbssZUH72eD6e1KTb3OalyyYJryT6kkShTGI1PmgnPODtB7GrqzyXFsTJOty7MdqZG8heMbvTOeDXnE+oW9veNJIjBUYGNCCN3XqR6ZrYt7yR/siaXc5Uj5yX2seMlCpx059DWSu9dzd0UmrEQnnfUJonDsrNhl7qR7dcV1GjaXZiaFDMMSMPkORngnNcjeapNJqSm7VknCKF+TBOOnP0PWrond2EjOcn26Hv8AWojaJ1Q5prlTsew6fbxrallQdMKTwoxVpbsSWsnlKWKr90+vT+lc/wCEtSaax8q5ClIwFDBuv5966K3Um3cpg5z94Yyemfau7Dy5tD5/E03CbU97k1lPFHbiBXCOig7Dn065pxmRN7NyMgA8gk1SvLS4+yILa7a2mZlCsUVjjnjB4x2qPUJESUqqsFLHIJzt/qfrWzdt1scrSctC4rrKpVFypbeeBxz/AFxUs7FMAHJblRj7vYCs+wWKGBtrMGblT2wf6d6lnmBugz5Kqdo7Z9DisJS91K4/Z3loaVggjxGrfeXjaelJeoREwwd2372MZ/8Ar8Utm/yqwDBcZx2q1c/MjiT7pUZAPSu2m7RsjnkmpNnl/i+ze4dbrBdkYrjHIHdf1BrE8L3vl3HiyyhmcxG0JiDAHgA4zn3wMCuj8YwTQ280sLYjxmRM/eGOD9a8/wDDN1/ZPjdEnXdDcqsLL0B34I/Dn9a4pK0tT3KDcqL1MXQbmWRFmuQD5rbkJ6f3SP0rrNPjaeHfFL8ykMjE49B/OuGhgls/FGo6dKW2QzuqLzhRuPFd5pCLB5Rl6BsBeoyenFcNVcs7Hr0581Pm6nV6SkzpJDeBJopGARUbLMxOO/OeM/hVLWNJvLybUFmkSO9sBxGzbZp4scMTnDjPHY8d67DwtotrdW6RX8UW6Rgz5bH0YHsR6ijxzoNs0MT21zctfWYxDHIxk4HVfM64I5GSRXrU6PNST3PMWNjGvyL8jxmG7eaUwFm8mZsmMcfPg9B6+vrisi+kAMyuR5ExIxjH0IFaOuRSpdM0kZQlty88g+n1rEu5o5RJwFZhzz0I9K82ejaPf05dDN0WNpg0SEedG5XGa9D8A388T21v5cDpkgPtyw/HsMZrySC/a31hwCFduRj16GvoXwBpdvBp63E8W6PYGAQEuc9cD6Vni5OjytdT5zF1Yzg0+mliHxndaXb2wXULNnAUv50R5jAx8o7jJ6HNeeC2j1Pznt2kCmNriOSYAb1yfl45zkYHrXdfFa1trjSp20uS4jYJgfKV3AnLA5+lcHoepRaTo5uZo/PumjEVmjHHlKp3b2xycHOB3710YN+0jeTOHCud7QZg3hZGEbh0lXIdSMYOeRXKeJrrzttuGXc5+YjsBWvq+orGkkjOzSOSc/xMT3/WuU2s0jSuQXyMjGcCvWw1LmdzDNsVb3EyRSpZ0j+UDA6/nU0SA+UuQMEtgDoo9aZtcI3IBY4PuOvP6VKAdjBDgBMfXnNeutD5iTuIOrMqbg2SCRSqBtYKGOBknP8AnvUj5IYHLFVCrtXaAT/+umIAGwyq0YJBIzycU7akXLfkn+8fzop/ln1k/KijkY+YyJCSxy3GTz+NHyFV6hdp6HqKa7YkJB+78vI70mBtQKcseMCsUzccNwTcMA5yT3wK6Hw1Mfsu0Z54J9K5xsCTj1wO9bHhuTbK8ZJPzdBXDj481I9bKJ8uJV+p3No2QAn3wB9DgVv2oeF02KMSY69DnmuVjchQ6naO4HSt/SLg3E3kNGJBtJ2k4BPr7cV86rJ2Z+g0/huek6NH56FoZI9rcYXC/Pj5tueRj9a6WGV3ZoribcGTKyFx8rDp07Vz3hi9WFVgMMYmBwoZQQOmcDqcV0UmoWgjEAijiK8gL0Yg11wlGKueJiXJytYZlLsgvF5UwwzBuQduCwH5Vz+sRx3rPblXYkFgeQp59OnpW7LNA6iaIPujkJ+7kkHjBJrN1BWuo3ubZlVwjqUBwUOQSCa0lBSjdo5YtqR474zhNteyx4wgJUfnkfTrXK/bwZSZxI8+Sxk3Els85JNd/wCO7ZZLqW5hQmJwrZHOG29D6V5lqu6LZLGdzY6CsYRvKzPTrS5KEZrc6BtSmnktY7gsygbkdlxkf5Fdbo6rNHEoK4LZIz3/AP1H9K8q0/Wrie8t7e4mkeNW2orNwnPQenJPFe1eAbaWS1Ytsxuw2RyODn8MVniKbhJJmeCxUalJ1F0O00GGSCwCqQXOEyV445J/GustfkWaM7QSAyqBxgjp+dYWlw/O5iTEZOR8wIz14FdHZEMjKWViOCCcc5regrO/U83Fy5m2xCnnWY+bB2glscfUVy2rXL2rLLcKksYVtzbsNjPX9B+ddXbMUCrkeWF4IH3uQMH0rmfFmmSyWzMTt2o44HqOuK6J3av1MaSXPaWxn6Rqizh4xIu5MEEDOQR09hzVwXqTz+WuCUH3lOfpXleiXclr4st7Pc3l7T5eBjkHJyP6V6bBGpljKD72ZA/bJP3fbvXBJyb1O6dOMHodZpjFkTG4ggkZGOfpV5wXVhuBLAZz+tZdlM5eXA2qMAD1445rRfaGUBi3mYIHv3r0acjyai945LxTBuhPmSKoPOcZA+ntxXjfiPz4r+PDN58YVFI7YA2sPrx+Veu+NQyzEOrjK/KATzzjt6evvXlvxCjmtbnez4A2SxEckDrj8K5cQ/eZ7WAXu+ph63fm+8QR6oF8trpQZMcDeAAa7fQGVkjbf8+7cpbpkdj39a831clLtSmfJdt6A9AT1x9a6fR7t3hTy8bm4Lf3a5at+ZM9GnG8HBHsXhfW/s15tZ4wp2rHhd2GJ9fSuj8asz2EdysvmiX5GiZeeh44/wA815NoEkSbJb2Rcglydw3Zx1x3r1zRtS0jUPDhkkuf3oUI2FYkH1IA4r1cFVcouD+R4+NoexqRqxT7bHhfieSNrucnaHHBReAeK4y4VEZgAADwK6zxVewtqbFUUHcRwpHy54ODXM30iEhVQgjtiuCp8TPeppxjbyOA8VK0N4sqHBHfHeu98LfFbVLO0tLaYxNHA4wSuCV7j8sVyHimI3ELMVAYciuYtTuiAY4CN+NelToQxNNKa2PjcwnKjXk1sz2bxN8Q5NXthGkgt1LEud2d47CuDvtZQqI0LSMOhrnVChclG5BC881KBvKbeWbkn09q6KOAhT0RwvMJxVoKw6d3ndZJck5yAe1KqlY2QnGWBPPAxmnKRztYnnj8uacAxRioxubazH9BXoxjy6I8uc3LVi8EMXyQMZ46+1OQGRs54U55/lQdzNj5eABwOMD+tKv3XdsBfukZ/pVmTFRlCplCVGW+pPSiM/LGquFZjknqQPpSYQwqqAmUE5zyAOgH9aEwCpUcrnfjvTJNHZF/z8N+tFQYH9wfnRUWKs+5kTkebNkHCMSMd6cg3bXRQgJ47mmsVE247gCxH1601SwQddxbHNZI6LEkKsMBsjAJJq9obmO7UDsvU1nKBu+Y/Lxk1e00lr9cHCchRWGJjekzqwcuWvF+Z6BYlJIRkDzMd/SrVhGYZFlGM5IGBkHNUtJcjawHI/EGtyYhozHCOc/xdA1fLS3P0alNpadTp/Cd5Z/a4RdRlhuweM5J6c56Z/lXousWkEltE2n2RwvAkjUAn6+teM2kbpBtbcCepB616d4K1a4h08m4inmRQMgpnb2wCa6MLO96c9jhxtKSaqwfyGQzwrbzPchjklWCdVxxyfUVd2RLBcwypI7lUY4IG7sCD6dKz/FtxI5FvFZSQmTG55GUcDqRg8jb61LZWn2KeCOW6Jjnj8lHc4Vcrlc+wOMfWupxcU7bI5Jx5ld6XOY8U2QNtI8fzJOA6RhejqMEcfTNeQ6rCGhYBVUqd4988GvXtQkudNnjju1aKV3zC6Y+TBIJx2z6GvMvEyqZWKJtx09PesG+WR1RpylDl6HCXEHlXCzLkFHBIr6C8GvCtlbyzFyp2lAo6AcnmvD7lFkTGMN1ya9K8Nao0GhQomTmMZOT6Y/pVYmfMotnJhKPLKcF1PUfDeoRGe8eJWUM5YKFwcYxn65Irq9Nn82aWNd2QykcdcgZz+RrxnTNaMU8EMUh3uz44GSWIxz2r0Tw3qscsxLTCVgxGxOoPOcY+tZ0Z62Zri8I0nJHTtG4mZRtXJBGf7pOTTdViW4stgAbjbtJ68Guc1zxFPYXSxxw7n+ZeWGOM8Y98VJe69DJpQldwvnLnAbGAen4g10c9m0cEsLVtGR5HfLLb+J7KeM4dJ2QNjJHynt+FepwoBbQoo2A7Ruxgnr615Nq12H8URSNkH7QHyO4P0+temwXAZLdfmZkO0sT0zjH4c1yaM6qyasdROSFcplZMjbzgVcilmFtFOrIAvduw/qKzLi1d7MsXIX5SGBxnB5/CtPR7dktGhaOMrKCnzsQM9seh/xruop81nscU0lG5yni673XLRXBURupQlScxv6Y9O/oa8+8Wp9s0Mup3tbymGQ8EsCMqc/mPwr034gWJ820uEtlebaV2LnBx/LmvN5XeaS4ijGUkRiyNyPl5I+o5rHEXjLlZ62A5ZUk4nmFxceZZPE+TLEwKknsBXReHJ08hS4zkZODXLa4PJvX2fxgkV0PhWcLaR7x8rLyKwqq8Ezow8/38oHWWLRQss0bFtpzkDPGMY/+vXr3h/XbRNDG2/tYbeRTuErbSB3P4djXkGlaj9ndm3eXAylSm0HIrtPh5Np1tf747Rrm6YgIphWT5s8fe6fh71vgpcsko9TTG0lUptyWxS8fWNpPE9/ZyrdLJPtgKAkAYBYb+hOecV5bqDSMyb0KkdsV9E+OdN1XUtPRnuChWRpCiQquB9ck+2a8I1+w+yNja4wOrHJ+ldGNo8srlYCqqlK19Tj9RjEiEHA6964naYNQKjjdxk9jXe3kS7DgfnXI+ILbawlCgFfXnNXhJ2Pns8w9pcyIouWjC5LHgMT2qVQQeWbbtbYRgZqKBg3ltksxUH2FS4/dowzwSCT3Ne1HVHyU97EpOFIXgdCT6kUAjao3HGMkD19DQQcnLfL1Y/hSjkcK3zHdye1WZMUEbdoySRwMdOaVACT8u5Spyc96Rhh0wDuIHfk5oLfLtKkBQVIA6mqIYrMxjZiAARtAUYp2CoZdwBYAEdaVUCNiUnIj3AAZy3pSKkgEaBVAO1j06kdTS31E2W8z+iflRVzEf/PxF+X/ANaijkXcOZ9jmp8GV1Ynh8nHQU2Nl3gsTgZ49cUpZ0NwsfAc8jHXnNHy7iXHJ6gHBJrBHUIpJUk/xAcfjVuxbbfRuVxuJFVUOSc8EnnHSrFmMXsAxj5sdazrL92zeg7VI+p3enMsaq+0cngf/WroYLtY9rsmC/OccnPf/wCtXPaeqeQGJ+7/AA5ra09GuPK2rkKOuM18pUWp+iUmmkaglLSo8auSQPlIHNeh+DzKtlLMybgx27QxO5umD27Vyem2HnoikZz/ABIuPfmvSdLi/s6xSGPYwByZP4UOOp9fatMPG0tTPFVV7PkJrmNbeIzXkaRyONoYPubGQdgX06ZJrn9Yu5IdOuLW+USXLXCzxgjI2dD9Pp7V0TiJ5owGEwg+Z5G4Jdvug+o9q5rXrKWW4naaeRUmGUZxlsgjn68dPT6V21HzR0PPoxTl7xxetXZupk2b5lUkbm+YkEdCfaua8SZmMhZVJLFi3A3V1+qQ+RBHaqy7nKuqJxn6n+lcZrA+d8psOQCqngHp3rkqaq57NGmpao5C+tyoUjr6V0/hptuiwu3JwVGB/td/yrPvYuFDY9/firuhx7tLtlUZKsQR6nJqJzbgZzoclXmNrTrN1uPtBQPsIYHqDg55FdJ4Td4Lgb4pvLLNtCnJJz6e4BFY0LeTcC2BIDYb5D0rb0Rjb64FnlODIo3kgdevsK0oXumbSk3TdzqNdtFv7Wea28xVj/eYf72RjHU9K4zWE2Wph3sIlTcpHbPUH6V6hrGg+fCUt22stufMZMkt8wwDjr0NeN6q00haNmcAHHI6V04uHK9UcuCmqisnscrfS+XdRHrslBUg5yM8/wCNes6Z5T21s6Sn+Bs9ceoP868e1uJ4lLHna3Hsa7/wjeNc6Vbojjcxz6nAznH51xJ+7qTi4LmZ7HHKlxYeVuyShI56VqW0C+QY5EO44ZSOxwOc1y2lKUji3SZfZnnGcnB/GupsJ5J7cGNWKDIbK7fwz2r1MLJTeqPArpxVkYXiaQqkcazbuoY5wVGa8ukmSG+Vo2ZcuUJYH5QwKke/XrXqfiWJG8ySR4kfZ0zk8dQe1eR69dxs77dyhucj17Vz4tcsj1csacbI848bxfZrsDPAyAfX3rU8IRxzWuZSQQMgisjx85kZJSSdwHbjPFaPhhvLt42xuwOlYVEvYR9TqoJyxs0uyOgRvIwuN6A46EVuaFaas+pwJpVyLS5lYBWcgBT61mRPHJIm/nk4Ud69P+FdnG2rl7uMEtsEbkjamc9vWrwlH2k0meji6vsaMqltkOvdF8fw+bLP4htpztDbCcbgeo+7xjHTFeZeJbO+UTPqSK1yx5c5IUe3rX1F4gtRDIs9vBCXC7SWGCcnBwcdcV4j8Ybi3UW8VtG0MgLeYGQhj0wc9MYr18TQiqfOm7ep4+V4915JcqV+ySPGr9QoIA6d6wNYhDQ8jqCK6SUZzyCB+tY+rKOdo98152HdpDzmF6bZyGnsfJaIgfIWBbPI/wAmrIO4Nu3ZDDapHbvVeADz7hcZHmDH41aDc9cucDPpXv0neKPgKqtIkK91GMEngZ+pp20hRhmYdyPT0pMthd24Pk7u5/KpFKquOreZjGMBRit0rnM2OT/W4VNuFJy3I45pBuATzON2f/10rbBE4VjlmP4gdefypCFLhmzgAKw96b30MwVmQQlXwzEtyeAemaQokkzs7jy1JyCeoHtTeqnI+f1HQDvmnzjLSGQoQRuIB446ClqM0/tSf8+A/M/40VBh/wDY/wC+j/jRRzSDliYUwJlbk5JJH0FN3AqMAYznrTmA3vtGDuIzn9KABwuCozjHpXOdbFcgrIG+8MMSB0qe2I+2QliOXwPXJqFQAQ235R8vpmnREq+TtDBxjPbntU1NYtF0naafmdpDIQoX04OeRXfeF7H7TAojbG5sbD0IxzXnkD5ZckcAHp2rvvC8ziOMxvjOVA7den1r5eqtT7+E26SaPQ0WPT4hHEiNvOScfdX0HuSKTUZ/LtY/LEhX70cacGQ+30x1rGhuEETr5mZNuWY9BjtirVnLHHMbi4mDJECDjJLHso+vpUqWqCK6s3tIEzLb3V44M8gYwxE4VOuXI6nA6E+tQeIZXiton3qjBwwExKqASBj3IBJxV3TJ5ZpnuJ0CS3CALGyYKqOgHeqXiG2sJoTkF5pPlRiN3zZyQB/n8K9CCvG6M4tKp7xi39tDDbTySukwgChJExtwO4781w+smK4O5HzuO48/drUudTvFDRRh13IVJwCGHQ1jOyBV8wKGU546muScm32R6dGDizNe18x0KtkZIweex5pdJcR/ard8qUIdB65Oc1qNarthu1f75K4XjYR6j0NY2pSxw6jHdxcISYpVPbPQ1lKN0XVnfU21vd0wJCsQQce47Gu0i1Gy1HWotsP2eF4413Rxg8heucdDXm9o6C7w4ByCMg+9dV4auVS6jtpguyVgPm6/h6VVCbTs3oKtCLjfyPatNu/tU12FlZhGFRiRgY5O3A6mvEfGnyatdxRADZIxHGOOv9a9aRriLSfstkFjzlRg5JJJOSa8z8V6XdjVwDH8+MsF/iz7V6GMnzQsjystUY15M841nDwuAc9a3vhtOr20URfayE/MB0Gec1jaxGUaQMMHB4Hal+HsuJJEzgliCcZ4Ned9lvsz0MYlzq3VM92haRrUiLbIyfLgNyW9Afz4rX0e51JJmSRDHFkAmXgAfTp+NcV4Wu92oSJNcFI0jLbRjDEEdPf/ABNen6IsNzGJIbh4SuVOTuUjHPPP54rsw0XOWmh4WKSpRaaucx4kffFIA8crqRgoMYOc9fTFeU6+/mxlgFUMQMjGT15r1jxRpkBWSRSYpfXdhTj7p468V5Z4qaFGeGIbt3Kt0IPcenepxEWnrsehl9rXR5v4lRpbVQRx1B+narvhyUBI8kdOKk1S33W5VvXIPc5rP0YFEZc4wcN7Vk9aduzOhJQxXN3R1cMq+Z8zfIh3Yr0fwX430nQpbg3kc0scgG1YwMLx05/nXkcEpa4SELvcnAz2rv8AwppthJcyrM1vcTKMJE5+Vm54P/66mjiJUJc1ysdiaU4OnU1R2+sfFI30IXTkljG7HlzbQqjAweOfWvNPFGrm9DhneSVmy0snzM30Pp7dq6PW9JsI7Z2kWzimVfuQLySSMjrntXGrFHd5eMACPAkBPQk8Y/Diux4qddctzkwVXDwfLTjYwpFCn5xnIrK1BV8tmIJxxzXQapHJ5zF4fLZmxtx0Ht+H86wdZlCROvCxKMDuTjnNKlG0hZtUvSucXEm64uCuDiTGD0qyoG1wBwzgbunNQWWfIYg8vknsPWrURO5MEE8YAHc969+lG0Ufn9aV2ySMM/3SFdwB15xTkUCHHyglhjPOMUkYBTEi/Kpx6c5pY2UgfKxIzt7DP1rdWOZsUuT5Xy5wucdi2aUB23MGTLnJJHTFO4Zolfaq4GcdF55z70xsMxI4XdztHGM02QLtHmOEO/P8Weg7n86a+3cioF2qCu4fxe9K+HiDoxUhiOnUU7egO4dB8o75PrQl0GW/Nb+7H+VFTeSP+ekX5Gilbz/Id0c3KV3vkkKCcHHJNIOVYJluc7vUU5ifOdjtJBPBOBzQmQDx82MfQd65kjrDK/MMErkd8ZoYkqSRwWz9KYp4Yg5yePpnpUgU4wchG5JA4NHkNOx09hJvjiODyoH1rqLK8MB4bIIxyeAfWuQ0iUi0j2nleK10uEjOSOT29K+ZxMHzn3eXyUqSudNDfXkhX5+B1A4H4+tdBpl6Ga2aWVjHFhsYwckctg9e2K5KxWSQFiyJtwQrdf8AIq5Je/Ktvvj2k5DAY5z0Ldf6VzqHLqz0JVIPRHoFr4gW1YiCRvNzlJZMMQOcj/64qvL4jknGI0jBLlgMcKT1wa529ghjihEM8Vxdtt81oC2Ih/dyeG+oqJIrg6ukaSRId5HK5TIwe5HYVr7XlfKmcqlD4rF+WRbmSVmYIqkYA5LAn/PFZ8kMDOshceWBsI989/arNwVVlljCrucgFGyGXPUd+Dximx6ebqS5SHYuzBKZHJH1rS/M/M9ChUjNXTsjLvLl4y/ljEfTB4waxJz5sLxsDkggZ57V0+r23k2UZDlpmYh1b19gPwrm5Yn2lwMoG5OOlZSi09TplGLg7FTR7nfujc/PHxyOa6qxv1s/LlUBpByu7rnmuCMnkaqjDgOSDXW2iiQx/mOOKmUdbrqc1J+0i4vpoemeG9d1W9tRLZqvmjhzIePbjrUEt9d3AuVvMNLklTnBHOMDPvWdozSQBktZhAzqNwjf5nx/CB3PIp/iS/d3EMtuLZwCvk4xg4GSff8AHNdGvL73/AOF0Eqj5UcV4yjZIGm45+X3rD8DsyXczKcfMAQK6TX2hurCVdwDKMe3+Oetc94LBS+ljXBaR8Yz1rHaDNZRk6kb9D0PTX8lvNkUbcffIyefavU/DEbajHlZXVlQIEt3Vd/oxPf0/nXniFY9IxIxjh3Z55Oe+B+dWdF1C4lv5rHT/JEEuELs+1RnowJ6GtKM/ZzWhhXpSqxdtD029sBbWc6xRC1QE7pJBuY8ep5zXiHieGCNZvKD+YHOWfG7k967LV9Xm0QJbXZ+2M4KJfSzNLGuRn7mMZH9K4XVpfIikkSOWZGYh7kjhz7eldOJnB+ReBw84Xcne5yt8rC3XIYY7jvWbj7Pqrh+VlXPPetydozFj5myDzjH0/GsbUgJbVHUjzYjw3fjpXPFG1ZP4uxfltmSa3kRgVcMQw9v617NpNnZ6dYWcNpZyedIiyzN1JO3JOf8K8U0SVtSuYIA2wnIyecZ4Jr3vw28l3byQ/YzHCsnlpIfvIoCjH5Z+vtXlY6XLNJnk4qd3eJ5vrGq20mn3qT27/bVYeUVOxVOTkn1P5Vm6Paq96fs0j7hHHLIGGOcnBJ/ImvSfHmkW8eg3MyWMarwFxgZIPLDHtXCaPHpw0i81HUb/wCz7gkaQJzLKFxkAemec12YB8z8jKhVjfmMrVmXzZXkcM7DJCtkLz3P5mvP/F8zLGIVcsWPlgf59q7nxNrEN1cLdSIkbBSPKTgKMcCvMb65N7fNO/EfIjz1Az1r3MPTcpnJmeLXJydRojYYQ42ld2AcYqaPL4KAAY/IDvUKqSUDHHPryam3/wCsUfdAODjtXso+Um7kgBCgSHaD2PXvzTo33TKnmL5Y5JYcD3P4U0Y3kshLd1xmlTd5aZBKk5yR1x6Gq9DFigHywGKfNlunJFAPzBGXCuQSqjHFCqfvcAjAwRnNIrFGDFgT03Hnt+lN6WEK7AurtkYGWIwPwFMwuSzDauc4FLn5I40GTncT3PHSkwScuMCRsY9KARs+bb/8+h/7+UUbR/dT8qKdpCsjlpT88qkdXOB0NGcucnA25PbPtSzLudiuSc4z1ye4pFwXBP3etch3DsEhTwu75yM4xinxys/locmIMdqk8Djt6UNEUMW7GSoYHIOQfWmKBtQHO7HQU7Cumaujyfu2TOdpNbml3UEGpn7VAZl8tioB+62OD+dc1pMoF8Af9W4wB9K2L3EN9E8Z5eHdjGO5GK8bE07TZ7+Grv6ukujOrt7yNbSWFfmkd9w2jjGPXrxTXWIy5UhRgHGe3pVax028vriFdMQXKlV8wJywJOCMdcD1rvb/AML2nh3SJH1KRrvWLgrDBboCVgUtwSf7xGfzryKq5Xqz1aWKUbJbs5yzkaECTDLHKp8lugIyVJB+oNEskst/k7iNrH5yeQFrXurfUdahtBZ6SLS0s4/JCKp2Abtx5bnOe3vUthpuy7vI7pwTFbzPgc52jt+Vc0316HTGrp725i2d7HZ20UTqTKs6OpxnA7/Uf4131hpRntp7vTSGdLgiPOcMu3knjHr+VeZanuRQ4wAq8EfXFe3fCli+k2rskjMI/NI2/eXvn6np9K9PLX7SXKzecvYwc4nneoXmJme4Qq+QrRkDBA7H0NYl+RGsqBflSXcO/GP161v+O54rnWEkhh8ppB8yYwVbJHJ9cVzF3vWHDKV2uSxPVs06tk2kenJ+4pbXOO1XK3CsvHz+ldNpco8hDux83PHtXM6mA0sZDcl+R6VsWDtsCjG33rKa91HPh7upP5HViTYPMjndXUYU9N9TLJc6hZuQ00EDKPkkYM0pHoAM44+lVtCgN5MsFvFNKSpzEULr68Y6V0Nha32o3TadbxRWzBMSyytzEmc8HPetKUHK3mVU92V+xwepgxrs3Egjr6/5NZnhxympS4O3kGu+8SaEn2uaFcRr5JkjZhjzGUgFcD7vHQV55aj7PrGDxuBGT0zUzg43Rc5KSjI9Fgup5IY0DZQHywmeT6jit3Q7Z49RhW6crbzYEm0cgZzye3auT064WIBiwyG7evbNdTpWpxEwyBvmU5yXxyPc+/b0zU0tZpsmotLJHs+oW2h3OjpFdxxyJ5fzKSGUYHYf1rw3xfplpYXs0ekPKI5CGeHJxg9Dz2zXryeK/C7+H3gubuwZ4oxGQcb93c7evPtxXkHjS6tLi+/0CcGNU2LjooySFHqPevaxcoSp6WbPJymM4zkpJ2v12OEuEMUjJndvPFUkClpUIX94OM9iPWtW5t5CjSY5ReSOmc9PwyKzLxd0SyYXLZ3Yb+IV5SgetXs0Z+nXA0nW0lYkRgnPpXvXhfxLp99FHDZXschkjWV4wu3bgYbt6mvn/UYcxEnqy7q5bTtRutMuZBbs37t8hT/ninUwCxWvU+Sx1T2Uj6h8bXEmraM0yXESabZo0hYNkEgcnj6YA968SF3D5Kmdj5SrhY0OMtj37e9Y6eJbqK1ltIY1jt2ILpvJUnOcc+9ZdzPPeM4k4Qk4C8A/WujCZZKldHnvHOHwkmtahNeyEAnZ/EwGMn0HtVTYqsMOAMYGOpp2zcgYOvOQRjkAU8fLnIALd+4Fe5SpqCsjy6taVR3Y+DdlflBdQXyT0H+NKNqxqpA2ghyQeSKdgElS2QFztxjk/wA6QqrRxlBgD8z71ujlbuPEmxJHQ5J4wB90Hvmgkjy17jkY7g4oUrhmckx/TqaG6ocEhfvcciqJHhQZ9u7HzZyPrSAFbdpQSWB2A5GST14+lLgr5pDNnuvqD79u1N4by4Q6cHezAdPUZobJQA8xFBsGCpY/xGmBsO4G445XHJJ7fhTyDIi9RlzhSf4uOv4UhcearYVei8fzNDGi3vk9W/I0VNsH/P0v60UWZV12ObfmTnJG5ge1LGQEySCq5GOmTSuAzFi3G/nJ6jvimtt+bOQADgDoBXKdYZ/duOOmc9efrUgwZlTdtUgAntTM5Zh16t7dKeMSSREkj7vHXvQIRZTGYHxhVc5welbc0gmuSxPAVRn2/wAmsR0G0x4GTxk9v/r1veErc32t2tqEaZn+QKOScVw46DtznfhKiV4M9O+HV3ZN453x5hcqkNusIIUgJ85P1xXsmsW8MduzwRhrpBuQt1OPQn8a8z8OaJ5eqLNpkceIkCOEARlJ+VgRkkYIPNeg+JtQvJla2srGUs8qQeb0ADAEvuHTAz9a+SxSU2pfI9SK99commWepT2afaYZbZCMsyn7zdNxB6f/AFqbL4O0uOKF7q4uXu5laJZVfLHKn5Qo46DNU79fFM2sRWl5N5FrK7wRtCMhogCysRzjGfzrRt9Ou7fxHaHUL6eW1hZZVLcb3KkHp0H1raMoR0Sua2mve5kuuh5X490KfS3+zOu+IDcLgLhWHr/Q+9el/Di4Fl8OFvDiRgvzg8BFXpn8vyNUfi3NEfD+FdQXJKjvg5zk/gKi8LXEg+HLW7SLiJsgtwsgz1/SuzKXaq+mjserSbr0FfurnK+IminCSp/rJRvYYxjkkEenpXG6ncjyiPkJwc7T0NdTrbxnzBI+ZVG0DnkYOPwPFefa1dGNmU854PtzWk9ZWPTrSUY36IzWInvYlHQc/jXRWFvudcbdpBrmtHKzyyS9drbVrqLORA6kHnH51FVcrURYCanFzXU7fw+XtYrhLa7NorR4MijD5/u/Q1rW2ow21tCltd21ndEbQyKXLAnJYsO3sa5fSpWhDyW3ly93EnA/Wuz0iC51GURzwfZH5ILRgRSA/wBzHLduldeDlJ+6tzStyxu5GPrEEd7pzyRTyTXNrHiZGYgEFuHTgZUjGfpXmut25tblJFAJQ7jg54716rrCfZryzt7uRxEZGiE0cLxbCchQS3JXJHHYV53roaSadJkAcHOQPX0pYiOuq1Ji+aFltuNS6LLE+8bDyCB/nmtPQ40uZWF0szE8AKMBT15rldPldY7hVDO0AMgwM7R6kenavXPAum21xbrE5A3goeCWbgEsD+IH415mJl7FK3U4MRimr+RTuorKYRCa2toUaPK4j2nOOpasO4tbHMLLHBOqqXdYZtkgUHvxj9K9D1/SYxNLG8DbJo1W2lX7qrnk8dMYOc15v4otI9O1QfZvMUwr8zHkZwMkUoYl7Pc5aeIlL4WS6ZZrcyRIs4+yyZdZXPyhFyWU44zkYrm9QG3qMI3BAHX6e9dT4XtWt9A8/UGSO0cO8PALF3IyMduBk+3TrXN6vJG8z+SCsQYiNCfur2/H1r0/spnoKpzXuzEuxtiYbs7BjOK4eQj7bcNjK+YAB9BXXazcCCFiSCMZNchAC0aueVZ9xA9TXo4ODvc+SzWqpTshyAErkH14PU1YCq3J9MEA02BHIGASzN27D61IpA4CEAZ5Pv3r0UjxJsc5JkLcKM844HtUjYG8GTauM7u5qPgkZPGPrk1JtQiQhct5ZwQeOtUjFizEhUyAFZQwX9BQ292cng42gDgYoOJH2x5w2CDjv/hTcAgITlz2xn8v1qyCVcbDEg2xuQck88f0ppGcMW53BQPUUEnaGGQq/KD65708q6k4+RYjyR6+9CJB923yw4XcQzIBz9DTFcDgbgGPI6fhTnYDfs3EnqehHY005CFSwARR/wAC/wDr03vcEA3HbwAFbHXrTnKkOo2rubKqhyRzTMqHZirBdv4k96UcIo2gtt3DI9O30pJhYv4T0f8ASipPNH/Psn/fR/xop6DuznZARI+5huxkd8c0wkegyQVOaJOZHJ3YLEH+lGN0jZyQOBXNc67D33MG7fIMmnNgzDaAFztIHfvTcCSQED7wGRmk5EbDuPm696Yh6nG5lI479+a6j4ZtPF430W5iikkjS5jV32nahJ9ex74rlsAb8LyQD1ya+j7/AMXeH/BvgTwp4Z0VBd3jmG6uPs7ggudrkvgHfknGOowPQCsMTHmpSj5CVX2c0kjofGmm3mkaq+q6SkcssgUNER8gYgqTx3PB+orstO1CWV4Y4/Kjfy/mjcc/KcEH3HX8aj8VyQ22hw3NxA2LmTMQHLKQpbp6AA/SngZsJboIXMu2ZWwOAwGRz0HGfxr5meGnTavselDExqx8zYimmltx5Yi8wcBwuQKz9UuoYpzZrIZLiRAAuAcMSev4Cqttq80k0cdnbyMZFPlzBPlLDjBB78ZrH1PWYNOTyreaGXWZ2CySsRi3JGMsfXPQVrDDxaUnv+B0UKc5vlRlfFPTd3hfSrWSNEe6vQJCxwVQAs2Pb3qpc3Ntp+jwQ20LND5eWDNuG/H3VPpj8jUWuWtrZSRrJqM91qGGRzJIZSR6gdAO2BXOa5fKsJR0liYgRiHgcjufT6VrTpexvfc+rwNBQpqLd+pzOp3byiWUrjdxx6D3/CuC8UXezPzZboK7DU5tkb7wRg49K8z1ib7ZqLIn3E+8c1phaXPUTMM5xihS5Ua/h+Qw2wLHOSSSK6XR1m1GeOK2TcWbHLAZ/OuX0pVaywpydxAxXa6PNbWVpYRO7iRw0g+QYZt2MZ9MD86jFJKfmcOExtSnRjGPY7DQvCWq3Vgl02ILd5CC0k3LqMjKgdBnvU5vvEfh186fefaIA2QsZDbfwPfGK6Lw7qNtf20S3izi2UHAQFQAuMjJ4zn+tT3ukJcahJ/Zce+QMro8n8CZ5x2xyT715kcTOE9XoU8bObal/wAAl0rUl+INvcW7ziDVYGa4i+X5GONpQqTkEYH4V5Frd1cPeTrcoYpdxR0AwAw6gD610d1NFp/xG1GazIC21zHLGUzjcAM/XnNWPirYRtqMd5Z+X9nlQFAD87epI7c17bm8RQUuq/E9PBy5Wl0auvI4LSL59K1uK6iRJIpQ1vPEzYEkbjDAnsMGup8Mas2i3yywSy3MMTPCvPLIDkH64rh9SjYbl53dxS6Bd7x9mnkESkkbvSuGvR9rCxyYyLhN26n0vpV3bS2istxnzRlPkBwDzjHbGcV5v41srh1kubnfIZVdIu258HCjHvXO2GszxvE0l4vl24L7YkOZcH7v5d6l1HxTeX7QyzMiW9u7PAi8MCV4we2P51z08FytSbvY8qDqKd0tC7r6Q2Wn2tlbTIzIF82MjEiyhfnU/wCzx19q4q9k2qXLAJ3PQ1PqN6fLea4kVZZWZtqEk4PbnoP/AK9chqmpGYGKBgATz3C16tKk6ktjor49UKfKnqV9auRcu8asQv8AEf5Cqij5lzHhd2MZwc01VwdzHPHcdGqYfediOTwPb3r2adNQVj5itVdSXMxQgDdNzlvmPZfYU4ZVMBgM8n1NIGYfKuQq8kdM0BdsYzjAOMHgk1qczH/wxqduDnGO9PdhvZFXHOI1HbPrRE/liOVRukifcEIyPx/EU7ayldrk3DMSxHRaq1jNu7AENtznHTaDyaBuC4A+fO3aOw9M0RhUkV1YhQMg96avWNEABZgcjqf/AK1VqSOOcSAOCqHJK9D2p/llVIMbKFXcxz1J6fpTASCygALyd2OOB0p0hOzyzy7fMzHrn0poTFlcu4ULtUR469RnvURVdwVhyG4xzxUhC+bskIKqQWHqO4pC4Kb87W3ZUdwtHW4LTYUuztIyjB24Hpj1oP8Ar1AkPK4z6kjkfSkbCthwxLbR19OtDnmY+WRtOVHXHPWhgaPlv/cj/MUUze3/AD0k/Kip0/plWZzso/ey5I+XPI7+9CkD5mztC8e5NEmRKwAxn5SRzTt2UwxBDDGAOmPSsInUx+1Sw6dMA9B05ppGYgqjjAJJ9KTGS2WwN2B+VKpwzjHIXv25qtydh/ypJI5B4GMY9q9K+G+teFdH1bTNS1VWaa2bfIskZkDHHBXtx2rzUHcyLkZOST60xWAddxJYdhwKTVyZR51a57J4i+LkeofFK11yKC6l8OWaGAWbEcq4+d1XpuJ5wfTFdtpnxK0DT7W9Y6h9psiVS2gUEyuoyRx0BA2g596+ZFZlCsSSxOfb8aBgEksVweSOCa462EjUs07M2p2hp0PadQ8dajqsfz3BtbUElbaByoGeck9SazI9Vk3r5b459eteXwXl1EVCvkHoGPSrqaxcJjCK2D1zXE8HUT0PpsJm1ClHl5bHp0OpiFlkL5kbgNv5AB71U1LVQ5coxdsAB25xXn51+42HbEBz696r3GoXVzhZJMKF3lVNOGDm9HsbVc9ppXjuaeu6uWQxwEM+Dk54Fc5FGAVMaklurE9TnmlC5VWI+9ycnrTyUcvtOVRcLnpXo0aKpI+dxWLniJc0jT0As8UqAjdk4Pbn+ldVAIJbKOQTBZ7YDYjcMWJzgcciuHtrprW4ieIEkcOAeD7V0Vjfxy/MpVhxx3z9K8/F0HzXPQwU41YqN7NHsOg+JNMvbxbrxG00LyYRI7dN0a/3wV6jdxyK6HxTrtnpPhyd/DtzBe3t7IYUMBJWJO27HTAxgcV4umpu8e1pMscKCByK27vxRe3Vtb285jS1iUYjiQLlgMbjjqfc15qw9NNs9anl6co80rou2VmLTSftM1zuu5pC0hZstnHJ9cn+lZmr6lNdkCSRiU+Ud+M5rPe/LA7mJx3NUJ7xSOeRnt2FdEZPltE9vnhSXvML1g+0kg4OcHoa5rVrlrZlNs22Vm+X2zVrUNSUZCkbm7A1g7jMTNLy33VHYeld2Gw99z5TNMepStA24PELqpWSPcQcFgM4qVvEbojJErHJ6Hj8KwdpZTnOBjJ6c5xUqj5wwT5VOM4rrWEp3vY8eWNqWs2SS3c85YyMckfKinqTUCR7GBCFio7+tTLuWAMSB1XA65NHtwMct6e1dMacY7HHOq5bjAAIQnoeCerUAhXyu4nduTP9aUheNpbAXnjvngUhJI3Zzk8A8Y96om9xcNglmJJBbHfrSogO471YqRlz/Sl2gPLjLADnHc9/wzSIQAvTPU5xgU7EllSTBIVIBZwFTux9fpTGOEIRxhep/vE8Gi1JDSKiht4PMn8Iz1H5UyMIqNggneAB7VV7mdiTaC0K/eIGckYHJoUMcjChSQp45GO1IWxIS5Ukvk49u1CMUO6TliTgZ6H1P50XTESKz8ZJBIPJ6kE4/lTgwScGQBmViSoPeowgELkHOW2deTg/yoBwyYAXJ5LeuapCsADgPyitnDE9etPbaWUoM7u7d8dsU1+Q2WBWRiQcYBHPNKwzGz8Z3DaAeg9aF2QhypGSzNyIV3sQfvHOAP1FNCOYXUgKV+dm9fQUjfvGChgAMjJ4ycdPelZBLHK8TERgqoBPUf5GaLXAs+X/ALS/nRUu1P8Anuf++KKmxpc55/8Aj5I7n7opIiFEWVOQT71amgUSyNubcpBBzQ9su9RufHlbuvesEdNirECXQY7E9aVMbAT1k4POelWkt0DZBbK4we/IohgUxqCT8uVHTpiqTEyuTuwQ33R+Xc0wHn5CdxY5zVs2yDygC3zIc89cnFDW6hQAzfKCQffpRuCKrjaZSSMqAqikYZOACeMZ7Dmrn2WPnluGXvSeQjxAsWzJJyc+lK3UZUYhQQgy2MMe2SacW5UnoWA29hxirS20YVOvzSYNL9mjdS5yMgsAOgPtQBWXhCzLld2Bjv8ASmls+YXOGAAPHXpxWg1qkVvCVLc5ODj1FRJbI0qEs3OSeetDEioAreUFYBmzuzTs5bcB8oOFHr9atLaxmJ3JbduIoe1jDsAWwGAAz04oQiopIIUcqo6ge1RodpDp8m1cgj+tXzaR70Us5ATPXrUXkKV5LYC9M9cGk0mrMuLs9CS21Oe3ZWJDnI5IwatR62rBt6vweT/jVI26+bJ8z/KRjn1pr2yLFhSw3DJ/OuaWGpy1sdlPGVoaJl59b38IrsB04xVOe8uJ2VASqkbiAcmkaBd5UMwBKocelOFuiI5UtktsznoD6VUMPTi9iamMq1PiZUUbRIxwGGAMnrmpUwzfNghcNgdBxVxbSNZyo3YRPlH4UlvbowQEsQTuPTriuhaaHG3fUqMW8uSTsV2gYzmp5GOwDcdudwFKtsjqAxY53DrVkW6yXC7mY4j456YFXEiRVxvDPu43gkd+mM0rM7RtgBVYgYI61PJArSSEs3K5PPWk+zIVTlvmJJ/Wq22JsVnKh2JO8KQQB3pu0gFc9sD271dFum08kEt1prWqBiAWwevTnmpuNFY7TkoCsZAByeSaUJhSHfaNuW9WyRwKsvbrkrubCjA/OnLAou41UkAc8evH+NUSV5G8w5ClYSeATzkAdaQhfLMasScgscd/SrC2yB35bhsdvf8Awp0Ue2SMgnPXt2NPrYT8iKU7XYhW4AAHr/8AXpE4kdpFLsVLnnHP/wBapjAv79tz5PJ560LCrmPcWPPr7CnexNtCAZUAkjd1HvU7RmG4XzFDPu5X/GpGtUVtoLfeC54zinNbJ5sa5b5nyTnk84pprYllcSbJIzgEgnGRkAc9vxpECLbh5Dlt4Ax6d60rm0iiu7mBAQnnsvuAG4A/KmfZkd5N5YhZcY6Zz9KdraE30KaEfaEZlHlmVvk/PH86hU/6GmeBv2kdsgf/AK6uGBSTIS275fwoitY0O7Bbau4BuRml1K8yx5Ef/PtN/wB8mirXn3H/AD9TfmP8KKOaIe//AEz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dermatophyte infection of the nail can serve as a source of recurrent tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34468=[""].join("\n");
var outline_f33_42_34468=null;
var title_f33_42_34469="Perineal proctosigmoidectomy";
var content_f33_42_34469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Perineal proctosigmoidectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 687px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures depict the basic approach to the perineal proctosigmoidectomy, also known as the Altemeier procedure.",
"    <br>",
"     Figure A: An incision&nbsp;is made through the seromuscular layer anteriorly,&nbsp;within 1 to 2 cm of the dentate line.",
"     <br>",
"      Figure B:&nbsp;The incision is extended circumferentially.",
"      <br>",
"       Figure C: The prolapsed rectum is everted and fully mobilized. The peritoneal reflexion is incised.",
"       <br>",
"        Figure D: The mesorectum is divided. Full-thickness, nonabsorbable&nbsp;interrupted sutures are placed between the divided bowel and residual cuff.",
"        <br>",
"         Figure E: The anastomosis&nbsp;is completed.",
"         <br>",
"          &nbsp;",
"          <div class=\"footnotes\">",
"          </div>",
"          <div class=\"reference\">",
"          </div>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34469=[""].join("\n");
var outline_f33_42_34469=null;
var title_f33_42_34470="Gliclazide: Drug information";
var content_f33_42_34470=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gliclazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/58/39844?source=see_link\">",
"    see \"Gliclazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Gliclazide&reg;;",
"     </li>",
"     <li>",
"      AVA-Gliclazide;",
"     </li>",
"     <li>",
"      Diamicron&reg;;",
"     </li>",
"     <li>",
"      Diamicron&reg; MR;",
"     </li>",
"     <li>",
"      Gliclazide MR;",
"     </li>",
"     <li>",
"      Gliclazide-80;",
"     </li>",
"     <li>",
"      Mylan-Gliclazide;",
"     </li>",
"     <li>",
"      Novo-Gliclazide;",
"     </li>",
"     <li>",
"      PMS-Gliclazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F176186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sulfonylurea",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F176150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose must be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Recommended initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80-320 mg/day (maximum dose: 320 mg/day);  dosage of &ge;160 mg should be divided into 2 equal parts for twice-daily administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Modified release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maturity-onset diabetes:",
"     </b>",
"     Oral: May consider conversion from insulin to gliclazide therapy in patients receiving &lt;40 units/day insulin. Prior to conversion, discontinue insulin for 48-72 hours with close monitoring (&ge;3 times/day) of urine for glucose and ketones. Patients with ketonuria and glycosuria 12-24 hours after discontinuing insulin should not be converted to gliclazide therapy and should remain on insulin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F176151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: Initial dosage adjustments are not required; however, as gliclazide is primarily excreted in the urine, dose reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F176152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment:  Initial dosage adjustments are not required; dose reductions may be necessary; however, as gliclazide is primarily excreted in the urine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diamicron&reg;: 80 mg [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, modified release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diamicron&reg; MR: 30 mg [lactose free], 60 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11233826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F176127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia. Administer with meals (modified release tablet should be administered with breakfast). May split the 60 mg modified release tablets in half; however, the 30 mg modified release tablets must be swallowed whole. Modified release tablets should not be crushed or chewed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F176126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5977967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F176184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hypoglycemia (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (3% to 4%), angina (2%), peripheral edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (4% to 5%), dizziness (2%), depression (1% to 2%), insomnia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin disorder (2%), dermatitis (1% to 2%), rash (1%; includes maculopapular, morbilliform), pruritus (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (2%), hyperlipidemia (1%), lipid metabolism disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (2% to 3%), constipation (1% to 2%), gastroenteritis (1% to 2%), abdominal pain (1%), gastritis (1%), nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (4% to 5%), arthralgia (3% to 4%), weakness (2% to 3%), arthrosis (2%), myalgia (2%), arthritis (1% to 2%), neuralgia (1%), tendonitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Otitis media (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (4% to 5%), rhinitis (4% to 5%), pharyngitis (4%), upper respiratory infection (3% to 4%), cough (2%), pneumonia (1% to 2%), sinusitis (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Viral infection (6% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, albuminuria, allergic vasculitis, allergy, anal fissure, anemia, appetite increased, arteritis, arthropathy, asthma, balanitis, breast neoplasm (female; benign), bursitis, bullous reactions, cardiac failure, carpal tunnel syndrome, cataracts, cholestatic jaundice, colitis, coma (hypoglycemic), conjunctival hemorrhage, diplopia, disulfiram-like reaction, duodenal ulcer, eczema, erythrocytopenia, esophagitis, fecal incontinence, fungal dermatitis, fungal infection, gastroesophageal reflux, GI neoplasm (benign), glaucoma, glycosuria, gout, hearing decreased, hemolytic anemia, hepatitis, hepatomegaly, hernia (congenital), hypercholesterolemia, hyperkeratosis, hypertriglyceridemia, hyponatremia, hypotension, hypothyroidism, impotence, leukopenia, mastitis, melena, MI, neuropathy, nocturia, onychomycosis, palpitation, pancreatitis, pancytopenia, prostatic disorder, renal calculus, renal cyst, retinal disorder, skin ulceration, spine malformation, tachycardia, thrombocytopenia, thrombophlebitis, tracheitis, vaginitis, vitreous disorder, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F176130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gliclazide, other sulfonylureas or sulfonamides, or any component of the formulation; unstable and/or type 1 diabetes mellitus (insulin dependent, IDDM); diabetic ketoacidosis; diabetic pre-coma and coma; severe renal or hepatic impairment; stress conditions (eg, serious infection, trauma, surgery); concurrent use with miconazole (systemic or oromucosal gel); pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F176112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular mortality: U.S. product labeling of sulfonylureas states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS), have not supported an association.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia; the incidence of hypoglycemia is least with gliclazide compared to other sulfonylureas (eg, glimepiride or glyburide) (Canadian Diabetes Association [CDA], 2008). Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients and in patients with endocrine disorders, severe vascular disease, or impaired renal or hepatic function. Hypoglycemic effects (eg, dizziness, weakness) may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is contraindicated in the product labeling due to the risk of cross-reaction that exists in patients with allergy to any of these compounds, especially when the previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in hepatic impairment (undergoes hepatic metabolism); dose reductions may be necessary. Cholestasis, jaundice, and hepatitis have been reported rarely; discontinue use if cholestatic jaundice occurs. Use in severe impairment is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in renal impairment (primarily excreted in urine); dose reductions may be necessary. Use in severe impairment is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: Use during periods of stress (eg, trauma, infection, surgery) is contraindicated. It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Formulation may contain lactose; avoid use in patients with galactose intolerance, glucose-galactose malabsorption or Lapp lactose deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary failure: Loss of efficacy may be observed following prolonged use as a result of the progression of type 2 diabetes mellitus which results in continued beta cell destruction. In patients who were previously responding to sulfonylurea therapy, consider additional factors which may be contributing to decreased efficacy (eg, inappropriate dose, nonadherence to diet and exercise regimen). If no contributing factors can be identified, consider discontinuing use of the sulfonylurea due to secondary failure of treatment. Additional antidiabetic therapy (eg, insulin) will be required.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F10466084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclic Antidepressants: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GLP-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with GLP-1 agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. This appears to be particularly concerning early in the course of combination therapy. Quinolone Antibiotics may diminish the hypoglycemic effect of Sulfonylureas. With longer-term combination, there is a greater risk of hyperglycemia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F176143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may cause hypoglycemia and/or rare disulfiram reactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid chromium, garlic, gymnema (may cause hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F176132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during pregnancy is contraindicated. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F176155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F176133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potential for neonatal hypoglycemia in a nursing infant contraindicates use.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F176134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals. Individualized medical nutrition therapy (MNT) based on CDA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F176120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of hypoglycemia, fasting blood glucose, hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ; renal and hepatic function (baseline [all patients] then periodically thereafter in patients with mild-moderate dysfunction)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F176124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F176135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azide (PK);",
"     </li>",
"     <li>",
"      Azukon (IN);",
"     </li>",
"     <li>",
"      Azukon MR (IN);",
"     </li>",
"     <li>",
"      Beclazide MR (TH);",
"     </li>",
"     <li>",
"      Cadicon (TH);",
"     </li>",
"     <li>",
"      Clizid (PH);",
"     </li>",
"     <li>",
"      Diabeside (TH);",
"     </li>",
"     <li>",
"      Diabeton (RU);",
"     </li>",
"     <li>",
"      Diamicron (AR, AT, BE, BR, CH, CN, CO, DE, DK, ES, FR, GB, GR, HK, IE, IN, IT, KP, LU, MX, MY, NZ, PE, PH, PK, PT, TH, TW, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Diamicron MR (AR, BB, BM, BR, BS, BZ, CH, CL, CN, CO, CR, DO, GB, GT, GY, HK, ID, JM, KP, MY, NI, NL, NZ, PA, PE, PH, PR, PY, SR, SV, TH, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Diamitex (MY);",
"     </li>",
"     <li>",
"      Dianorm (PH);",
"     </li>",
"     <li>",
"      Diaprel (BG, CZ, EE, HN, HR, HU, PL);",
"     </li>",
"     <li>",
"      Diaprel MR (BG, CZ);",
"     </li>",
"     <li>",
"      Diclazide (TW);",
"     </li>",
"     <li>",
"      Diglucron (TH);",
"     </li>",
"     <li>",
"      Dimetus (TH);",
"     </li>",
"     <li>",
"      Glicada SR (HK);",
"     </li>",
"     <li>",
"      Glikamel (ID);",
"     </li>",
"     <li>",
"      Glimicron (HK, JP, MY);",
"     </li>",
"     <li>",
"      Glizide (SG);",
"     </li>",
"     <li>",
"      Glubitor-OD (PH);",
"     </li>",
"     <li>",
"      Gluctam (EE, HU);",
"     </li>",
"     <li>",
"      Glyade (AU, TW);",
"     </li>",
"     <li>",
"      Linodiab (ID);",
"     </li>",
"     <li>",
"      Mellihexal (AU);",
"     </li>",
"     <li>",
"      Mezide (TW);",
"     </li>",
"     <li>",
"      Nidem (AU);",
"     </li>",
"     <li>",
"      Oziclide MR (AU);",
"     </li>",
"     <li>",
"      Plecaz MR (MY);",
"     </li>",
"     <li>",
"      Ranclazide MR (TH);",
"     </li>",
"     <li>",
"      Reclide (VE);",
"     </li>",
"     <li>",
"      Suclear (HK);",
"     </li>",
"     <li>",
"      Sunglizide (HK, MY);",
"     </li>",
"     <li>",
"      Unava (PY);",
"     </li>",
"     <li>",
"      Xepabet (ID);",
"     </li>",
"     <li>",
"      Zebet (PH);",
"     </li>",
"     <li>",
"      Ziclin (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F176111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates insulin release from the pancreatic beta cells; reduces insulin uptake and glucose output by the liver; insulin sensitivity is increased at peripheral target sites. Reduces microthrombosis by  decreasing platelet aggregation and adhesion, and by restoring fibrinolysis with an increase in tissue plasminogen activator (t-PA) activity. Antioxidant effects include a decrease in plasma levels of peroxidized lipids and increased erythrocyte superoxide dismutase activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F176129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of action: Modified release tablet: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release formulation: Rapid; Modified release formulation: Slow and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:  Hepatic (via CYP2C9 and CYP2C19; Elliot, 2007) to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release tablet: 10 hours; Modified release tablet: 16 hours (range: 12-20 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Immediate release tablet: 4-6 hours; Modified release tablet: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 70%; &lt;1% as unchanged drug); feces (10% to 20%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/42/34470/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elliot DJ, Suharjono, Lewis BC, et al, &ldquo;Identification of the Human Cytochromes P450 Catalysing the Rate-Limiting Pathways of Gliclazide Elimination,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2007, 64(4):450-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/42/34470/abstract-text/17517049/pubmed\" id=\"17517049\" target=\"_blank\">",
"        17517049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/42/34470/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8785 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34470=[""].join("\n");
var outline_f33_42_34470=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176147\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176186\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176150\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062829\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176151\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176152\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076300\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233826\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176127\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176126\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5977967\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176184\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176130\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176112\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10466084\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176116\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176143\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176132\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176155\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176133\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176134\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176120\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176124\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176135\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176111\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176129\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8785|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/58/39844?source=related_link\">",
"      Gliclazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_42_34471="Clinical manifestations and diagnosis of fibromuscular dysplasia";
var content_f33_42_34471=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of fibromuscular dysplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     David P Slovut, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     Jeffrey W Olin, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34471/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/42/34471/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromuscular dysplasia (FMD) is a non-inflammatory, nonatherosclerotic disorder that leads to arterial stenosis, occlusion, aneurysm, and dissection. It has been observed in nearly every arterial bed. The most often involved arteries are the renal and internal carotid arteries, and less often are the vertebral, iliac, subclavian, and visceral arteries.",
"   </p>",
"   <p>",
"    Disease presentation may vary widely, depending upon the arterial segment involved and the severity of disease. Common manifestations are hypertension, transient ischemic attack, stroke, headache, dizziness, tinnitus, and pulsatile tinnitus (abnormal swooshing sound in ears) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of FMD in adults will be reviewed here. The treatment of renal FMD and the general assessment for possible renovascular hypertension and stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26631?source=see_link\">",
"     \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fibromuscular dysplasia (FMD) have involvement of the renal arteries nearly 70 percent of the time and involvement of the extracranial cerebrovascular arteries (eg, carotid arteries) approximately 65 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately two-thirds of patients have multiple arteries involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among adults, FMD is more common among females. In most large series, 85 to 90 percent of cases are in women. There does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be a female predominance in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, it was believed that FMD was a disease of young women. However, older individuals account for a large proportion of affected patients in several cohorts. As an example, in the United States Registry for Fibromuscular Dysplasia, the mean age at presentation was 55 years. In another series of 70 patients undergoing treatment for FMD of the cerebral circulation, the mean age at presentation was 62 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with renovascular hypertension, FMD accounts for 35 to 50 percent of cases in children and 5 to 10 percent of cases in adults under the age of 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. It can also occur in older patients either in isolation or in combination with atherosclerosis, but the prevalence is not well described. FMD of the renal arteries is bilateral in 35 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. Approximately 65 percent of patients with renal artery FMD also have carotid or vertebral FMD, and, similarly, patients with carotid or vertebral FMD are likely to have renal involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    FMD of the renal arteries can be an incidental finding. In two large series of healthy potential kidney donors, for example, FMD was found in 7 percent of catheter-based renal angiograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/12\">",
"     12",
"    </a>",
"    ] and 3 percent of computed tomography angiograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other arteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracranial cerebrovascular (eg, carotid and vertebral arteries) involvement is common in patients with established renal FMD. Data from the first 447 patients entered into the United States FMD Registry reveal that approximately 65 percent have extracranial cerebrovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/2\">",
"     2",
"    </a>",
"    ]. Older literature indicated that carotid artery involvement was present in 25 to 30 percent of patients with FMD. There is often bilateral carotid involvement, co-existing vertebral artery disease, and, less commonly, disease in the external carotid, middle cerebral, anterior cerebral, basilar, and anterior communicating arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/2,14,15\">",
"     2,14,15",
"    </a>",
"    ]. FMD may also be associated with intracranial aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Carotid FMD is an uncommon incidental finding, occurring in 0.6 to 3.2 percent of patients undergoing cerebral angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. In an unselected series of autopsies, carotid FMD was found in only 0.02 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FMD of the visceral arteries is less common and typically involves the celiac, superior mesenteric, inferior mesenteric, hepatic, and splenic arteries. In the lower extremities, FMD occurs most often in the external iliac arteries, although it also has been described in the femoral, popliteal, and peroneal arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In the upper extremities, FMD is identified most frequently in the brachial, radial, and ulnar arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrous lesions are classified into the following categories based upon the arterial layer (intima, media, or adventitia) in which the lesions predominate and the composition of the lesions (",
"    <a class=\"graphic graphic_table graphicRef54161 \" href=\"mobipreview.htm?15/45/16092\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medial fibroplasia represents the most common dysplastic lesion, accounting for more than 80 percent of fibromuscular lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Angiographically, medial fibroplasia is characterized by the classic \"string of beads\" appearance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef85822 \" href=\"mobipreview.htm?35/50/36644\">",
"       image 1",
"      </a>",
"      ). This appearance is due to alternating fibromuscular webs and aneurysmal dilatation. In areas of aneurysmal dilatation, the internal elastic lamina is absent, which is possibly the primary defect. Total occlusion is uncommon.",
"     </li>",
"     <li>",
"      Intimal fibroplasia (~10 percent) is caused by circumferential or eccentric deposition of collagen in the intima. The internal elastic lamina may be intact, fragmented, or duplicated, the latter especially in the childhood form. There is no inflammatory or lipid component.",
"     </li>",
"     <li>",
"      In perimedial fibroplasia, large parts of the media, in particular the outer zone, are replaced by collagen, with irregular thickening of the media. Total occlusion may occur with development of collateral vasculature. \"Beading\" is present in this type, but the \"beads\" are less numerous and smaller than in medial fibroplasia. Aneurysm formation is uncommon.",
"     </li>",
"     <li>",
"      Medial hyperplasia (rare) is caused by smooth muscle cell hyperplasia without fibrosis.",
"     </li>",
"     <li>",
"      Periarterial hyperplasia, a rare manifestation , is caused by expansion of the fibrous adventitia; collagen extends into the periarterial fat, with accompanying inflammation. This may be associated with idiopathic retroperitoneal fibrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of fibromuscular dysplasia (FMD) remains unknown. A variety of factors have been implicated. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic predisposition with a reported autosomal mode of inheritance in some families [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hormonal influence, given the predominance in women of childbearing age",
"     </li>",
"     <li>",
"      Mechanical factors, such as stretching of smooth muscle cells and trauma to the blood vessel wall",
"     </li>",
"     <li>",
"      Ischemia of the blood vessel wall due to fibrotic occlusion of the vasa vasorum",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease manifestations may result from the following mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemia related to stenosis",
"     </li>",
"     <li>",
"      Spontaneous dissection and occlusion of major arteries",
"     </li>",
"     <li>",
"      Rupture of aneurysms",
"     </li>",
"     <li>",
"      Embolization of intravascular thrombi from aneurysmal segments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, disease presentation may vary widely, depending upon the arterial segment involved, the length and degree of stenosis, and the type of fibromuscular dysplasia (FMD). The condition may be asymptomatic and discovered incidentally or, in its extreme form, may present as a multi-system disease mimicking necrotizing vasculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Occasionally, associated aneurysms can rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical manifestations of renal FMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is the most common manifestation of renal artery FMD. A decrease in renal perfusion activates the renin&ndash;angiotensin-aldosterone system, which has direct effects on sodium excretion, sympathetic nerve activity, intrarenal prostaglandin concentrations, and nitric oxide production. These ultimately lead to renovascular hypertension.",
"   </p>",
"   <p>",
"    Thus, renal artery FMD should be suspected, particularly in women under the age of 50 years, in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe or resistant hypertension, which should prompt an evaluation for secondary causes of hypertension (including FMD)",
"     </li>",
"     <li>",
"      Onset of hypertension before the age of 35 years, which should prompt an evaluation for secondary causes of hypertension (including FMD)",
"     </li>",
"     <li>",
"      A sudden rise in blood pressure over a previously stable baseline",
"     </li>",
"     <li>",
"      A significant increase in the serum creatinine concentration (&ge;0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [44 to 88",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      that occurs after the institution of therapy with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) in the absence of an excessive reduction in blood pressure (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19398?source=see_link\">",
"       \"Renal effects of ACE inhibitors in hypertension\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A systolic-diastolic epigastric bruit",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical manifestations of extrarenal FMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of extracranial cerebrovascular FMD are usually caused by critical stenosis, aneurysm rupture, dissection, or cerebral thromboembolism. Patients with cerebrovascular FMD may present in a variety of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonspecific manifestations include headache (most common), pulsatile tinnitus, and lightheadedness that are severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent.",
"     </li>",
"     <li>",
"      Symptoms more suggestive of brain ischemia, including amaurosis fugax, Horner's syndrome, transient ischemic attacks, or stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/14,15,30\">",
"       14,15,30",
"      </a>",
"      ] may also occur.",
"     </li>",
"     <li>",
"      Carotid bruits can commonly be detected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with lower extremity FMD may present with intermittent claudication, critical limb ischemia, or microembolism that manifests as painful, cyanotic toes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/20\">",
"     20",
"    </a>",
"    ]. Rarely, iliac dissection, occlusion, or aneurysm rupture may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/31\">",
"     31",
"    </a>",
"    ]. In the upper extremities, FMD may present with weakness, paresthesias, or upper extremity claudication or critical limb ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/21\">",
"     21",
"    </a>",
"    ]. Physical examination may reveal diminished pulses and cyanosis.",
"   </p>",
"   <p>",
"    Chronic mesenteric ischemia or intestinal angina may occur when two of the splanchnic arteries are occluded and the third is severely stenotic. Occasionally, mesenteric ischemia may occur with superior mesenteric artery stenosis alone, although extensive collaterals in the mesenteric circulation generally prevent ischemia when only one splanchnic vessel is occluded. Patients may present with the classic triad of postprandial abdominal pain, weight loss, and an epigastric bruit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/32\">",
"     32",
"    </a>",
"    ]. In rare cases, the stenosis progresses to total occlusion, which leads to acute intestinal ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF FMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with suspected fibromuscular dysplasia (FMD), the diagnosis is confirmed most frequently by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or duplex ultrasonography, and less frequently by catheter-based digital subtraction angiography (DSA). DSA is the reference standard. The performance of noninvasive techniques varies depending upon the involved vascular bed and the expertise of a given institution. As examples, extracranial cerebrovascular FMD can be diagnosed with CTA, MRA, or duplex ultrasonography, while mesenteric FMD is usually diagnosed with CTA.",
"   </p>",
"   <p>",
"    Patients suspected of having FMD should first undergo a noninvasive imaging test (such as duplex ultrasound or CTA) to search for FMD. The choice of test should be based upon local expertise. If the noninvasive test is inconclusive, the patient should undergo DSA provided that the pretest probability of FMD remains high and that an intervention would be performed if FMD were to be diagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for evaluating FMD in the renal artery and other vascular beds is catheter-based DSA, which improves visualization of the arteries by eliminating background soft tissue and bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/19\">",
"     19",
"    </a>",
"    ]. However, noninvasive imaging techniques are usually sufficient, and therefore DSA is not commonly performed. The angiographic appearances of the different pathologic lesions are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      String of beads appearance with the diameter of the beading larger than the diameter of the artery in medial fibroplasia",
"     </li>",
"     <li>",
"      Beading, in which the beads are smaller and less numerous than the diameter of the artery in perimedial fibroplasia (and smaller than the beads in medial fibroplasia)",
"     </li>",
"     <li>",
"      Concentric smooth, band-like focal stenosis in intimal fibroplasia",
"     </li>",
"     <li>",
"      Long tubular areas of stenosis in intimal fibroplasia or periadventitial fibroplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When DSA is performed, a resting pressure gradient of &gt;10 mmHg assessed using a pressure wire confirms that the lesions are significant.",
"   </p>",
"   <p>",
"    There are several noninvasive imaging modalities that also can be used to evaluate FMD in the renal artery and other vascular beds, such as duplex ultrasound, computed tomographic angiography (CTA), and magnetic resonance angiography (MRA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal artery duplex ultrasound can detect elevated blood flow velocities in the mid- and distal portions of the artery, the most common locations for FMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. The diagnostic accuracy of renal duplex may be improved by examining the more readily insonated segmental arteries to identify abnormalities of intrarenal Doppler parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/38\">",
"     38",
"    </a>",
"    ]. The accuracy of renal artery duplex is unproven with intrarenal disease in FMD and is highly dependent on center and operator experience. On ultrasound reports, we often use the following statement: \"there is increased velocity (peak systolic velocity of 450",
"    <span class=\"nowrap\">",
"     cm/sec),",
"    </span>",
"    turbulence, and tortuosity in the mid- and distal renal artery consistent with FMD;\" this wording is more accurate than assigning a diameter stenosis (ie, 50 to 70 percent) to an artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     CT angiography (CTA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multirow detector CTA has excellent diagnostic accuracy for FMD of the main renal arteries, although the sensitivity decreases when FMD is only present in the branch renal arteries. In one study in which CTA reconstructions including multiplanar reformatted images, maximum intensity projections, and axial images were evaluated in patients with known FMD, CTA detected FMD lesions in 100 percent of 37 arteries studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple detector-row CT scanners, which offer more rapid image acquisition, variable section thickness, three-dimensional rendering, diminished helical artifacts, and smaller contrast requirements, may gain an increased role in the diagnosis and follow-up of renal artery FMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     MR angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRA offers inconsistent detection of FMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/34,41\">",
"     34,41",
"    </a>",
"    ]. In one series, the sensitivity was only 22 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/34\">",
"     34",
"    </a>",
"    ]. The spatial resolution in the branch vessels is not adequate, and artifact may occur, suggesting \"beading\", when none is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conditions that most commonly mimic the presentation of fibromuscular dysplasia (FMD) are atherosclerotic vascular disease and vasculitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both atherosclerosis and FMD may cause renal artery stenosis. Patients with atherosclerosis are usually older and have typical cardiovascular risk factors such as dyslipidemia, diabetes mellitus, and a history of tobacco use, whereas individuals with FMD are usually younger and have fewer cardiovascular risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/19\">",
"       19",
"      </a>",
"      ]. However, given that FMD can occur in older patients, age alone does not exclude the diagnosis.",
"      <br/>",
"      <br/>",
"      Atherosclerosis usually involves the ostial or proximal segments of the arteries, whereas FMD involves the middle or distal segments. In addition, the string of beads appearance is unique to FMD.",
"     </li>",
"     <li>",
"      Multi-system involvement is observed in both vasculitis and FMD. Unlike patients with a vasculitic process, those with FMD generally will not have associated anemia, thrombocytopenia, or abnormalities of acute phase reactants (eg, erythrocyte sedimentation rate or C-reactive protein) given that it is a non-inflammatory process. An exception might be in the setting of an acute infarction.",
"     </li>",
"     <li>",
"      Other possibilities that may be initially considered before renal artery FMD is diagnosed include essential hypertension and any of the potential causes of secondary hypertension, pulmonary edema due to cardiovascular disease, and slowly progressive chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"       \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of hypertension in adults\", section on 'History'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview of hypertension in adults\", section on 'Testing for renovascular hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link\">",
"       \"Evaluation of acute decompensated heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MONITORING DISEASE PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who is being treated medically (eg, not eligible for or refusing intervention) should have monitoring of the blood pressure response to antihypertensive therapy and serum creatinine levels every three months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26631?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of fibromuscular dysplasia of the renal arteries\", section on 'Medical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive imaging tests, such as duplex ultrasound, should be obtained every 6 to 12 months. Since radiation exposure is high, CT angiography should only be repeated if there is a strong clinical suspicion regarding the progression of the disease. If the patient has an aneurysm, he or she can be followed with MR angiography to follow the size of the aneurysm. However, assessing disease progression by angiographic criteria may be difficult, especially with medial fibroplasia, where it is hard to gauge the degree of stenosis.",
"   </p>",
"   <p>",
"    Some reports suggest that disease progression may be better monitored by measuring the renal parenchyma. Compared with patients who have essential hypertension, patients with unilateral renal FMD had significantly decreased mean cortical thickness and reduced renal length as determined by CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/42\">",
"     42",
"    </a>",
"    ]. In the contralateral, unaffected kidney, cortical thickness was also markedly decreased, although renal length was preserved. Atrophic changes in the renal parenchyma generally represent chronic ischemic damage and are not reversed after renal revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34471/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibromuscular dysplasia (FMD) is a non-inflammatory, non-atherosclerotic disorder that leads to arterial stenosis, aneurysm, or dissection. It is more common among women and, while initially thought to only occur in the young, may occur at any age.",
"     </li>",
"     <li>",
"      The most often involved arteries are the renal (70 percent) and internal carotid and vertebral arteries (approximately 65 percent), and less often are the iliac, subclavian, and visceral arteries. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis is uncertain, but genetic factors, hormonal influence, and ischemia may contribute. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common manifestations are hypertension, headache, dizziness, tinnitus, transient ischemic attack, and stroke, but other manifestations may occur, depending upon the arterial segment involved and the severity of disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of renal artery FMD should be suspected in patients with severe or resistant hypertension and an increase in serum creatinine after initiation of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) (particularly in women under the age of 50), onset of hypertension before the age of 35 years, and a systolic-diastolic epigastric bruit.",
"     </li>",
"     <li>",
"      The conditions that most commonly mimic FMD are atherosclerotic vascular disease and vasculitis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom there is a suspicion for renovascular hypertension, a noninvasive imaging test (such as duplex ultrasound or CTA) should be performed first. The choice of test should be based upon local expertise. If noninvasive tests are inconclusive and pretest probability of FMD is high, the patient should undergo catheter-based digital subtraction arteriography. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Imaging techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated medically, we suggest following the blood pressure and serum creatinine levels every three to four months, and kidney size with ultrasound every 6 to 12 months. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring disease progression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/1\">",
"      Olin JW, Pierce M. Contemporary management of fibromuscular dysplasia. Curr Opin Cardiol 2008; 23:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/2\">",
"      Olin JW, Froehlich J, Gu X, et al. The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation 2012; 125:3182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/3\">",
"      L&uuml;scher TF, Keller HM, Imhof HG, et al. Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron 1986; 44 Suppl 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/4\">",
"      Olin JW, Sealove BA. Diagnosis, management, and future developments of fibromuscular dysplasia. J Vasc Surg 2011; 53:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/5\">",
"      Estepa R, Gallego N, Orte L, et al. Renovascular hypertension in children. Scand J Urol Nephrol 2001; 35:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/6\">",
"      Chiche L, Bahnini A, Koskas F, Kieffer E. Occlusive fibromuscular disease of arteries supplying the brain: results of surgical treatment. Ann Vasc Surg 1997; 11:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/7\">",
"      Deal JE, Snell MF, Barratt TM, Dillon MJ. Renovascular disease in childhood. J Pediatr 1992; 121:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/8\">",
"      Piercy KT, Hundley JC, Stafford JM, et al. Renovascular disease in children and adolescents. J Vasc Surg 2005; 41:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/9\">",
"      Kl&oslash;w NE, Paulsen D, Vatne K, et al. Percutaneous transluminal renal artery angioplasty using the coaxial technique. Ten years of experience from 591 procedures in 419 patients. Acta Radiol 1998; 39:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/10\">",
"      Krijnen P, van Jaarsveld BC, Steyerberg EW, et al. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/11\">",
"      Pascual A, Bush HS, Copley JB. Renal fibromuscular dysplasia in elderly persons. Am J Kidney Dis 2005; 45:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/12\">",
"      Neymark E, LaBerge JM, Hirose R, et al. Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology 2000; 214:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/13\">",
"      Lorenz EC, Vrtiska TJ, Lieske JC, et al. Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. Clin J Am Soc Nephrol 2010; 5:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/14\">",
"      Mettinger KL. Fibromuscular dysplasia and the brain. II. Current concept of the disease. Stroke 1982; 13:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/15\">",
"      Mettinger KL, Ericson K. Fibromuscular dysplasia and the brain. I. Observations on angiographic, clinical and genetic characteristics. Stroke 1982; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/16\">",
"      Cloft HJ, Kallmes DF, Kallmes MH, et al. Prevalence of cerebral aneurysms in patients with fibromuscular dysplasia: a reassessment. J Neurosurg 1998; 88:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/17\">",
"      Wesen CA, Elliott BM. Fibromuscular dysplasia of the carotid arteries. Am J Surg 1986; 151:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/18\">",
"      Schievink WI, Bj&ouml;rnsson J. Fibromuscular dysplasia of the internal carotid artery: a clinicopathological study. Clin Neuropathol 1996; 15:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/19\">",
"      Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med 2004; 350:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/20\">",
"      Sauer L, Reilly LM, Goldstone J, et al. Clinical spectrum of symptomatic external iliac fibromuscular dysplasia. J Vasc Surg 1990; 12:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/21\">",
"      Kolluri R, Ansel G. Fibromuscular dysplasia of bilateral brachial arteries--a case report and literature review. Angiology 2004; 55:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/22\">",
"      Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol 2000; 12:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/23\">",
"      Stanley JC, Gewertz BL, Bove EL, et al. Arterial fibrodysplasia. Histopathologic character and current etiologic concepts. Arch Surg 1975; 110:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/24\">",
"      Harrison EG Jr, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc 1971; 46:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/25\">",
"      Perdu J, Boutouyrie P, Bourgain C, et al. Inheritance of arterial lesions in renal fibromuscular dysplasia. J Hum Hypertens 2007; 21:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/26\">",
"      L&uuml;scher TF, Lie JT, Stanson AW, et al. Arterial fibromuscular dysplasia. Mayo Clin Proc 1987; 62:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/27\">",
"      Dziewas R, Konrad C, Dr&auml;ger B, et al. Cervical artery dissection--clinical features, risk factors, therapy and outcome in 126 patients. J Neurol 2003; 250:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/28\">",
"      Schievink WI, Bj&ouml;rnsson J, Parisi JE, Prakash UB. Arterial fibromuscular dysplasia associated with severe alpha 1-antitrypsin deficiency. Mayo Clin Proc 1994; 69:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/29\">",
"      Siegert CE, Macfarlane JD, Hollander AM, van Kemenade F. Systemic fibromuscular dysplasia masquerading as polyarteritis nodosa. Nephrol Dial Transplant 1996; 11:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/30\">",
"      So EL, Toole JF, Dalal P, Moody DM. Cephalic fibromuscular dysplasia in 32 patients: clinical findings and radiologic features. Arch Neurol 1981; 38:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/31\">",
"      Honjo O, Yamada Y, Kuroko Y, et al. Spontaneous dissection and rupture of common iliac artery in a patient with fibromuscular dysplasia: a case report and review of the literature on iliac artery dissections secondary to fibromuscular dysplasia. J Vasc Surg 2004; 40:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/32\">",
"      Guill CK, Benavides DC, Rees C, et al. Fatal mesenteric fibromuscular dysplasia: a case report and review of the literature. Arch Intern Med 2004; 164:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/33\">",
"      Olin JW, Piedmonte MR, Young JR, et al. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 1995; 122:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/34\">",
"      Vasbinder GB, Nelemans PJ, Kessels AG, et al. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med 2004; 141:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/35\">",
"      Gowda MS, Loeb AL, Crouse LJ, Kramer PH. Complementary roles of color-flow duplex imaging and intravascular ultrasound in the diagnosis of renal artery fibromuscular dysplasia: should renal arteriography serve as the \"gold standard\"? J Am Coll Cardiol 2003; 41:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/36\">",
"      Carman TL, Olin JW, Czum J. Noninvasive imaging of the renal arteries. Urol Clin North Am 2001; 28:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/37\">",
"      Leung DA, Hoffmann U, Pfammatter T, et al. Magnetic resonance angiography versus duplex sonography for diagnosing renovascular disease. Hypertension 1999; 33:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/38\">",
"      Malatino LS, Polizzi G, Garozzo M, et al. Diagnosis of renovascular disease by extra- and intrarenal Doppler parameters. Angiology 1998; 49:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/39\">",
"      Sabharwal R, Vladica P, Coleman P. Multidetector spiral CT renal angiography in the diagnosis of renal artery fibromuscular dysplasia. Eur J Radiol 2007; 61:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/40\">",
"      Funabashi N, Komiyama N, Komuro I. Fibromuscular dysplasia in renovascular hypertension demonstrated by multislice CT: comparison with conventional angiogram and intravascular ultrasound. Heart 2003; 89:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/41\">",
"      Fink C, Hallscheidt PJ, Hosch WP, et al. Preoperative evaluation of living renal donors: value of contrast-enhanced 3D magnetic resonance angiography and comparison of three rendering algorithms. Eur Radiol 2003; 13:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/42\">",
"      Mounier-Vehier C, Lions C, Jaboureck O, et al. Parenchymal consequences of fibromuscular dysplasia renal artery stenosis. Am J Kidney Dis 2002; 40:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34471/abstract/43\">",
"      Mounier-V&eacute;hier C, Haulon S, Devos P, et al. Renal atrophy outcome after revascularization in fibromuscular dysplasia disease. J Endovasc Ther 2002; 9:605.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3874 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-6DA085BC69-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34471=[""].join("\n");
var outline_f33_42_34471=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal arteries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical manifestations of renal FMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical manifestations of extrarenal FMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS OF FMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - CT angiography (CTA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - MR angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MONITORING DISEASE PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3874\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3874|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/50/36644\" title=\"diagnostic image 1\">",
"      MRA renal arteries FMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3874|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/45/16092\" title=\"table 1\">",
"      Classification of FMD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/0/26631?source=related_link\">",
"      Treatment of fibromuscular dysplasia of the renal arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_42_34472="Nocturnal asthma";
var content_f33_42_34472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nocturnal asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Richard J Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34472/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/42/34472/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal worsening of asthma has become a recognized and important problem that must be considered in the management of this disorder. It is quite common, as a survey of almost 8000 patients with varying degrees of asthma found that approximately 75 percent of asthmatics awaken at least once a week with symptoms, 64 percent three times per week, and 39 percent every night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/1\">",
"     1",
"    </a>",
"    ]. In one allergy specialty practice, a 67 percent prevalence of nocturnal asthma symptoms was found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/2\">",
"     2",
"    </a>",
"    ]. Eleven percent awakened every night, 16 percent three to six nights per week, 20 percent one to two nights per week, and 20 percent one night per month.",
"   </p>",
"   <p>",
"    The occurrence of these symptoms is also reflected in mortality statistics. As an example, over a one-year period, 53 percent of asthma deaths in one report occurred at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the time of death does not completely reflect when asthma worsened; 79 percent of these patients had premortem complaints of asthma affecting their sleep, which occurred every night in 42 percent.",
"   </p>",
"   <p>",
"    The high incidence of nocturnal asthma does not simply represent the waning of medication through the night. The vast majority of dyspneic episodes without medication still occur between 10 PM and 7 AM (",
"    <a class=\"graphic graphic_figure graphicRef58146 \" href=\"mobipreview.htm?16/16/16653\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/4\">",
"     4",
"    </a>",
"    ]. An overview of nocturnal asthma will be presented here; the general management of asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CIRCADIAN RHYTHMS AND ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronobiology of asthma has been summarized in a 1998 NHLBI workshop [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/5\">",
"     5",
"    </a>",
"    ]. Asthma is associated with a circadian pattern in lung function, with best function occurring at approximately 4 PM, and a worst at around 4 AM (",
"    <a class=\"graphic graphic_figure graphicRef62825 \" href=\"mobipreview.htm?12/36/12877\">",
"     figure 2",
"    </a>",
"    ). The normal population also experiences this circadian change in lung function, but the peak-to-trough swings in peak expiratory flow rate are only 5 to 8 percent compared to a variation which can reach 50 percent or more in asthmatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bronchial responsiveness to inhaled bronchoconstrictors is also markedly increased at night in asthmatic subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Larger circadian change in bronchial reactivity predicts a greater overnight fall in peak expiratory flow rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OBJECTIVE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simplest home measuring device is the peak flow (PF) meter. The most commonly used time points to determine the 24 hour variability in lung function are bed-time and morning. However, it has been demonstrated that this method fails to detect 55 to 80 percent of the circadian variability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal asthma appears to reflect an exaggeration of the effects of normal changes in neurohormonal activation that have time-related rhythms (chronobiology) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Location of the inflammatory response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Study of nocturnal asthma has furthered understanding of the location of the inflammatory process in asthma. Using endobronchial (airway) and transbronchial (alveolar tissue) biopsies, the greatest inflammation in nocturnal asthmatics occurred in the alveolar tissue area at 4 AM compared to 4 PM; only eosinophilic alveolar inflammation correlated with the overnight fall in lung function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/13\">",
"     13",
"    </a>",
"    ]. These findings were supported by another study evaluating epithelial cell markers obtained by brushing the proximal and distal airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/14\">",
"     14",
"    </a>",
"    ]. Only in the nocturnal asthma group was the expression of CD51 correlated to airway obstruction at 4 AM. This increase in CD51 in nocturnal asthma patients suggested a relationship to the lung inflammatory and repair processes in response to injury.",
"   </p>",
"   <p>",
"    Since the CD4+ T-lymphocyte is felt to be the principal controller cell in eosinophil recruitment, lymphocyte and eosinophil influx into the alveolar tissue was evaluated at 4 AM and 4 PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/15\">",
"     15",
"    </a>",
"    ]. At 4 AM, there were more alveolar tissue CD4+ cells in the nocturnal asthma group compared to the asthma control group. In addition, only alveolar tissue and not airway tissue CD4+ cells correlated inversely to lung function and positively with EG2+ eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a well described, inverse relationship between lung volume and airway resistance. In asthmatics, hyperinflation plays a role in decreasing airway resistance by increasing circumferential traction on the airway walls. In one study, patients with nocturnal asthma had reduced lung volumes during sleep, accompanied by a greater than expected increases in airway resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/16\">",
"     16",
"    </a>",
"    ]. Airway resistance remained high when lung volumes were normalized. The loss of the normal volume-resistance coupling of the respiratory system is probably due to inflammation of the distal airways.",
"   </p>",
"   <p>",
"    One investigation attempted to correlate noninvasive tests of pulmonary function with the distal inflammatory response. In this study, the degree of distal lung eosinophilic infiltration was significantly correlated to thoracic gas volume and total lung capacity (measured in a body plethysmograph), but not to flow rates or other measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/17\">",
"     17",
"    </a>",
"    ]. Thus, lung volumes appear to more accurately reflect distal airway inflammation than other non-invasive measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Airway cells and mediators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown increased airway eosinophils, neutrophils, CD4 lymphocytes, superoxide production, and mediators of bronchoconstriction when lavage is performed at 4 AM in subjects with nocturnal asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Nocturnal lung function significantly improves when the inflammatory process is altered. Inhaled antiinflammatory therapy has difficulty reaching the alveoli and the combination of oral and inhaled antiinflammatory agents may be required to yield better therapeutic outcomes. In one study, for example, a 50 mg oral dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 3 PM significantly reduced the overnight fall in FEV1 and produced a reduction in all cell types obtained by bronchoalveolar lavage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glucocorticoid receptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the inflammatory response is increased at night, the question arises if the steroid receptor functions appropriately during that time period. One investigation demonstrated that steroid receptor binding affinity as well as steroid responsiveness exhibited a circadian variation in subjects with nocturnal asthma. There was a reduced binding affinity and suppression of peripheral blood mononuclear cell proliferation at 4 AM. This was not observed in normal subjects or asthma control subjects. Thus, inhibition of the antiinflammatory effect of glucocorticoids occurs at night and may contribute to the nocturnal inflammation discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurohormonal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several hormones are secreted in a circadian pattern that can contribute to nocturnal airway inflammation and asthma in predisposed individuals. With cortisol, for example, peak levels occur upon awakening while trough levels are noted around midnight (",
"    <a class=\"graphic graphic_figure graphicRef53078 \" href=\"mobipreview.htm?41/50/42798\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the effects of hypothalamic and pituitary control of the cortisol response in nocturnal asthma by measuring corticotropin-releasing hormone, corticotropin and cortisol levels every two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/24\">",
"     24",
"    </a>",
"    ]. Corticotropin peak levels and the area under the 24-hour curve were significantly higher in nocturnal asthmatics, but these elevations were not accompanied by a commensurate increase in cortisol levels, which were the same in nocturnal asthmatics as in non-nocturnal asthmatics and healthy controls. These findings suggest a blunted adrenal response to corticotropin in nocturnal asthma, which may play a permissive role in the nocturnal worsening of asthma.",
"   </p>",
"   <p>",
"    Melatonin, a sleep inducing hormone, has a proinflammatory effect in subjects with nocturnal asthma. At 4 PM, peripheral blood mononuclear cells (PBMCs) from nocturnal asthmatics produced significantly greater amounts of IL-1, IL-6 and TNF-a in response to costimulation with melatonin than did non-nocturnal asthmatics or controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/25\">",
"     25",
"    </a>",
"    ]. However, at 4 AM, non-nocturnal asthmatics demonstrated an increased response to melatonin, whereas PBMCs from nocturnal asthmatics were unable to be stimulated further. These observations suggest that the nocturnal asthma phenotype is associated with a chronically enhanced inflammatory milieu, which blunts the ability of PBMCs to respond further to stimulation at night.",
"   </p>",
"   <p>",
"    A separate investigation focused on endogenous melatonin demonstrated that peak melatonin levels occurred at approximately 2 am, and that these levels were significantly greater in nocturnal asthmatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/26\">",
"     26",
"    </a>",
"    ]. Furthermore, in nocturnal asthmatics alone, peak melatonin level was inversely associated with overnight change in lung function, such that higher peak melatonin levels were associated with a greater overnight fall in lung function.",
"   </p>",
"   <p>",
"    Epinephrine release also varies in a circadian fashion, with peak levels during the afternoon and trough levels during the early morning (",
"    <a class=\"graphic graphic_figure graphicRef53078 \" href=\"mobipreview.htm?41/50/42798\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/23\">",
"     23",
"    </a>",
"    ]. The infusion of physiologic doses of epinephrine has been reported to lessen but not abolish the overnight decline in lung function in patients with nocturnal asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The levels of bronchoconstrictor mediators such as leukotrienes, interleukins, and histamine have also been shown to be elevated at night in asthmatics with nocturnal worsening and, for certain mediators, in normal subjects as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/19,23,27-30\">",
"     19,23,27-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=see_link\">",
"     \"Pathogenesis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pulmonary capillary blood volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with nocturnal asthma, unlike asthmatics without nocturnal asthma, the capillary blood volume significantly increases during sleep by 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/31\">",
"     31",
"    </a>",
"    ]. This may be a contributing factor in recruiting additional inflammatory cells and producing more edema in the airways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cholinergic tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinergic (vagal) tone is increased at night and may contribute to the circadian change in airway function. A role for cholinergic tone is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      to subjects with nocturnal asthma produced improvement in the peak expiratory flow rate (PEFR) at 4 AM compared to 4 PM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report studied the heart rate variations induced by deep breathing, Valsalva maneuver, and standing from the recumbent position in asthmatic and non-asthmatic subjects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/33\">",
"       33",
"      </a>",
"      ]. The asthmatic patients had evidence of enhanced parasympathetic neural drive to the sinoatrial node consistent with increased parasympathetic activity, both during the day and at night.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Beta-2 adrenoceptor function and gene regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the number and physiologic function of beta-2 receptors are significantly decreased from 4 PM to 4 AM in asthmatics with nocturnal worsening compared to non-nocturnal asthmatics and normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/29\">",
"     29",
"    </a>",
"    ]. This phenotypic downregulation may be related to a polymorphism within the genetic coding block of the beta-2 receptor. Specifically, glycine at position 16 (Gly16) imparts an accelerated downregulation of the receptor compared to arginine at this position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/34\">",
"     34",
"    </a>",
"    ]. In one study, the frequency of the Gly16 allele was 80 percent among nocturnal asthmatics, compared to 52 percent for non-nocturnal asthmatics (odds ratio (OR) 3.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/35\">",
"     35",
"    </a>",
"    ]. A subsequent metaanalysis of this study and four others noted a similarly increased frequency the Gly16 allele among nocturnal asthmatics compared to non-nocturnal asthmatic control patients (OR 2.2; 95%CI 1.56-3.11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15239?source=see_link\">",
"     \"Beta-2 adrenergic receptor dysfunction and polymorphism in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDIRECT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of nocturnal asthma consists of both indirect and direct approaches. Indirect interventions are effective in only a small proportion of the asthmatic population. For a given patient, however, they may be of significant importance in controlling the nocturnal component. There may also be a beneficial carryover to daytime lung function and symptom control. The indirect measures include control of contributing factors such as sleep apnea, gastroesophageal reflux, rhinitis, and sinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Environmental control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although allergen exposure does not explain nocturnal asthma in general [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], dust mite,",
"    <span class=\"nowrap\">",
"     dog/cat,",
"    </span>",
"    or other sensitivities must be considered in any given patient, and interventions should be taken, ranging from elimination to desensitization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nasal continuous positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant obstructive sleep apnea can cause worsening of nocturnal asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .) In one report, for example, all such patients treated with nasal continuous positive airway pressure (nasal CPAP) experienced a marked improvement in nocturnal and daytime asthma symptoms with an associated reduction in the use of bronchodilators and lung function (",
"    <a class=\"graphic graphic_figure graphicRef72049 \" href=\"mobipreview.htm?18/14/18670\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact reason for improved lung function with nasal CPAP is not clear. Proposed mechanisms include elimination of",
"    <span class=\"nowrap\">",
"     pharyngeal/laryngeal",
"    </span>",
"    irritation with reflex bronchoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/39\">",
"     39",
"    </a>",
"    ], improvement in hypoxia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased vagal tone. Nocturnal asthma is not improved with nasal CPAP in the absence of sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between gastroesophageal reflux (GER) and nocturnal asthma is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=see_link\">",
"     \"Gastroesophageal reflux and asthma\"",
"    </a>",
"    .) In one study, hydrochloric acid was infused during sleep with simultaneous and continuous measurements of lower airway resistance and esophageal pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/41\">",
"     41",
"    </a>",
"    ]. The increase in lower airway resistance over the night was not affected by the presence or absence of acid in the esophagus. Additionally, in a double-blind crossover study in nocturnal asthmatics with gastroesophageal reflux, there were no differences in peak expiratory flow measurements, symptoms, or bronchodilator use in patients treated with placebo versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/42\">",
"     42",
"    </a>",
"    ]. However, in awake asthmatics with reflux, acid infusion in the supine position produced a decrease in peak flows and an increase in specific airway resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, GER with aspiration could play a role in nocturnal asthma in a given patient. Treatment of GER in nocturnal asthma should be based upon symptoms of reflux, and not worsening of asthma. The possibility of reflux with aspiration should be considered if the patient complains of a sour taste in the mouth upon arising or has unexplained infiltrates on the chest radiograph.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inspiratory muscle training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inspiratory muscle training can result in increased strength and endurance, with an associated improvement in asthma symptoms. In one study of muscle training, the treatment group experienced improvement in nocturnal symptoms, morning tightness, daytime asthma, and cough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/44\">",
"     44",
"    </a>",
"    ]. Inhaled beta-2 agonist use, emergency department visits, and sick leave days were also significantly reduced. These observations suggest that inspiratory muscle training has potential as a nonpharmacologic therapy in nocturnal asthma.",
"   </p>",
"   <p>",
"    Since this form of therapy is not widely used, exact recommendations are not available. It can be tried when a decrease in inspiratory or expiratory muscle strength (PImax; PEmax) is found. An example of a respiratory muscle \"trainer\" is the Threshold&reg; device from Healthscan Products. Starting with the lowest threshold resistance, the patient should build up to 15 minutes, twice daily, and then progress to the maximum resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus clearance mechanisms are decreased during sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/45\">",
"     45",
"    </a>",
"    ]. As a result, asthmatic patients with chronic sinus disease can aspirate the inflammatory components of \"postnasal drip\". One report showed that induced sinus inflammation in an animal model does not produce an increase in pulmonary resistance by itself, but resistance will increase if aspiration of inflammatory components occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIRECT PHARMACOLOGIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimization of the dosage of daytime asthma medications and appropriately timed use of medications such as a long-acting inhaled beta-2 agonist, a once-daily sustained",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    preparation, oral glucocorticoids, or leukotriene modifiers may be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Beta-2 adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to timing of dosing and duration of action of beta-2 agonists is often beneficial in nocturnal asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Inhaled beta-2 adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer, long-acting inhaled beta-2 agonists have been evaluated in nocturnal asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. They can lead to improved overnight lung function but not total elimination of the decrement in lung function. As an example, in one double-blind, placebo-controlled study of 20 patients with nocturnal asthma,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    at a dose of 50 mcg BID significantly improved overnight PEFR by a mean value of 69",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    and led to an improvement in sleep quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/47\">",
"     47",
"    </a>",
"    ]. A higher dose (100 mcg BID), however, may produce central stimulation and decreased slow wave sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/47\">",
"     47",
"    </a>",
"    ]. Other studies of salmeterol in nocturnal asthma have demonstrated its efficacy not only in improving overnight lung function but also improving both global and domain scores on the Asthma Quality of Life Questionnaire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Oral beta-2 adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar benefit can be achieved by manipulating oral medications to include overnight coverage. One report, for example, showed the advantage of an unequal morning-evening treatment schedule with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    (5 mg at 8 AM and 10 mg at 8 PM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/51\">",
"     51",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    in a slow release preparation (8 mg) may also lead to clinical improvement as manifested by a significant increase in morning PEFR and a decrease in wheezing and shortness of breath when compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/52\">",
"     52",
"    </a>",
"    ]. One study compared a once daily oral beta-2-agonist, bambuterol, to a long acting inhaled agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    , in symptomatic asthmatics on inhaled steroids. Both medications were tolerated and there were no differences in the multiple efficacy outcome variables. The primary outcome of morning peak flow showed a 50",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    increase on bambuterol and a 55",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    increase on salmeterol (P=0.53). The oral agent was less expensive than the inhaled medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/53\">",
"     53",
"    </a>",
"    ], and the unequal dosing of a sustained released albuterol preparation (4 mg in the AM and 8 mg in the PM) gave equivalent outcomes in peak flow and FEV1 data as did salmeterol in patients with nocturnal asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    preparations differ in their pharmacokinetics and, therefore, improve or stabilize nocturnal pulmonary function to a greater or lesser degree. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    .) As an example, twice-daily theophylline preparations designed to produce consistent plasma theophylline concentrations have yielded varying drug levels over 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Other preparations are specifically formulated to produce higher nighttime levels to meet increased nocturnal demands without compromising daytime asthma control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One dosing schedule strategy is to administer a once-daily preparation (eg, Uniphyl) in the evening at 6 to 7 PM, aiming for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    levels of 15",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    at night in order to attenuate nocturnal symptoms and early morning bronchoconstriction. Daytime levels fall to approximately 8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    without deterioration in asthma control. Lung function is better during the day, so that comparably high drug levels are not needed at that time. This regimen has been found to be clinically superior to conventional twice daily dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/58,59\">",
"     58,59",
"    </a>",
"    ] and can improve patient compliance.",
"   </p>",
"   <p>",
"    In addition to having a bronchodilator effect,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    can improve nocturnal asthma by decreasing neutrophil influx into the lung and LTB4 levels from alveolar macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, antiinflammatory effects of theophylline appear to play a role in the improvement of nocturnal asthma.",
"   </p>",
"   <p>",
"    Comparison of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    and sustained-release oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    suggests that effectiveness in controlling nocturnal asthma is not significantly different between the two agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/61\">",
"     61",
"    </a>",
"    ]. However, there may be fewer nocturnal arousals with inhaled salmeterol than with sustained release oral theophylline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronotherapy is particularly relevant with the use of oral steroids. The timing of the glucocorticoid dose affects both lung function and the inflammatory milieu associated with nocturnal asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A series of studies by one group of investigators demonstrated a time-dependent pharmacology of corticosteroids with respect to managing asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/62-64\">",
"       62-64",
"      </a>",
"      ]. The optimal dosing time was around 3 PM compared to 7 AM, 7 PM, or 3 AM. There was no increase in adrenal suppression with 3 PM compared to morning dosing.",
"     </li>",
"     <li>",
"      Another study evaluated the effect of single, variably timed doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (8 AM, 3 PM, 8 PM) on airway inflammation and lung function in nocturnal asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/21\">",
"       21",
"      </a>",
"      ]. Only prednisone at 3 PM resulted in a reduction in the overnight fall in FEV1 (",
"      <a class=\"graphic graphic_figure graphicRef77820 \" href=\"mobipreview.htm?36/10/37037\">",
"       figure 5",
"      </a>",
"      ); this regimen was also associated with a pancellular reduction in 4 AM BAL cytology (",
"      <a class=\"graphic graphic_figure graphicRef66032 \" href=\"mobipreview.htm?33/39/34429\">",
"       figure 6",
"      </a>",
"      ). These benefits were not seen with the other dosing regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids, cromolyn, and nedocromil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several studies tout inhaled glucocorticoids, cromolyn and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    as beneficial in nocturnal asthma, at best a 50 percent clinical response is seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Inhaled glucocorticoids dosed at 3 PM produce equal or better efficiency than dosed four times daily or once daily at 8 AM or 5:30 PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. More information is needed on chronotherapy with these agents to determine if the response can be improved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=see_link&amp;anchor=H2#H2\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Limitations on availability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Agents affecting leukotriene synthesis or action",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the advent of this category of medications, studies have demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    (a 5-lipoxygenase inhibitor),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (LTD4 receptor antagonists) can improve nocturnal asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/27,69,70\">",
"     27,69,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Anticholinergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled anticholinergic agents are short-acting and have little effect on the overnight fall in pulmonary function seen in nocturnal asthma. However, parasympathetic blockers produce better bronchodilation during the night than in the daytime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34472/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal asthma is a significant clinical problem that should be addressed aggressively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple to use peak flow meters should be used to allow both the patient and clinician to understand how the patient's lung function is altered day to night and to allow objective evaluation of interventions.",
"     </li>",
"     <li>",
"      Sleep apnea, symptomatic GER, and sinusitis should be controlled when present.",
"     </li>",
"     <li>",
"      Medications should be appropriately timed and consideration should be given to the use of a long-acting inhaled or oral beta-2 agonist, a leukotriene modifier, and inhaled corticosteroids. A once-daily sustained release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      preparation, and changing the timing of oral corticosteroids to the mid-afternoon can be used in unresponsive cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of nocturnal asthma can be summarized according to an approach based on asthma severity:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Mild asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since inhaled corticosteroids are now considered primary therapy in asthma, they should be used initially. However, if objective monitoring of peak flow does not show an elimination of symptomatic nocturnal fall, then either a long-acting inhaled beta-2 agonist such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , one to two actuations at bedtime, or oral sustained release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    (Volmax), 4 to 8 mg in the evening, or a leukotriene modifier can be added to the program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Moderate asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this situation both an inhaled corticosteroid and either the above described beta-2 agonist or leukotriene modifier will most likely be needed. A once-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    preparation (eg, Uniphyl) given with the evening meal (6-7 PM) can also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Severe asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;This type of patient will be receiving inhaled steroids, a beta-2 agonist, and most likely a leukotriene modifier. A chronotherapeutic approach should be undertaken, as this will not only improve the nighttime control, but will also have a carry-over effect on daytime control. Strong consideration should be given to a 3 PM dosing schedule if oral steroids are needed. Clinically, better asthma control may be obtained with lower doses of oral steroids at 3 PM.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/34/27173?source=see_link\">",
"     Tiotropium",
"    </a>",
"    , a 24&mdash;hour anticholinergic agent, is now available in the United States, and may be of benefit in certain patients with nocturnal asthma.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    can also be considered.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/1\">",
"      Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med 1988; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/2\">",
"      Storms WW, Bodman SF, Nathan RA, Byer P. Nocturnal asthma symptoms may be more prevalent than we think. J Asthma 1994; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/3\">",
"      Robertson CF, Rubinfeld AR, Bowes G. Deaths from asthma in Victoria: a 12-month survey. Med J Aust 1990; 152:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/4\">",
"      Dethlefsen, U, Repgas, R. Ein neues therapieprinzip bei nachtlichen asthma. Clin Med 1985; 80:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/5\">",
"      Martin RJ, Banks-Schlegel S. Chronobiology of asthma. Am J Respir Crit Care Med 1998; 158:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/6\">",
"      Hetzel MR, Clark TJ. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax 1980; 35:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/7\">",
"      Barnes PJ, Chung KF, Page CP. Inflammatory mediators and asthma. Pharmacol Rev 1988; 40:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/8\">",
"      deVries, K, Goei, JT, Booy-Noord, H, et al. Changes during 24 hours in the lung function and histamine hyperactivity of the bronchial tree in asthmatic and bronchitic patients. Arch Allergy Appl Immunol 1962; 20:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/9\">",
"      Martin RJ, Cicutto LC, Ballard RD. Factors related to the nocturnal worsening of asthma. Am Rev Respir Dis 1990; 141:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/10\">",
"      D'Alonzo GE, Steinijans VW, Keller A. Measurements of morning and evening airflow grossly underestimate the circadian variability of FEV1 and peak expiratory flow rate in asthma. Am J Respir Crit Care Med 1995; 152:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/11\">",
"      Sutherland ER. Nocturnal asthma: underlying mechanisms and treatment. Curr Allergy Asthma Rep 2005; 5:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/12\">",
"      Sutherland ER. Nocturnal asthma. J Allergy Clin Immunol 2005; 116:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/13\">",
"      Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/14\">",
"      Kraft M, Striz I, Georges G, et al. Expression of epithelial markers in nocturnal asthma. J Allergy Clin Immunol 1998; 102:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/15\">",
"      Kraft M, Martin RJ, Wilson S, et al. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med 1999; 159:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/16\">",
"      Irvin CG, Pak J, Martin RJ. Airway-parenchyma uncoupling in nocturnal asthma. Am J Respir Crit Care Med 2000; 161:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/17\">",
"      Sutherland ER, Martin RJ, Bowler RP, et al. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004; 113:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/18\">",
"      Martin RJ, Cicutto LC, Smith HR, et al. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991; 143:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/19\">",
"      Jarjour NN, Busse WW, Calhoun WJ. Enhanced production of oxygen radicals in nocturnal asthma. Am Rev Respir Dis 1992; 146:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/20\">",
"      Doi S, Murayama N, Inoue T, et al. CD4 T-lymphocyte activation is associated with peak expiratory flow variability in childhood asthma. J Allergy Clin Immunol 1996; 97:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/21\">",
"      Beam WR, Weiner DE, Martin RJ. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am Rev Respir Dis 1992; 146:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/22\">",
"      Kraft M, Vianna E, Martin RJ, Leung DY. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night. J Allergy Clin Immunol 1999; 103:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/23\">",
"      Barnes P, FitzGerald G, Brown M, Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med 1980; 303:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/24\">",
"      Sutherland ER, Ellison MC, Kraft M, Martin RJ. Altered pituitary-adrenal interaction in nocturnal asthma. J Allergy Clin Immunol 2003; 112:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/25\">",
"      Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. J Allergy Clin Immunol 2003; 112:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/26\">",
"      Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/27\">",
"      Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995; 152:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/28\">",
"      Jarjour NN, Busse WW. Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma. Am J Respir Crit Care Med 1995; 152:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/29\">",
"      Szefler SJ, Ando R, Cicutto LC, et al. Plasma histamine, epinephrine, cortisol, and leukocyte beta-adrenergic receptors in nocturnal asthma. Clin Pharmacol Ther 1991; 49:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/30\">",
"      Bellia V, Bonanno A, Cibella F, et al. Urinary leukotriene E4 in the assessment of nocturnal asthma. J Allergy Clin Immunol 1996; 97:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/31\">",
"      Desjardin JA, Sutarik JM, Suh BY, Ballard RD. Influence of sleep on pulmonary capillary volume in normal and asthmatic subjects. Am J Respir Crit Care Med 1995; 152:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/32\">",
"      Morrison JF, Pearson SB, Dean HG. Parasympathetic nervous system in nocturnal asthma. Br Med J (Clin Res Ed) 1988; 296:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/33\">",
"      Kallenbach JM, Webster T, Dowdeswell R, et al. Reflex heart rate control in asthma. Evidence of parasympathetic overactivity. Chest 1985; 87:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/34\">",
"      Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP. Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005; 115:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/35\">",
"      Turki J, Pak J, Green SA, et al. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995; 95:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/36\">",
"      Boezen HM, Postma DS, Schouten JP, et al. PEF variability, bronchial responsiveness and their relation to allergy markers in a random population (20-70 yr). Am J Respir Crit Care Med 1996; 154:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/37\">",
"      Epton MJ, Martin IR, Graham P, et al. Climate and aeroallergen levels in asthma: a 12 month prospective study. Thorax 1997; 52:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/38\">",
"      Chan CS, Woolcock AJ, Sullivan CE. Nocturnal asthma: role of snoring and obstructive sleep apnea. Am Rev Respir Dis 1988; 137:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/39\">",
"      NADEL JA, WIDDICOMBE JG. Reflex effects of upper airway irritation on total lung resistance and blood pressure. J Appl Physiol 1962; 17:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/40\">",
"      Martin RJ, Pak J. Nasal CPAP in nonapneic nocturnal asthma. Chest 1991; 100:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/41\">",
"      Tan WC, Martin RJ, Pandey R, Ballard RD. Effects of spontaneous and simulated gastroesophageal reflux on sleeping asthmatics. Am Rev Respir Dis 1990; 141:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/42\">",
"      Ford GA, Oliver PS, Prior JS, et al. Omeprazole in the treatment of asthmatics with nocturnal symptoms and gastro-oesophageal reflux: a placebo-controlled cross-over study. Postgrad Med J 1994; 70:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/43\">",
"      Harding SM, Schan CA, Guzzo MR, et al. Gastroesophageal reflux-induced bronchoconstriction. Is microaspiration a factor? Chest 1995; 108:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/44\">",
"      Weiner P, Azgad Y, Ganam R, Weiner M. Inspiratory muscle training in patients with bronchial asthma. Chest 1992; 102:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/45\">",
"      Sullivan CE, Murphy E, Kozar LF, Phillipson EA. Waking and ventilatory responses to laryngeal stimulation in sleeping dogs. J Appl Physiol 1978; 45:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/46\">",
"      Brugman SM, Larsen GL, Henson PM, et al. Increased lower airways responsiveness associated with sinusitis in a rabbit model. Am Rev Respir Dis 1993; 147:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/47\">",
"      Fitzpatrick MF, Mackay T, Driver H, Douglas NJ. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist. BMJ 1990; 301:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/48\">",
"      Dahl R, Earnshaw JS, Palmer JB. Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/49\">",
"      Holimon TD, Chafin CC, Self TH. Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists? Drugs 2001; 61:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/50\">",
"      Lockey RF, DuBuske LM, Friedman B, et al. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999; 115:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/51\">",
"      Postma, DS, K&ouml;eter, GH, Meurs, H, et al. Slow release terbutaline in nocturnal bronchial obstruction: Relation of terbutaline dosage and blood levels with circadian changes in peak flow values. Annu Rev Chronopharmocol 1984; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/52\">",
"      Moore-Gillon, J. Volmax (salbuterol CR 8 mg) in the management of nocturnal asthma: A placebo-controlled study (abstract). Eur Res J 1988; 1(Suppl 2):306S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/53\">",
"      Crompton GK, Ayres JG, Basran G, et al. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids. Am J Respir Crit Care Med 1999; 159:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/54\">",
"      Martin RJ, Kraft M, Beaucher WN, et al. Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma. Ann Allergy Asthma Immunol 1999; 83:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/55\">",
"      Smolensky MH, Scott PH, Kramer WG. Clinical significance of day-night differences in serum theophylline concentration with special reference to Theo-Dur. J Allergy Clin Immunol 1986; 78:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/56\">",
"      Scott PH, Tabachnik E, MacLeod S, et al. Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics. J Pediatr 1981; 99:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/57\">",
"      D'Alonzo GE, Smolensky MH, Feldman S, et al. Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis 1990; 142:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/58\">",
"      Martin RJ, Cicutto LC, Ballard RD, et al. Circadian variations in theophylline concentrations and the treatment of nocturnal asthma. Am Rev Respir Dis 1989; 139:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/59\">",
"      Welsh PW, Reed CE, Conrad E. Timing of once-a-day theophylline dose to match peak blood level with diurnal variation in severity of asthma. Am J Med 1986; 80:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/60\">",
"      Kraft M, Torvik JA, Trudeau JB, et al. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 1996; 97:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/61\">",
"      Selby C, Engleman HM, Fitzpatrick MF, et al. Inhaled salmeterol or oral theophylline in nocturnal asthma? Am J Respir Crit Care Med 1997; 155:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/62\">",
"      Reinberg A, Halberg F, Falliers CJ. Circadian timing of methylprednisolone effects in asthmatic boys. Chronobiologia 1974; 1:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/63\">",
"      Reinberg A, Gervais P, Chaussade M, et al. Circadian changes in effectiveness of corticosteroids in eight patients with allergic asthma. J Allergy Clin Immunol 1983; 71:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/64\">",
"      Reinberg A, Guillet P, Gervais P, et al. One month chronocorticotherapy (Dutimelan 8 15 mite). Control of the asthmatic condition without adrenal suppression and circadian rhythm alteration. Chronobiologia 1977; 4:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/65\">",
"      Horn CR, Clark TJ, Cochrane GM. Inhaled therapy reduces morning dips in asthma. Lancet 1984; 1:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/66\">",
"      Petty TL, Rollins DR, Christopher K, et al. Cromolyn sodium is effective in adult chronic asthmatics. Am Rev Respir Dis 1989; 139:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/67\">",
"      Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1995; 95:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/68\">",
"      Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997; 100:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/69\">",
"      Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34472/abstract/70\">",
"      Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 524 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34472=[""].join("\n");
var outline_f33_42_34472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CIRCADIAN RHYTHMS AND ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OBJECTIVE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Location of the inflammatory response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Airway cells and mediators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glucocorticoid receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurohormonal changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pulmonary capillary blood volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cholinergic tone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Beta-2 adrenoceptor function and gene regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDIRECT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Environmental control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nasal continuous positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inspiratory muscle training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIRECT PHARMACOLOGIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Beta-2 adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Inhaled beta-2 adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Oral beta-2 adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Inhaled glucocorticoids, cromolyn, and nedocromil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Agents affecting leukotriene synthesis or action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Anticholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Mild asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Moderate asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/524\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/524|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/16/16653\" title=\"figure 1\">",
"      Timing of nocturnal asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/36/12877\" title=\"figure 2\">",
"      Circadian lung function asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/50/42798\" title=\"figure 3\">",
"      Circadian hormones in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/14/18670\" title=\"figure 4\">",
"      Nasal CPAP in nocturnal asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/10/37037\" title=\"figure 5\">",
"      Prednisone in nocturnal asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/39/34429\" title=\"figure 6\">",
"      Nocturnal asthma - effect of prednisone on BAL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/56/15239?source=related_link\">",
"      Beta-2 adrenergic receptor dysfunction and polymorphism in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=related_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_42_34473="Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction";
var content_f33_42_34473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34473/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34473/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34473/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34473/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/42/34473/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/42/34473/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/42/34473/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred reperfusion therapy in many patients with an acute ST elevation (Q wave) myocardial infarction (STEMI) is primary percutaneous coronary intervention (PCI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/1\">",
"     1",
"    </a>",
"    ]. Fibrinolytic therapy is given to eligible patients if primary PCI cannot be performed in a timely fashion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients presenting to a PCI capable hospital, this is rarely an issue. It is more complicated, however, in patients who first present to a hospital without PCI capabilities. There are a number of studies showing benefit of transfer for primary PCI, even with substantial delays. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, there are circumstances in which initial fibrinolytic therapy is preferred. A complex issue, which will be reviewed here, is the role and appropriate timing of coronary angiography, and, if appropriate, PCI after fibrinolytic therapy. Historically, there have been a number of approaches to this question, leading to a somewhat confusing lexicon, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rescue or salvage PCI, for apparent failure of fibrinolysis",
"     </li>",
"     <li>",
"      Urgent PCI, for threatened reocclusion or hemodynamic instability",
"     </li>",
"     <li>",
"      Facilitated PCI, in which a fibrinolytic drug is given prior to planned PCI in an attempt to achieve an open infarct-related artery before arrival in the catheterization laboratory",
"     </li>",
"     <li>",
"      Adjunctive PCI, in which PCI is performed within hours after fibrinolysis",
"     </li>",
"     <li>",
"      A pharmacoinvasive approach refers to the routine administration of a pharmacologic agent (eg, fibrinolytic therapy or a glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor) prior to planned PCI for STEMI in an attempt to achieve an open infarct-related artery before arrival in the catheterization laboratory. (See",
"      <a class=\"local\" href=\"#H1293488\">",
"       'Pharmacoinvasive strategy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Early elective PCI, in which PCI is performed within a few days after fibrinolysis, usually because of recurrent ischemia or a positive stress test",
"     </li>",
"     <li>",
"      Late elective PCI to achieve an open artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the 2009 focused update of",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for management of ST elevation MI, it is suggested that these labels can be misleading, and recommendations are based according to whether a patient presents to a PCI-capable or non-PCI-capable hospital. Since the treatment decision made for patients presenting to non-PCI-capable hospitals draws heavily on data from rescue (including urgent) and facilitated PCI trials, we will review these here also. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMI FLOW GRADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical outcomes after fibrinolytic therapy are related to the degree to which flow has been restored in the infarct-related artery. This angiographic outcome has usually been assessed at approximately 90 minutes after fibrinolysis in clinical trials and in some of these trials it is the primary outcome.",
"   </p>",
"   <p>",
"    The TIMI classification is commonly used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TIMI 0 refers to the absence of any antegrade flow beyond a coronary occlusion",
"     </li>",
"     <li>",
"      TIMI 1 flow is faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete",
"     </li>",
"     <li>",
"      TIMI 2 flow is delayed or sluggish antegrade flow with complete filling of the distal territory",
"     </li>",
"     <li>",
"      TIMI 3 flow is normal flow which fills the distal coronary bed completely",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of fibrinolysis is to reestablish TIMI grade 3 flow in the infarct-related artery. This is an important issue because improved survival after fibrinolysis is primarily limited to patients who attain this goal (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"mobipreview.htm?15/40/16013\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"mobipreview.htm?9/52/10061\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESCUE PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary failure of fibrinolysis has most often been defined in clinical trials as persistent occlusion of the infarct-related artery (TIMI grade",
"    <span class=\"nowrap\">",
"     0/1)",
"    </span>",
"    by angiography performed at approximately 90 minutes, which occurs in 40 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, angiography is not routinely performed after fibrinolysis outside of clinical trials. Thus, primary failure is more often suspected clinically by persistent, severe, worsening chest pain, hemodynamic instability, or electrocardiographic markers of persistent ischemia. We agree with the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update on STEMI which considers less than 50 percent resolution in the ECG lead showing the greatest degree of ST-segment elevation at presentation as a marker of failure of fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCI in this setting is called rescue or salvage PCI and is the best therapeutic intervention for primary fibrinolytic failure. The efficacy of and recommendations for PCI for failed fibrinolysis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     URGENT PCI",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Threatened reocclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Threatened reocclusion of the infarct-related artery is characterized by the development of early recurrent ischemia after apparently successful fibrinolysis. Thrombotic reocclusion can be manifested by recurrent ST segment elevation, recurrent chest pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reinfarction. After apparently successful fibrinolysis by either clinical or angiographic criteria, early recurrence of ischemia or ST segment shifts (threatened reocclusion) has been observed in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], thrombotic coronary reocclusion in 5 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ], and reinfarction in 3 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/10-13\">",
"     10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two reviews of almost 76,000 patients from GUSTO-I, GUSTO-III, and the TIMI and InTIME II trials, reinfarction occurred in 4.3 percent of patients at a median of two to four days after fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The patients with reinfarction had a higher overall mortality rate at 30 days (11.3 to 16.4 versus 3.5 to 6.2 percent without reinfarction). The mortality associated with reinfarction can be markedly reduced with percutaneous coronary intervention (PCI) during the index hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, we recommend immediate transfer of all patients who have received fibrinolytic therapy either in a non-PCI hospital or in an ambulance (including those who appear to be at low risk) to a PCI capable hospital.",
"   </p>",
"   <p>",
"    PCI for threatened reocclusion, which is the best therapeutic option for patients with threatened reocclusion, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemodynamic instability and cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early invasive approach after fibrinolysis is the treatment of choice for patients in cardiogenic shock. This approach also may improve outcomes in other high-risk patients, such as those with moderate heart failure or pulmonary edema (Killip class II and III) (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of primary revascularization in patients in cardiac shock following an acute MI was first suggested in an observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/16\">",
"     16",
"    </a>",
"    ] and then demonstrated in the SHOCK trial in which 49 percent of patients in the revascularization group had initially been treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/15\">",
"     15",
"    </a>",
"    ]. The benefit was limited to patients under age 75 in whom 20 lives were saved per 100 treated at six months. The details of this trial are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison to primary PCI, fibrinolysis alone is relatively ineffective in patients with cardiogenic shock unless coronary perfusion pressure is increased by vasopressors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraaortic balloon counterpulsation. Thus, patients admitted to hospitals without facilities for revascularization should be immediately transferred to a tertiary care center with an intent for early revascularization; they can be treated with fibrinolysis (if indicated) and insertion of an IABP (if available) if there is a delay or the tertiary care center is far away. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FACILITATED PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facilitated PCI refers to pharmacologic therapy just prior to planned primary PCI for STEMI in an attempt to achieve an open infarct-related artery before arrival in the catheterization laboratory. Trials have been conducted using fibrinolytic agents, GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, anti-thrombins and combinations of these. The role of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy, either early after the diagnosis of STEMI is made or later in the catheterization laboratory during primary PCI, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H24#H24\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Facilitated PCI with either fibrinolytic therapy, half-dose fibrinolytic, or half-dose fibrinolytic with a glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor has been considered in patients who require transfer to a PCI center. In this setting the door-to-balloon time will often exceed the recommended time of less than 90 minutes for primary PCI. The potential utility of facilitated PCI was illustrated by a survey of 4278 transferred patients from the National Registry of Myocardial Infarction which found that only 4.2 percent of patients were treated within 90 minutes and 15 percent within 120 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H233521064#H233521064\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Transfer from a non-PCI center'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect evidence in support of possible efficacy of PCI facilitated by fibrinolysis came from data on preprocedural TIMI grade 3 flow from trials of primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In the PAMI trials, for example, 16 percent of patients had TIMI 3 flow before PCI (ie, spontaneous reperfusion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/19\">",
"     19",
"    </a>",
"    ]. Those with TIMI 3 flow had the following significant benefits: greater clinical and angiographic evidence of myocardial salvage; a lesser likelihood of presenting in or developing heart failure; and a lower rate of early and late mortality (six month mortality: 0.5 versus 2.8 and 4.4 percent with TIMI grade 2 and",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    flow, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     After full dose fibrinolytic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trials performed in the 1980s, such as TAMI-I and TIMI IIA, compared percutaneous transluminal coronary (balloon) angioplasty (PTCA) performed immediately after fibrinolysis to delayed PTCA at 18 hours to 10 days as indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/8,21,22\">",
"     8,21,22",
"    </a>",
"    ]. No benefit was noted in terms of left ventricular function, but immediate PTCA was associated with some adverse effects including an increased risk of bleeding and coronary artery bypass graft surgery (CABG) in TIMI IIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/21\">",
"     21",
"    </a>",
"    ], and more bleeding, recurrent ischemia, and mortality (7 versus 3 percent) in a European trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in management, including more consistent administration of antiplatelet therapy, and the use of low profile catheters, intracoronary stents, and distal embolic protection devices, have led to reexamination of facilitated PCI. Suggestion of possible benefit from an early invasive approach after fibrinolysis came from substudy analyses of over 1500 patients published in 2001 and 2002 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The CAPITAL AMI, ASSENT-4 and PACT trials provided outcomes of facilitated PCI using more current therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ASSENT-4 trial, the largest or these trials, was meant to definitively address the value of full dose fibrinolysis before primary PCI. In this study, 4000 patients with acute STEMI of less than six hours duration who were scheduled to undergo primary PCI with an anticipated delay of one to three hours were to be randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    or placebo prior to primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/26\">",
"     26",
"    </a>",
"    ]. The primary end point was the composite of death, heart failure, or shock within 90 days.",
"   </p>",
"   <p>",
"    The Data Safety and Monitoring Board recommended early cessation of enrollment after 1667 patients because of a significant increase in mortality in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    group (6 versus 3 percent). Among the patients who were randomized, facilitated PCI with tenecteplase was associated with significant increases in the primary end point (19 versus 13 percent, relative risk 1.39, 95% CI 1.11-1.74) and in the rate of in-hospital stroke (1.8 versus 0 percent; 8 of 13 classified strokes were due to intracranial hemorrhage) and, at 90 days, reinfarction (6 versus 4 percent) and target vessel revascularization (7 versus 3 percent).",
"   </p>",
"   <p>",
"    These adverse outcomes of facilitated PCI with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    were seen in most subgroups including time from symptom onset less than two hours, a setting in which the efficacy of fibrinolytic therapy should be maximized (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"     figure 3",
"    </a>",
"    ), randomization to first balloon time greater than two hours, which is greater than the recommended door-to-balloon time of less than 90 minutes, and high risk patients such as those with an anterior MI or diabetes.",
"   </p>",
"   <p>",
"    The median time between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    and PCI was 104 minutes. Assuming that it takes 30 to 45 minutes after tenecteplase injection and recanalization, the time gain for reperfusion was short in most patients. There was a trend toward better outcomes with facilitated PCI when tenecteplase was given in the ambulance and much worse outcomes when given at a PCI center, which is consistent with the importance of very early therapy (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Possible explanations for the benefit in CAPITAL AMI compared to ASSENT-4 are that the population was a higher risk and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    was given a mean of 109 minutes from symptom onset, well within the two to three hour interval when the efficacy of fibrinolytic therapy is greatest (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link&amp;anchor=H13#H13\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'Time from symptom onset'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2006 meta-analysis included six trials of facilitated PCI with fibrinolytic therapy involving almost 3000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/28\">",
"     28",
"    </a>",
"    ]. Approximately 75 percent of the patients came from ASSENT-4 and PACT and the results were similar to those in ASSENT-4. Facilitated PCI compared to primary PCI alone was associated with a significant increase in initial TIMI 3 (normal) flow (42 versus 15 percent) but no difference in final TIMI 3 flow after PCI (88 versus 90 percent).",
"   </p>",
"   <p>",
"    Despite the initial early perfusion benefit, facilitated PCI was associated with significant increases in the short-term rates of mortality (6 versus 4 percent), nonfatal reinfarction (4 versus 2 percent), urgent target vessel revascularization (5 versus 1 percent), and stroke (1.6 versus 0.3 percent), and a nonsignificant increase in major bleeding (7 versus 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     After half dose fibrinolytic and GP IIb/IIIa inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor and half-dose fibrinolytic agent is another approach to restoring vessel patency prior to PCI. An initial nonrandomized study suggested clinically important benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/29\">",
"     29",
"    </a>",
"    ]. However, two randomized trials &mdash; FINESSE and the much smaller BRAVE trial &mdash; showed no significant clinical benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the FINESSE trial, 2452 patients with an STEMI were randomly assigned to either early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    and half dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    prior to PCI or to abciximab given at the time of PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/30\">",
"     30",
"    </a>",
"    ]. All patients received unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    before PCI. There was no significant difference between the two groups in the composite primary 90-day end-point of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and heart failure (9.8 versus 10.5 percent, hazard ratio 0.91, 95% CI 0.67-1.23). In addition, combined therapy was associated with a trend toward an increase in intracranial hemorrhage and a significant increase in TIMI major and minor bleeding.",
"   </p>",
"   <p>",
"    A third arm of the FINESSE trial (early",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    ) given in the emergency room) was also not superior to abciximab given at the time of PCI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H28#H28\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Our approach to facilitated PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results from the various trials and the meta-analysis discussed above lead to the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Facilitated PCI with fibrinolytic therapy should be avoided in most patients because of significant increases in mortality, nonfatal reinfarction, urgent target lesion revascularization and stroke, and a trend toward a higher rate of major bleeding. Facilitated fibrinolytic therapy also increases the risk of free wall rupture.",
"     </li>",
"     <li>",
"      Facilitated PCI with reduced dose fibrinolytic therapy and GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor does not improve outcomes compared to GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor at the time of PCI and is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1293488\">",
"    <span class=\"h1\">",
"     PHARMACOINVASIVE STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;facilitated PCI&rdquo; was previously used to describe an approach where PCI is planned for all patients (as opposed to being reserved for those who fail fibrinolysis) and was performed immediately (as opposed to electively, prior to discharge). Immediate PCI after fibrinolytic therapy should be avoided because of significant increases in mortality, nonfatal reinfarction, urgent target lesion revascularization and stroke and a trend toward a higher rate of major bleeding. However, the delays associated with transfer from one hospital to another in a &ldquo;pharmacoinvasive strategy&rdquo; alleviate the &ldquo;immediate&rdquo; nature of PCI following fibrinolytic therapy. Data supporting this recommendation are presented separately. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Our approach to facilitated PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A pharmacoinvasive approach refers to the routine administration of a pharmacologic agent (eg, fibrinolytic therapy or a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) prior to planned PCI for STEMI in an attempt to achieve an open infarct-related artery before arrival in the catheterization laboratory. This approach is generally used prior to transfer a STEMI patient from a non-interventional hospital to one with PCI capability. The patient is then taken to the interventional lab within 3 to 24 hours of presentation for angiogram and planned PCI",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjunctive or early elective PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence to support a pharmacoinvasive approach comes from studies that evaluated adjunctive or early elective PCI. The distinction between adjunctive PCI (in which PCI is performed within",
"    <strong>",
"     hours",
"    </strong>",
"    after fibrinolysis) and early elective PCI (in which PCI is performed within a",
"    <strong>",
"     few days",
"    </strong>",
"    after fibrinolysis) is somewhat arbitrary and trials have overlap in the timing of PCI. In contrast to the adverse effects seen in ASSENT-4 when catheterization was performed usually within two hours of fibrinolysis (facilitated PCI), adjunctive PCI performed between 3 and 24 hours appears beneficial and safe. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Facilitated PCI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rationale for following fibrinolysis with PCI is that many patients have a persistent reduction in flow in the infarct-related artery. Although fibrinolysis restores patency (TIMI grade 2 or 3) in 80 percent of infarct-related arteries, normalization (TIMI grade 3) of blood flow is seen in only 50 to 60 percent of arteries. As mentioned above, the clinical benefits of fibrinolytic therapy are seen only with the restoration of normal flow (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"mobipreview.htm?15/40/16013\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"mobipreview.htm?9/52/10061\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H3#H3\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI flow grade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale to support adjunctive or early elective PCI after fibrinolysis comes from studies showing that the routine use of PCI after fibrinolysis is equivalent to PCI and studies comparing PCI after fibrinolysis and PCI only for an indication such as spontaneous or provocable ischemia.",
"   </p>",
"   <p>",
"    Evidence suggesting that the routine use of PCI after fibrinolysis is equivalent to PCI comes from the GRACIA-2 trial and the FAST-MI registry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the GRACIA-2 non-inferiority trial, patients were randomly assigned to full dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"       tenecteplase",
"      </a>",
"      followed by stenting within 3 to 12 (mean of 4.6) hours of randomization or to primary stenting within three hours of randomization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/33\">",
"       33",
"      </a>",
"      ]. Compared to primary PCI alone, the early routine post-fibrinolysis PCI group had a significantly higher frequency of complete epicardial and myocardial reperfusion (21 versus 6 percent), which was defined as TIMI 3 epicardial flow, TIMI 3 myocardial perfusion, and resolution of the initial sum of ST-segment elevation &ge;70 percent. Both groups were similar in terms of the extent of left ventricular myocardial damage (area under the CK and troponin curves and left ventricular ejection fraction at six weeks) and in terms of the six month composite incidence of death, reinfarction, stroke, or revascularization.",
"     </li>",
"     <li>",
"      In the FAST-MI registry of 1714 real world STEMI patients treated with primary PCI, fibrinolysis followed by PCI, or no reperfusion, there was no significant difference with regard to in-hospital (4.3 versus 5.0) or one year mortality (6 versus 8 percent) between the two reperfusion groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adjunctive PCI has been directly compared to a strategy of fibrinolysis and standard care (either PCI for a clinical indication or routine late PCI) in the TRANSFER AMI, GRACIA-1, NORDISTEMI, CARESS-in-AMI, SIAM III, and other trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/33,35-38\">",
"     33,35-38",
"    </a>",
"    ]. Two meta-analyses of these trials comparing routine, early PCI after fibrinolysis to ischemia-guided PCI came to a similar conclusion: Patient outcomes are better with early routine PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In the 2010 meta-analysis, the incidence of death or reinfarction at 30 days was lower with early PCI (odds ratio [OR] 0.65, 95% CI 0.49-0.88) without a significant increase in major bleeding (OR 0.93, 95% CI 0.67-1.34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some details of the three more important trials are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In the TRANSFER AMI trial 1059 high risk STEMI patients, who presented to a non-PCI hospital and were treated with fibrinolytic therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14966?source=see_link\">",
"       tenecteplase",
"      </a>",
"      ) within two hours of the onset of chest pain, were randomly assigned to either urgent transfer for cardiac catheterization (PCI within six hours) or to standard care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/35\">",
"       35",
"      </a>",
"      ]. High risk was defined as ST-segment elevation &ge;2 mm in two anterior leads or ST-segment elevation &ge;1 mm in two inferior leads PLUS at least one of the following: systolic blood pressure of less than 100 mmHg, heart rate &gt;100",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      Killip class II or III (",
"      <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"       table 1",
"      </a>",
"      ), ST-segment depression &ge;2 mm in the anterior leads, or ST-segment elevation &ge;1 mm in right-sided lead V4 (V4R). Standard care was defined as transfer for rescue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urgent PCI or for routine catheterization after 24 hours.",
"      <br/>",
"      <br/>",
"      The mean time to catheterization after fibrinolysis was three hours in the urgent transfer group and 33 hours in the standard care group. At 30 days, the primary composite end point (death, reinfarction, heart failure, severe recurrent ischemia or shock) occurred significantly less often in the urgent transfer group (11 versus 17.2 percent; OR 0.64, 95% CI 0.47-0.87). Most of the benefit was attributable to a reduction in reinfarction or recurrent ischemia. The bleeding rates were similar in the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the NORDISTEMI trial 266 low to high risk patients with STEMI, with expected transfer delays of more than 90 minutes, were treated with fibrinolytic therapy and then randomly assigned to a strategy of either immediate transfer for",
"      <span class=\"nowrap\">",
"       angiography/possible",
"      </span>",
"      PCI or ischemia guided treatment in local hospitals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/41\">",
"       41",
"      </a>",
"      ]. In the invasive and conservative groups, PCI was performed in 89 and 71 percent and at a median time of 163 minutes and three days respectively.The primary end point of death, reinfarction, stroke, or new ischemia at one year did not differ between the invasive and conservative groups (20.9 versus 27.3 percent, hazard ratio [HR] 0.72, 95% CI 0.44-1.18 respectively). However, the secondary end point of death, reinfarction, or stroke at one year was significantly lower in the invasive arm (6.0 versus 15.9 percent, HR 0.36, 95% CI 0.16-0.81).",
"     </li>",
"     <li>",
"      In the GRACIA-1 trial, 500 patients with an acute STEMI were treated with full dose fibrinolytic therapy and then randomly assigned to either angiography and PCI if indicated or ischemia-driven cardiac catheterization in less than 24 hours (mean 17 hours) followed by PCI with stenting or CABG, if appropriate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/36\">",
"       36",
"      </a>",
"      ]. The primary end point was death, MI, or ischemia-driven revascularization. At one year, interventional therapy was associated with a significant reduction in the incidence of the primary end point (23 versus 51 percent) and a trend toward a reduction in the incidence of death or MI (17 versus 29 percent). Interventional therapy was also associated with significantly shorter hospitalization (7 versus 11 days) and no increase in bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518111166\">",
"    <span class=\"h2\">",
"     Our approach to a pharmacoinvasive strategy",
"    </span>",
"   </p>",
"   <p>",
"    &minus; We recommend diagnostic coronary angiography and PCI if technically possible for all patients who receive fibrinolytic therapy. We recognize that some patients at very low risk will be managed with a conservative strategy of 'watchful waiting' with monitoring for spontaneous recurrent ischemia and, if not is seen, stress testing to evaluate for provocable ischemia. If ischemia is present, patients should undergo angiography and revascularization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ANGINA AND INDUCIBLE ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI is recommended for recurrent angina or asymptomatic residual ischemia, which is typically documented with exercise testing or radionuclide myocardial perfusion imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. A predischarge low level exercise tolerance test (modified Bruce or Naughton protocol) is recommended for all patients who have not undergone coronary revascularization with PCI or CABG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of revascularization in patients with recurrent or residual ischemia was evaluated in the DANAMI trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/44\">",
"     44",
"    </a>",
"    ]. This trial consisted of 1008 patients with an acute STEMI who were treated with a fibrinolytic agent and had developed either spontaneous symptomatic angina or inducible post-MI ischemia on a predischarge exercise test; the patients were randomly assigned to conservative therapy or to revascularization with PCI or CABG two to ten weeks after the MI. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one, two, and four years, the primary end points (mortality, reinfarction, or admission for unstable angina) occurred significantly less frequently in the invasive group compared to those treated conservatively (15 versus 30 percent, 24 versus 37 percent, and 32 versus 44 percent, respectively) (",
"      <a class=\"graphic graphic_figure graphicRef58727 \" href=\"mobipreview.htm?28/0/28686\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The benefit was due to a lower rate of reinfarction and admission for unstable angina; mortality after a median follow-up of 2.4 years was equivalent in both groups (",
"      <a class=\"graphic graphic_figure graphicRef58727 \" href=\"mobipreview.htm?28/0/28686\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, patients with acute MI who have recurrent angina or ischemia on predischarge stress testing should undergo prompt coronary arteriography, followed by PCI or CABG based upon anatomic considerations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other indirect evidence for a benefit of late PCI in patients with ischemia comes from the SWISSI II trial, which randomly assigned 201 asymptomatic patients with silent myocardial ischemia after both STEMI (most were treated with fibrinolytic therapy) and non-ST elevation MI to either PCI or intensive anti-ischemic drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/45\">",
"     45",
"    </a>",
"    ]. During a mean follow-up of 10.2 years, there was a significant reduction in major adverse cardiovascular outcomes in the PCI group (adjusted hazard ratio, 0.33, 95% CI 0.20-0.55).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ELECTIVE PCI FOR TOTAL OCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that achieving patency in an asymptomatic occluded infarct-related artery hours to days after the acute event may have a beneficial effect by mechanisms other than myocardial salvage, such as prevention of ventricular remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two settings in which this might occur: in patients previously treated with fibrinolytic therapy, which will be reviewed here; and in previously untreated patients, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=see_link&amp;anchor=H26#H26\">",
"     \"Coronary artery patency and outcome after myocardial infarction\", section on 'Late PCI to open an occluded artery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of late elective PCI has been assessed in the TAMI-6, TOAT and SWISSI II trials. None of these small trials supported the efficacy of this approach.",
"   </p>",
"   <p>",
"    In TAMI-6, angiography was performed within 24 hours after fibrinolytic therapy, which was administered late at 6 to 24 hours after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/48\">",
"     48",
"    </a>",
"    ]. The 71 patients with an occluded infarct-related artery were randomly assigned to PTCA or no PTCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/48\">",
"     48",
"    </a>",
"    ]. PTCA was associated with improved LVEF at one month but not at six months, as there was a 38 percent spontaneous recanalization rate in the patients not receiving PTCA.",
"   </p>",
"   <p>",
"    Even later PCI was evaluated in the TOAT trial. The TOAT trial included 223 patients with an uncomplicated acute anterior STEMI (97 percent of who had undergone fibrinolysis) who had either a reduced LVEF or &ge;3 pathologic Q waves on the precordial ECG, but no clinical or stress test evidence of ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/49\">",
"     49",
"    </a>",
"    ]. Angiography, performed at three days to four weeks after the infarction, identified 66 patients with isolated persistent occlusion of the left anterior descending artery; these patients were randomly assigned to continued medical therapy or PCI with stenting at 26&plusmn;18 days. The following findings were noted at 12 months; this small study was powered only to compare left ventricular end-systolic volume:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who underwent PCI had significant increases in left ventricular end-systolic and end-diastolic volumes, indicating an",
"      <strong>",
"       adverse",
"      </strong>",
"      effect on ventricular remodeling. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/842?source=see_link\">",
"       \"Cardiac remodeling: Clinical assessment and therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical events (death, MI, stroke, heart failure, or revascularization) occurred significantly more frequently in the PCI group (53 versus 35 percent).",
"     </li>",
"     <li>",
"      Quality of life scores were unchanged after PCI but tended to deteriorate with medical therapy.",
"     </li>",
"     <li>",
"      Repeat angiography at one year revealed closure in 11 percent after PCI and spontaneous recanalization in 19 percent with medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations are generally consistent with those from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association and the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/42/34473/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary percutaneous coronary intervention is the recommended reperfusion strategy for most patients with acute ST elevation myocardial infarction (STEMI). However, many patients are not able to receive primary PCI in a timely manner. In such patients fibrinolytic therapy has been shown to be of benefit compared to no reperfusion therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for the management of patients treated with fibrinolysis in whom there is evidence of either primary failure of fibrinolytic therapy (such as ongoing ischemic chest pain or less than 50 percent resolution of the initial ST-segment elevation on ECG) or of threatened reocclusion, are found elsewhere. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rescue PCI'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Urgent PCI'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In stable STEMI patients who have received fibrinolysis, we make the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend NOT performing planned PCI within the first two hours (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This is known as facilitated PCI, and is associated with worse outcomes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Facilitated PCI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend coronary angiography with an intent to perform PCI of the infarct related artery rather than a strategy of PCI for ischemia only (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with high-risk features, including but not limited to anterior MI, Killip class &ge;2, inferior MI with evidence of right ventricular involvement, systolic blood pressure of less than 100 mmHg, heart rate &gt;100",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      angiography should be performed as soon as possible after two hours have passed since fibrinolysis.",
"      <br/>",
"      <br/>",
"      For patients not at high risk, the optimal timing of routine angiography and possible PCI for such patients has not been determined. We believe that it should be performed within 3 to 24 hours.",
"      <br/>",
"      <br/>",
"      While we recommend diagnostic coronary angiography for all patients who receive fibrinolytic therapy, we recognize that some patients at very low risk will be managed with a conservative strategy of 'watchful waiting' with monitoring for spontaneous recurrent ischemia and, if not is seen, stress testing should be performed to evaluate for provocable ischemia. If ischemia is present, patients should undergo angiography and revascularization.",
"     </li>",
"     <li>",
"      For stable patients, without",
"      <strong>",
"      </strong>",
"      evidence of either spontaneous or significant provocable ischemia, who are subsequently (after 24 hours) found to have an occluded infarct related artery, we recommend NOT performing PCI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Elective PCI for total occlusion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=see_link&amp;anchor=H24#H24\">",
"       \"Coronary artery patency and outcome after myocardial infarction\", section on 'IRA patency and outcome after PCI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have recurrent angina or ischemia on predischarge stress testing should undergo prompt coronary arteriography followed by PCI or CABG (based upon anatomic considerations), as opposed to a trial of medical therapy. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Angina and inducible ischemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/1\">",
"      Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/2\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/3\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/4\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/6\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/7\">",
"      Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/8\">",
"      Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/9\">",
"      Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 1990; 82:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/10\">",
"      Hudson MP, Granger CB, Topol EJ, et al. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation 2001; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/11\">",
"      Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003; 42:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/12\">",
"      Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. Circulation 2001; 103:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/13\">",
"      D&ouml;nges K, Schiele R, Gitt A, et al. Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results from the pooled data of the maximal individual therapy in acute myocardial infarction [MITRA], and the myocardial infarction registry [MIR]). Am J Cardiol 2001; 87:1039.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/15\">",
"      Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/16\">",
"      Berger PB, Holmes DR Jr, Stebbins AL, et al. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation 1997; 96:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/17\">",
"      Rott D, Behar S, Leor J, et al. Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures. Am J Cardiol 2001; 88:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/18\">",
"      Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/19\">",
"      Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/20\">",
"      De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/21\">",
"      Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. JAMA 1988; 260:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/22\">",
"      Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/23\">",
"      Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol 2001; 88:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/24\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/25\">",
"      Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005; 46:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/26\">",
"      Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/27\">",
"      Bates ER, Nallamothu BK. Commentary: the role of percutaneous coronary intervention in ST-segment-elevation myocardial infarction. Circulation 2008; 118:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/28\">",
"      Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/29\">",
"      Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000; 36:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/30\">",
"      Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/31\">",
"      Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004; 291:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/32\">",
"      Stone GW, Gersh BJ. Facilitated angioplasty: paradise lost. Lancet 2006; 367:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/33\">",
"      Fern&aacute;ndez-Avil&eacute;s F, Alonso JJ, Pe&ntilde;a G, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007; 28:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/34\">",
"      Danchin N, Coste P, Ferri&egrave;res J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008; 118:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/35\">",
"      Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/36\">",
"      Fernandez-Avil&eacute;s F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/37\">",
"      Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/38\">",
"      Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003; 42:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/39\">",
"      D'Souza SP, Mamas MA, Fraser DG, Fath-Ordoubadi F. Routine early coronary angioplasty versus ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis. Eur Heart J 2011; 32:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/40\">",
"      Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010; 31:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/41\">",
"      B&oslash;hmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010; 55:102.",
"     </a>",
"    </li>",
"    <li>",
"     Antman, EM, Hand, M, Armstrong, PW, et al. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008; 51:210. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/43\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/44\">",
"      Madsen JK, Grande P, Saunam&auml;ki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997; 96:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/45\">",
"      Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. JAMA 2007; 297:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/46\">",
"      Kim CB, Braunwald E. Potential benefits of late reperfusion of infarcted myocardium. The open artery hypothesis. Circulation 1993; 88:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/47\">",
"      Pizzetti G, Belotti G, Margonato A, et al. Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 1996; 28:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/48\">",
"      Topol EJ, Califf RM, Vandormael M, et al. A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation 1992; 85:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/49\">",
"      Yousef ZR, Redwood SR, Bucknall CA, et al. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol 2002; 40:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/50\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/51\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/42/34473/abstract/52\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 53 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34473=[""].join("\n");
var outline_f33_42_34473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMI FLOW GRADE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESCUE PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      URGENT PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Threatened reocclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemodynamic instability and cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FACILITATED PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      After full dose fibrinolytic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      After half dose fibrinolytic and GP IIb/IIIa inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Our approach to facilitated PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1293488\">",
"      PHARMACOINVASIVE STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjunctive or early elective PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H518111166\">",
"      Our approach to a pharmacoinvasive strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ANGINA AND INDUCIBLE ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ELECTIVE PCI FOR TOTAL OCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/53\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/53|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/40/16013\" title=\"figure 1\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/52/10061\" title=\"figure 2\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/18/31021\" title=\"figure 3\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/0/28686\" title=\"figure 4\">",
"      Rx post MI ischemia DANAMI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/53|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/59/4027\" title=\"table 1\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_42_34474="Pemphigus vulgaris DIF";
var content_f33_42_34474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82837%7EDERM%2F82838%7EPC%2F53466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82837%7EDERM%2F82838%7EPC%2F53466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus vulgaris direct immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intercellular pattern of IgG antibody binding is evident on direct immunofluorescence in this specimen from a patient with pemphigus vulgaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pemphigus foliaceus direct immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intercellular antibody binding is evident within the upper epidermis in this direct immunofluorescence specimen from a patient with pemphigus foliaceus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Direct immunofluorescence of bullous pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence discloses linear deposits of IgG and C3 along the dermoepidermal junction. Ultrastructurally, these antibodies and complement are present in the lamina lucida.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin, E, Farber, JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy;1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34474=[""].join("\n");
var outline_f33_42_34474=null;
var title_f33_42_34475="Histology of vaginal cancer";
var content_f33_42_34475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of histologic subtypes of primary vaginal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell",
"       </td>",
"       <td>",
"        627",
"       </td>",
"       <td>",
"        83.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenocarcinoma",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoma",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melanoma",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undifferentiated",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small cell",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcinoid",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        753",
"       </td>",
"       <td>",
"        100.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Berek JS, Hacker NF (Eds). Practical Gynecologic Oncology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34475=[""].join("\n");
var outline_f33_42_34475=null;
var title_f33_42_34476="Oral antibiotics used in exit-site and tunnel infection";
var content_f33_42_34476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing (adult) of oral antibiotics used in peritoneal catheter exit-site and tunnel infections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"       </td>",
"       <td>",
"        250 to 500 mg two times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalexin",
"       </td>",
"       <td>",
"        500 mg two to three times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin*",
"       </td>",
"       <td>",
"        250 mg two times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarithromycin",
"       </td>",
"       <td>",
"        500 mg loading dose, then 250 mg once or two times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dicloxacillin",
"       </td>",
"       <td>",
"        500 mg four times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin",
"       </td>",
"       <td>",
"        500 mg four times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucloxacillin (or cloxacillin)",
"       </td>",
"       <td>",
"        500 mg four times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluconazole",
"       </td>",
"       <td>",
"        200 mg once per day for 2 days, then 100 mg once per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flucytosine",
"       </td>",
"       <td>",
"        0.5-1 g/day titrated to response and serum trough levels (25-50 &micro;g/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid",
"       </td>",
"       <td>",
"        200-300 mg once per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        400-600 mg two times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metronidazole",
"       </td>",
"       <td>",
"        400 mg three times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin*",
"       </td>",
"       <td>",
"        400 mg once per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ofloxacin*",
"       </td>",
"       <td>",
"        400 mg first day, then 200 mg once per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyrazinamide",
"       </td>",
"       <td>",
"        25-35 mg/kg up to 3 g per dose three times per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin (rifampicin)&bull;",
"       </td>",
"       <td>",
"        <p>",
"         Patients weighing less than 50 kg: 450 mg once per day",
"        </p>",
"        <p>",
"         Patients weighing greater than or equal to 50 kg: 600 mg once per day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (co-trimoxazole)",
"       </td>",
"       <td>",
"        80-400 mg (one single strength tablet) once per day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Slowly resolving or recurrent Pseudomonas exit site infections should be treated with a second antipseudomonal drug. See text.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Rifampin (rifampicin) is reserved for combination treatment with an oral penicillin or first generation cephalosporin for slowly resolving and severe S. aureus exit site infections. Due to rapid emergence of resistance, rifampin is not appropriate for use as a single agent.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Li, PK, Szeto, CC, Piraino, B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393. Published in Peritoneal Dialysis International. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34476=[""].join("\n");
var outline_f33_42_34476=null;
var title_f33_42_34477="Hemoglobin and viscosity";
var content_f33_42_34477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between hemoglobin concentration and whole blood viscosity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 435px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Experimental relative viscosities of hemoglobin solutions at various concentrations; the temperature is 37&deg;C.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Cokelet, GR, Meiselman, HJ, Science 1968; 162:275.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34477=[""].join("\n");
var outline_f33_42_34477=null;
var title_f33_42_34478="SVR genotype viral load AASLD";
var content_f33_42_34478=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sustained virologic response rates with peginterferon alfa-2b (pegIFN) and ribavirin (RBV) therapy for 48 weeks according to hepatitis C virus genotype and viral concentration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 364px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2004; 39:1147.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34478=[""].join("\n");
var outline_f33_42_34478=null;
var title_f33_42_34479="Intraabdominal hypertension and abdominal compartment syndrome";
var content_f33_42_34479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Intraabdominal hypertension and abdominal compartment syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraabdominal hypertension (IAH) is defined as a sustained intraabdominal pressure &gt;12 mmHg. Abdominal compartment syndrome (ACS) is defined as a sustained intraabdominal pressure&gt;20 mmHg that is associated with new organ dysfunction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from: Abdominal perfusion pressure. AdominalCompartmentSyndrome.org",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_42_34479=[""].join("\n");
var outline_f33_42_34479=null;
